(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number
WO 2004/096980 A2

(51) International Patent Classification[7]: C12N

(21) International Application Number:
PCT/IL2004/000078

(22) International Filing Date: 27 January 2004 (27.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/426,002 30 April 2003 (30.04.2003) US

(71) Applicant *(for all designated States except US)*: **COMPUGEN LTD.** [IL/IL]; 72 Pinchas Rosen Street, 69 512 Tel Aviv (IL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AYALON-SOFFER, Michal** [IL/IL]; 14 HaNoter Street, 47 210 Ramat HaSharon (IL). **POLLOCK, Sarah** [IL/IL]; 16 Hoshea Street, Apt. 2, 63 506 Tel Aviv (IL). **DIBER, Alex** [IL/IL]; 4 HaNeurim Street, Apt. 3, 46 308 Herzlia (IL). **LEVINE, Zurit** [IL/IL]; 4 Reihan Street, 46 419 Herzlia (IL). **NEMZER, Sergey** [IL/IL]; 5 HaRenanim Street, 52 595 Ramat Gan (IL). **DAHARY, Dvir** [IL/IL]; 23 Pinkas Street, 62 662 Tel Aviv (IL). **SOREK, Rotem** [IL/IL]; 15 Aharonovich Street, 76 564 Rehovot (IL). **LEVANON, Erez** [IL/IL]; 73 Menachem Begin Street, 49 732 Petach Tikva (IL). **ROTMAN, Galit** [IL/IL]; 5 Yair Shtern Street, 46 412 Herzlia (IL). **SAVITSKY, Kineret** [IL/IL]; 44 Metudela Street, 69 548 Tel Aviv (IL). **CHERMESH, Chen** [IL/IL]; 58b Kordova Street, 50 297 Mishmar HaShiva (IL). **MINTZ, Liat** [US/US]; 2 Kulessa Court, East Brunswick, NJ 08816 (US). **FREILICH, Shiri** [IL/IL]; 119 Aba Hushi Street, 34 987 Haifa (IL). **BECK, Nili** [IL/IL]; 4/10 Mota Gur Street, 44 405 Kfar Saba (IL). **ZHU, Wei-Yong** [US/US]; 308 Quail Ridge Drive, Plainsboro, NJ 08536 (US). **WASSERMAN, Alon** [US/US]; 564 First Avenue, Apt. 13a, Ne, NY 10016 (US). **AZAR, Idit** [IL/IL]; 29 Shalom Aleichem Street, 63 344 Tel Aviv (IL). **BERNSTEIN, Jeanne** [IL/IL]; 23 Harimon Street, 40 300 Kfar Yona (IL).

(74) Agent: **G. E. EHRLICH (1995) LTD.**; 11 Menachem Begin Street, 52 521 Ramat-Gan (IL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/096980 A2

(54) Title: NOVEL POLYNUCLEOTIDES ENCODING SOLUBLE POLYPEPTIDES AND METHODS USING SAME

(57) Abstract: An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

NOVEL POLYNUCLEOTIDES ENCODING SOLUBLE POLYPEPTIDES AND METHODS USING SAME

FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to novel soluble polypeptides and polynucleotides encoding same and more particularly, to therapeutic and diagnostic methods and kits utilizing same.

Extracellular proteins including receptors and their corresponding ligands play active roles in the formation, differentiation and maintenance of multicellular organisms. Any fate of an individual cell including proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from distant cells and/or the immediate environment. This information is often transmitted by secreted polypeptides such as, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones, which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or signaling molecules are normally transferred through the cellular secretory pathway to reach their site of action at the extracellular environment.

Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors. Most protein drugs available to date, including thrombolytic polypeptide sequences, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins. Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic polynucleotide or polypeptide sequences. For example, receptor immunoadhesins, can be employed as therapeutic polynucleotide or polypeptide sequences to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.

For these reasons, efforts are being made by both industry and academia to identify new, native, membrane-bound or secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for such proteins. Examples of such screening methods and techniques are described in, for example, Klein et al., Proc. Natl. Acad. Sci. 93:7108-7113 (1996); U.S. Pat. No. 5,536,637

The present inventors have previously designed algorithms, which allow for the mass prediction of yet unknown gene products and for annotating these [see US patent No: 6,625,545; U.S. Pat. Appl. No. 10/426,002; a U.S. patent application entitled METHODS AND SYSTEMS FOR ANNOTATING BIOMOLECULAR SEQUENCES (Attorney Docket No. 26940), filed concurrently herewith, assigned to the same assignee hereof and contains subject matter related, in certain respects, to the subject matter of the instant application, the teachings of all of which are incorporated herein by reference; and Example 1 of the Examples section which follows].

While applying the above-mentioned algorithms the present inventors uncovered novel naturally occurring variants of extracellular gene products, which as described above, play pivotal roles in disease onset and progression. As such these variants can be used in the diagnosis and therapy of a wide range of diseases.

SUMMARY OF THE INVENTION

According to one aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to further features in preferred embodiments of the invention described below, the nucleic acid sequence is as set forth in SEQ ID NO: 3 or 4.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 1 or 2.

According to another aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 3 or 4.

According to yet another aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 1 or 2.

According to still another aspect of the present invention there is provided a nucleic acid construct comprising any of the isolated polynucleotide of the present invention.

According to still further features in the described preferred embodiments the nucleic acid construct further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

According to still further features in the described preferred embodiments the nucleic acid construct further comprising a positive and a negative selection markers for selecting for homologous recombination events.

According to an additional aspect of the present invention there is provided a host cell comprising the nucleic acid construct.

According to yet an additional aspect of the present invention there is provided An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still an additional aspect of the present invention there is provided An antibody or an antibody fragment being capable of specifically binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to a further aspect of the present invention there is provided an oligonucleotide specifically hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to yet a further aspect of the present invention there is provided A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided A method of treating Met-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters, thereby treating the Met-related disease in a subject.

According to still a further aspect of the present invention there is provided An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 7 or 8.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 5 or 6.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 7 or 8.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 5 or 6.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland

(http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating an IL-6-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters, thereby treating the IL-6-related disease in the subject.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 11 or 12.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 9 or 10.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 11 or 12.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 9 or 10.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide

having an amino acid at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a IL-7 polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 15 or 16.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 13 or 14.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 15 or 16.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 13 or 14.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 19 or 20.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 17 or 18.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 19 or 20.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 17 or 18.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating TNFR9-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as

determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 27 or 28.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 25 or 26.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 27 or 28.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 25 or 26.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-4R-related disease in a subject, the method comprising

upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 23 or 24.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 21 or 22.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 23 or 24.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 21 or 22.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 31 or 32.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 29 or 30.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 31 or 32.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 29 or 30.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using

the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating TGR2-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 35 or 36.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 33 or 34.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 35 or 36.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 33 or 34.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating ITAV-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 39.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 37 or 38.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 39.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 37 or 38.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating IL10-R-B-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37 as determined using the LALIGN

software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the nucleic acid sequence is as set forth in SEQ ID NO: 43 or 40.

According to still further features in the described preferred embodiments the polypeptide is as set forth in SEQ ID NO: 41 or 42.

According to still a further aspect of the present invention there is provided an isolated polynucleotide as set forth in SEQ ID NO: 43 or 40.

According to still a further aspect of the present invention there is provided an isolated polypeptide as set forth in SEQ ID NO: 41 or 42.

According to still a further aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

According to still a further aspect of the present invention there is provided an antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided an oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still a further aspect of the present invention there is provided a pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41,

as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention there is provided a method of treating INR1-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to still further features in the described preferred embodiments the upregulating expression of the polypeptide is effected by: (i) administering the polypeptide to the subject; and/or (ii) administering an expressible polynucleotide encoding the polypeptide.

The present invention successfully addresses the shortcomings of the presently known configurations by providing novel soluble polypeptides and polynucleotides encoding thereof, which can be used in the diagnosis and treatment of a wide range of diseases.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the

description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

In the drawings:

FIGs. 1a-b present the nucleic acid sequence (Figure 1a) and amino acid sequence (Figure 1b) of the Met variant of the present invention (SEQ ID NO: 3 and 1, respectively).

FIG. 2 is a schematic illustration depicting a graphical viewer scheme presenting the new variant of Met (transcript_9) as compred to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 3 is an amino acid sequence alignment between wild-type c-Met protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 4 is a schematic illustration showing the protein domain structure of wild-type c-Met protein and the variant of the present invention (SEQ ID NO: 1). Unique region is indicated by U (SEQ ID NO: 2).

FIGs. 5a-b present the nucleic acid sequence (Figure 5a) and amino acid sequence (Figure 5b) of the IL-6 variant of the present invention (SEQ ID NO: 7 and 5, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 6 is a schematic illustration depicting a graphical viewer scheme presenting the new variant of IL-6 (transcript_6) as compred to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 7 is an amino acid sequence alignment between wild-type IL-6 protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 8 is a schematic illustration showing the protein domain structure of wild-type IL-6 protein and the variant of the present invention (SEQ ID NO: 5). Unique region is indicated by U (SEQ ID NO: 6).

FIGs. 9a-b present the nucleic acid sequence (Figure 9a) and amino acid sequence (Figure 9b) of the IL7 T7 variant of the present invention (SEQ ID NO: 11 and 9, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIGs. 9c-d present the nucleic acid sequence (Figure 9c) and amino acid sequence (Figure 9d) of the IL7 T8 variant of the present invention (SEQ ID NO: 15 and 13, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 10 is a schematic illustration depicting a graphical viewer scheme presenting the new variants of IL7 (Transcript_7 and Transcript_8) as compred to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIGs. 11a-b are amino acid sequence alignment between wild-type IL-7 protein and the protein variants (T7 and T8) of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 12 is a schematic illustration showing the protein domain structure of wild-type IL-7 protein and the variants of the present invention (SEQ ID NOs: 9 and 13). Unique regions are indicated by U (SEQ ID NO: 10 and 14).

FIGs. 13a-b present the nucleic acid sequence (Figure 13a) and amino acid sequence (Figure 13b) of the TNFR9 variant of the present invention (SEQ ID NO: 19

and 17, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 14 is a schematic illustration depicting a graphical viewer scheme presenting the new variant of TNFR9 (Transcript_4) as compred to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 15 is an amino acid sequence alignment between wild-type TNFR9 protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 16 is a schematic illustration showing the protein domain structure of wild-type TNFR9 protein and the variant of the present invention (SEQ ID NO: 17). Unique region is indicated by U (SEQ ID NO: 18).

FIGs. 17a-b present the nucleic acid sequence (Figure 17a) and amino acid sequence (Figure 17b) of the IL-4R T4 variant of the present invention (SEQ ID NO: 23 and 21, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 17c present the nucleic acid sequence of the IL-4R T11 variant of the present invention (SEQ ID NO: 27). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 18 present the amino acid sequence of the IL-4R T11 variant of the present invention (SEQ ID NO: 25). Unique sequence region is highlighted.

FIGs. 19a-b are amino acid sequence alignments between wild-type IL-4R protein and the protein variants of the present invention (Figure 19a - alignment of IL-4R-T4, and Figure 19b alignment of IL-4R-T11), as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 20 is a schematic illustration showing the protein domain structure of wild-type IL-4R protein and the variants of the present invention (SEQ ID NOs: 21 and 25). Unique regions are indicated by U (SEQ ID NOs: 22 and 26).

FIGs. 21a-b present the nucleic acid sequence (Figure 21a) and amino acid sequence (Figure 21b) of the TGR2 variant of the present invention (SEQ ID NO: 31 and 29, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 22 is a schematic illustration depicting a viewer scheme presenting the new variant of TGR2 (Transcript_7) as compred to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 23 is an amino acid sequence alignment between wild-type TGR2 protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 24 is a schematic illustration showing the protein domain structure of wild-type TGR2 protein and the variant of the present invention (SEQ ID NO: 29). Unique region is indicated by U (SEQ ID NO: 30).

FIGs. 25a-b present the nucleic acid sequence (Figure 25a) and amino acid sequence (Figure 25b) of the ITAV variant of the present invention (SEQ ID NO: 35 and 33, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 26 is a schematic illustration depicting a viewer scheme presenting the new variant of ITAV (Transcipt_3) as compred to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation;

grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 27 is an amino acid sequence alignment between wild-type ITAV protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 28 is a schematic illustration showing the protein domain structure of wild-type ITAV protein and the variant of the present invention (SEQ ID NO: 33). Unique region is indicated by U (SEQ ID NO: 34).

FIGs. 29a-b present the nucleic acid sequence (Figure 29a) and amino acid sequence (Figure 29b) of the IL-10-R-β variant of the present invention (SEQ ID NO: 39 and 37, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 30 is a schematic illustration depicting the viewer scheme presenting the new variant of IL-10-R-β (Transcript_1) as compred to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 31 is an amino acid sequence alignment between wild-type IL-10-R-β protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap.

FIG. 32 is a schematic illustration showing the protein domain structure of wild-type IL-10-R-β protein and the variant of the present invention (SEQ ID NO: 37). Unique region is indicated by U (SEQ ID NO: 38).

FIGs. 33a-b present the nucleic acid sequence (Figure 33a) and amino acid sequence (Figure 33b) of the INR1 variant of the present invention (SEQ ID NO: 43 and 41, respectively). Start and stop codons are highlighted. Unique sequence region is highlighted.

FIG. 34 is a schematic illustration depicting a viewer scheme presenting the new variant of INR1 (Transcript_11) as compred to the wild type mRNA. The ESTs supporting the new variant are indicated. Transcript indicated as "0" represents known mRNA. The color code is as follows: red= genomic DNA; pink= refseq mRNA; light blue= known genbank mRNAs; purple=ESTs aligned in the same directinality as their annotation; black= ESTs aligned in the opposite directinality to their annotation; grey= ESTs without direction annotation; dark blue= predicted transcripts; turquoise = predicted polypeptide.

FIG. 35 is an amino acid sequence alignment between wild-type INR1 protein and the protein variant of the present invention, as determined using the Smith and Waterman model query db, with the following parameters: -mode=qglobal -onestrand -gapext=0 -matrix=identity -out=g -gapop=40 -dfmt=fastap, FIG. 36 is a schematic illustration showing the protein domain structure of wild-type INR1 protein and the variant of the present invention (SEQ ID NO: 41). Unique region is indicated by U (SEQ ID NO: 42).

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of novel soluble polypeptides and polynucleotides encoding same, which can be used for the diagnosis and treatment of a wide range of diseases, such as cancer and inflammatory diseases.

The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

Extracellular proteins including receptors and their corresponding ligands play active roles in the formation, differentiation and maintenance of multicellular organisms. Any fate of an individual cell including proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often

transmitted by secreted polypeptides such as, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones, which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides are normally processed by the cellular secretory pathway to reach their site of action in the extracellular environment.

Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors. Most protein drugs available at present, such as thrombolytic polynucleotide or polypeptide sequences of this aspect of the present invention, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins. Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic polynucleotide or polypeptide sequences of this aspect of the present invention. For example, receptor immunoadhesins, for instance, can be employed as therapeutic polynucleotide or polypeptide sequences of this aspect of the present invention to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.

For these reasons, efforts are being undertaken by both industry and academia to identify novel, native, secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for such proteins. Examples of such screening methods and techniques are described in, for example, Klein et al., Proc. Natl. Acad. Sci. 93:7108-7113 (1996); U.S. Pat. No. 5,536,637

The present inventors have previously designed algorithms which allow for the mass prediction of yet unknown gene products and for annotating same [see US patent No: 6,625,545; U.S. Pat. Appl. No. 10/426,002; a U.S. patent application entitled METHODS AND SYSTEMS FOR ANNOTATING BIOMOLECULAR SEQUENCES (Attorney Docket No. 26940), filed concurrently herewith, assigned to the same assignee hereof and contains subject matter related, in certain respects, to the subject matter of the instant application, the teachings of all of which are incorporated herein by reference; and Example 1 of the Examples section which follows].

While applying the above-mentioned algorithms, the present inventors uncovered novel naturally occurring variants of extracellular gene products, which, as

is described in the Examples section which follows, play pivotal roles in disease onset and progression. As such these variants can be used to design therapeutic and diagnostic tools for a wide range of diseases.

Met splice variant

According to one aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

As used herein the phrase "an isolated polynucleotide" refers to a single or double stranded nucleic acid sequences which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence and/or a composite polynucleotide sequences (e.g., a combination of the above).

As used herein the phrase "complementary polynucleotide sequence" refers to a sequence, which results from reverse transcription of messenger RNA using a reverse transcriptase or any other RNA dependent DNA polymerase. Such a sequence can be subsequently amplified *in vivo* or *in vitro* using a DNA dependent DNA polymerase.

As used herein the phrase "genomic polynucleotide sequence" refers to a sequence derived (isolated) from a chromosome and thus it represents a contiguous portion of a chromosome.

As used herein the phrase "composite polynucleotide sequence" refers to a sequence, which is at least partially complementary and at least partially genomic. A composite sequence can include some exonal sequences required to encode the polypeptide of the present invention, as well as some intronic sequences interposing therebetween. The intronic sequences can be of any source, including of other genes, and typically will include conserved splicing signal sequences. Such intronic sequences may further include cis acting expression regulatory elements.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 3 or 4.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of a Met gene (Swissprot Locus No. : MET_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the Met polypeptides of the present invention. Examples include but are not limited to ligand binding, antibody specific recognition, inhibition of cell-proliferation, scattering, angiogenesis, motility, morphogenesis and/or invasion (see Example 2 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 1 or 2.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 3 or 4 under moderate to stringent hybridization conditions.

Moderate to stringent hybridization conditions are characterized by a hybridization solution such as containing 10 % dextrane sulfate, 1 M NaCl, 1 % SDS and 5 x 10^6 cpm ^{32}P labeled probe, at 65 °C, with a final wash solution of 0.2 x SSC and 0.1 % SDS and final wash at 65°C and whereas moderate hybridization is effected using a hybridization solution containing 10 % dextrane sulfate, 1 M NaCl, 1 % SDS and 5 x 10^6 cpm ^{32}P labeled probe, at 65 °C, with a final wash solution of 1 x SSC and 0.1 % SDS and final wash at 50 °C.

The present invention also encompasses novel polypeptides (e.g., of the Met gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 1 or 2. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 1 or 2. Finally, the present invention also encompasses fragments of the above

described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 2 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "Met-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular domains while retain the extracellular region of Met (i.e., HGF binding site) and therefore are likely to compete with HGF binding to the functional, membrane bound, Met receptor and as a consequence block Met activation and signaling pathway.

The above-mentioned "Met-related disease" refers to a disease in which Met-activity and/or expression contribute to disease onset and/or progression. Examples of Met-related diseases include, but are not limited to, cancer, such as, hereditary and sporadic papillary renal carcinoma, breast cancer, ovarian cancer, childhood hepatocellular carcinoma, metastatic head and neck squamous cell carcinomas, lung cancer (e.g., non-small cell lung cancer, small cell lung cancer), prostate cancer, pancreatic cancer and gastric cancer, and other diseases such as diabetic retinopathy.

It will be appreciated that the polypeptides of this aspect of the present invention may also have agonistic properties. These include increasing the stability of Met-ligand (e.g., HFG), protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof). As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which Met plays a favorable role. Examples include, but are not limited to, regenerative processes such as wound healing and conditions, which require enhanced angiogenesis such as atherosclerotic diseases, ischemic conditions and diabetes. As mentioned the Met ligand is the hepatocyte growth factor, suggesting that the biomolecular sequences of this aspect of the present invention may have hepatoprotective properties and therefore may be used to diseases of the liver such as hepatic cirrhosis and hepatic dysfunction.

Thus, the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of this aspect of the present invention, which are capable of upregulating expression of the

polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

IL-6 splice variant

According to another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 7 or 8.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of an IL-6 gene (Swissprot Locus No. IL6_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the IL-6 polypeptides of the present invention. Examples include but are not limited antibody specific recognition and inhibition of IL-6 binding to the receptor (see Example 3 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 5 or 6.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 7 or 8 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., products of the IL-6 gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 5 or 6. The present invention also

encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 5 or 6. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 3 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "IL-6-related diseases", since, without being bound by theory, the IL-6 splice variant of this aspect of the present invention (SEQ ID NO: 5), contains the N-terminal 157 amino acids of wild-type IL-6, while lacks the last 50 amino acids of the protein, and as such may serve as an antagonist of IL-6 by several mechanisms. For example, this polypeptide variant can exhibit binding only to IL-6Rα, and no, or reduced binding to gp130, the second IL-6 receptor subunit. Since gp130 is the signaling subunit of the IL-6R complex, IL-6 splice variant of this aspect of the present invention, will not be able to activate the receptor. Thus it might serve as an antagonist of IL-6 signaling by binding the IL-6 receptor without activating it.

The above-mentioned "IL-6-related disease" refers to a disease in which IL-6-activity and/or expression contributes to disease onset and/or progression. Examples include, but are not limited to, inflammatory, autoimmune, and malignant diseases, such as, rheumatoid arthritis (RA), Castleman's disease, Crohn's disease, multiple myeloma/plasmacytoma, mesangial proliferative glomerulonephritis, psoriasis and Kaposi's sarcoma.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

IL-7 splice variants

According to yet another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 9 or 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 11, 12, 15 or 16.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of an IL-7 gene (Swissprot Locus No. IL7_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the IL-7 polypeptides of the present invention. Examples include but are not limited to, antibody specific recognition, inhibition of IL-7 binding to the receptor, enhancement of anti-tumor immunogenic reaction, reduction of tumor-induced suppression of immunogenic reaction, inhibition of cell proliferation (e.g., B-cells, see Example 4 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 9, 10, 13 or 14.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 11, 12, 15 or 16 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the IL-7 gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 9, 10, 13 or 14. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50

%, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 9, 10, 13 or 14. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 4 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "IL-7-related diseases", since, without being bound by theory, they may bing only one IL-7 receptor subuit to thereby produce dysfunctional ligand-receptor complexes.

The above-mentioned "IL-7-related disease" refers to a disease in which IL-7-activity and/or expression contributes to disease onset and/or progression. Examples of IL-7-related diseases include, but are not limited to cancer, such as acute and chronic lymphocytic leukemia, acute myelogenous leukemia, Sezary's syndome, Burkitt's lymphoma and Hodgkin's disease.

It will be appreciated that the polypeptides of this aspect of the present invention may also have agonistic properties, such as by binding to the IL-7 receptor with enhanced affinity as compared to the wild-type IL-7. As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which IL-7 plays a favorable role. Examples include, but are not limited to, cancer, such as melanoma, renal and colorectal cancer, in which IL-7 plays a therapeutic role by eliciting anti-tumor immunogenic responses. Furthermore, it is well established that IL-7 controls the growth and proliferation of immature B-cells and can stimulate the development of bone marrow cells into T-cells and B-cell precursors. Thus the polypeptides of this aspect of the present invention may be used establish a spectrum of lymphoid cell types following radiotherapy or chemotherapy.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

Tumor necrosis factor receptor 9 (TNR-9)/4-1BBR splice variant

According to still another aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 19 or 20.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of a TNR9 gene (Swissprot Locus No. TNR9_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the TNFR9 polypeptides of the present invention. Examples include but are not limited to 4-1BB binding, antibody specific recognition, inhibition of IL-2 production, cell-proliferation and differentiation, clonal expansion and survival of CD38+ cells, signaling (see Example 5 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 17 or 18.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 19 or 20 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the TNR9 gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 17 or 18. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %,

at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 17 or 18. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 5 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "TNR9-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular domains while retain the extracellular region of TNR9 and therefore are likely to compete with 4-1BBL binding to the functional, membrane bound, TNR9 receptor and as a consequence block TNR9 activation and signaling pathway.

The above-mentioned "TNR9-related disease" refers to a disease in which TNR9-activity and/or expression contribute to disease onset and/or progression. Examples of TNR9-related diseases include, but are not limited to, myocardial inflammation, induced by coxackievirus B3, herpetic stromal keratitis (HSK) induced by HSV-1 and inflammatory diseases, such as multiple sclerosis and Crohn's disease as well as prevention of graft rejection and graft-versus-host disease.

It will be appreciated that the polypeptides of this aspect of the present invention may also have agonistic properties. These include increasing the stability of 4-1BB-ligand, protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof). As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which TNR9 plays a favorable role. Examples include, but are not limited to, cancer, viral infections and autoimuune diseases such as spontaneous systemic lupos erythematosus (SLE), RA, and ulceratice colitis.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

Interleukin 4 receptor (IL4R) splice variants

According to an additional aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 21 or 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 23, 24, 27 or 28.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of an IL-4 receptor gene (Swissprot Locus No. IL4R_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the IL-4R polypeptides of the present invention. Examples include but are not limited to ligand binding, antibody specific recognition and inhibition of IL-4 signaling (see Example 6 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 21, 22, 25 or 26.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 23, 24, 27 or 28 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the IL-4R gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 21, 22, 25 or 26. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %,

at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 21, 22, 25 or 26. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 6 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "IL-4R-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular domains, while still retain a complete CRIA domain of the extracellular region of IL-4R and therefore are likely to compete with IL-4 binding to the functional, membrane-bound, IL-4 receptor and as a consequence block IL-4 activation and signaling pathway.

The above-mentioned "IL-4R-related disease" refers to a disease in which IL-4R-activity and/or expression contribute to disease onset and/or progression. Examples of IL-4R-related diseases include, but are not limited to, asthma and allergic disorders, autoimmune diseases, such as lupus, transplant rejection and graft-versus-host diseases

It will be appreciated that the polypeptides of this aspect of the present invention may also have agonistic properties. These include increasing the stability of IL-4R-ligand (e.g., IL-4), protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof). As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which IL-4 plays a favorable role. Examples include, but are not limited to, cancer, such as, leukaemia, kaposi's sarcoma, lymphoma and non-small cell lung cancer, anaemia and rheumatoid arthritis.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow. Such polynucleotide or polypeptide sequences of this aspect of the present invention and administration thereof are further described hereinbelow.

Transforming growth factor β receptor type II (TGF-β-R/TGR2) splice variant

According to yet an additional aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 31 or 32.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of a TGR2 gene (Swissprot Locus No. TGR2_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the TGR2 polypeptides of the present invention. Examples include but are not limited to ligand binding, antibody specific recognition, inhibition of TGR2 signaling such as through the type I receptor and SMAD proteins or through PI3K and p70S6K, tumor suppression and tumor promotion (see Example 7 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 29 or 30.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 31 or 32 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the TGR2 gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 29 or 30. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50

%, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 29 or 30. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 7 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "TGR2-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular domains while retain the extracellular region of TGR2 and therefore are likely to compete with TGF-β binding to the functional, membrane bound, TGR2 receptor and as a consequence block TGR2 activation and signaling pathway.

The above-mentioned "TGR2-related disease" refers to a disease in which TGR2-activity and/or expression contribute to disease onset and/or progression. Examples of TGR2-related diseases include, but are not limited to, cancer, such as glioblastoma where TGR2 acts as a tumor promoter (see Example 6 of the Examples section), organ remodeling diseases and fibrotic diseases, such as chronic renal disease or pulmonary fibrosis, scleroderma and eye scarring following glaucoma surgery.

It will be appreciated that the polypeptides of this aspect of the present invention may also have agonistic properties. These include increasing the stability of TGF β, protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof). As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which TGR2 plays a favorable role, such as in cancer onset where TGR2 plays a protective role, atherosclerosis and other injury-induced hyperplasias such as restenosis, rhematoid arthritis, psoriasis, multiple sclerosis, osteoporesis and articular cartilage damage, in which tissue repair is achieved by promoting TGFb2 Activity. The polypeptides of this aspect of the present invention may also be used for wound healing.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of polynucleotide or polypeptide sequences of

this aspect of the present invention, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof, as is further described hereinbelow.

Integrin-α-V (ITAV) splice variants

According to still an additional aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 33 or 34.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of a ITAV gene (Swissprot Locus No. ITAV_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the ITAV polypeptides of the present invention. Examples include but are not limited to ligand (e.g., extracellular matrix proteins, fibronectin) or receptor-partner binding , antibody specific recognition, inhibition of cell survival, proliferation and migration (see Example 8 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 33 or 34..

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 35 or 36 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the ITAV gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel

polypeptides are set forth in SEQ ID NO: 33 or 34. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 33 or 34. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 8 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "ITAV-related diseases", since, without being bound by theory, they are devoid of a transmembrane and intracellular domains while retain the extracellular region of ITAV and therefore are likely to compete with ligand binding to the functional, membrane bound, ITAV receptor and as a consequence block ITAV activation and signaling pathway. Alternatively these polypeptides can dimerize with a second receptor subunit to produce a dysfunctional heterodimeric complexes thereby blocking signaling.

The above-mentioned "ITAV-related disease" refers to a disease in which ITAV-activity and/or expression contributes to disease onset and/or progression. Examples of ITAV-related diseases include, but are not limited to, ocular diseases(e.g., persistent corneal epithelial defect), cancer (e.g., breast cancer, renal cancer, cervical cancer, colon cancer, prostate cancer, bladder cancer, lung cancer and melanoma), cardiovascular diseases (e.g., stroke and heart failure, atherosclerosis, restenosis, ischemia and reperfusion injury), immunological related diseases (e.g., immunodeficiency, allergies, asthma, psoriasis, RA and inflammatory bowl diseases e.g., Chrone's disease), metabolism related diseases, such as diabetes and diabetes related retinopathy, osteoporosis, sepsis and wound healing.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of agents, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof. Such agents and administration thereof are further described hereinbelow.

Interleukin-10 receptor β chain (IL-10-R β) splice variant

According to a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 39.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of an IL-10-Rβ gene (Swissprot Locus No. I10S_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the IL-10-Rβ polypeptides of the present invention. Examples include, but are not limited to, ligand binding, antibody specific recognition, regulation of IL-10R signaling (e.g., STAT activation) and regulation of immune responses (see Example 9 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 37 or 38.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 39 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the IL-10-Rβ gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 37 or 38. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %,

at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO: 37 or 38. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 9 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "IL-10-Rβ-related diseases", due to their enhanced agonistic properties. These include increasing the stability of the ligand (e.g., IL-10), protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof) to thereby increase the biological effects of the IL-10 signaling cascade. As such, the biomolecular sequences of this aspect of the present invention may be used to treat conditions or diseases in which IL-10R signaling plays a favorable role. Examples include, but are not limited to, inflammatory diseases, such as, psoriasis, inflammatory bowel diseases, Crohn's disease, colitis ulcerative, multiple sclerosis, RA, transplant rejection, allergic contact dermatitis, hepatitis C infection; HIV infection and atherosclerosis.

It will be appreciated, however, that since the polypeptide seuqneces of this aspect of the present invention are devoid of a transmembrane and intracellular domains while retain the extracellular region of IL-10-Rβ (i.e., IL-10 binding site), they are most likely to compete with IL-10 binding to the functional, membrane bound, IL-10-Rβ receptor and as a consequence block IL-10R activation and signaling pathway. Thus, due to their predicted antagonistic effects, the biomolecular sequences of this aspect of the present invention may be used to treat diseases which depend on IL-10R (i.e., activity and/or expression) for their onset or progression. Examples include, but are not limited to, cancer, such as lymphoma, melanoma and carcinoma , and infection with visceral leishmaniasis.

Thus, this aspect of the present invention envisages treatment of the above-mentioned diseases by the provision of agents, which are capable of upregulating expression of the polypeptides of the present invention in a subject in need thereof. Such agents and administration thereof are further described hereinbelow.

Interferon-α/β-receptor-1-INR1 splice variant

According to yet a further aspect of the present invention there is provided an isolated polynucleotide comprising a nucleic acid sequence encoding at least an active portion of a polypeptide having an amino acid sequence, which is at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, %, at least 85 %, %, at least 90 %, at least 95 % or more, say 100 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

According to one embodiment of this aspect of the present invention the nucleic acid sequence is as set forth in SEQ ID NO: 43 or 40.

Preferably, the polypeptide of this aspect of the present invention is at least an active portion of a naturally occurring protein product of an INR1 gene (Swissprot Locus No. INR1_HUMAN) and homologues thereof.

As used hereinabove the phrase "active portion" refers to an amino acid sequence portion which is capable of displaying one or more functions of the INR1 polypeptides of the present invention. Examples include but are not limited to ligand binding, antibody specific recognition, modulation of immune responses (see Example 10 of the Examples section).

Thus, the polynucleotide according to this aspect of the present invention preferably encodes a polypeptide, which is as set forth in SEQ ID NO: 41 or 42.

The isolated polynucleotides of this aspect of the present invention can be qualified using a hybridization assay by incubating the isolated polynucleotides described above with a probe having the sequence set forth in SEQ ID NO: 43 or 40 under the above-described moderate to stringent hybridization conditions.

The present invention also encompasses novel polypeptides (e.g., of the INR1 gene) or portions thereof, which are encoded by the isolated polynucleotide and respective nucleic acid fragments thereof described hereinabove.

Thus, the present invention also encompasses polypeptides encoded by the novel nucleic acids of the present invention. The amino acid sequences of these novel polypeptides are set forth in SEQ ID NO: 41 or 42. The present invention also encompasses homologues of these polypeptides, such homologues can be at least 50 %, at least 55 %, at least 60%, at least 65 %, at least 70 %, at least 73 %, at least 77 %, at least 80 %, at least 85 %, at least 95 % or more say 100 % identical to SEQ ID NO:

41 or 42. Finally, the present invention also encompasses fragments of the above described polypeptides and polypeptides having mutations, such as deletions, insertions or substitutions of one or more amino acids, either naturally occurring or man induced, either randomly or in a targeted fashion.

As is mentioned hereinabove and in Example 10 of the Examples section which follows, the biomolecular sequences of this aspect of the present invention may be used as valuable therapeutic tools in the treatment of "INR1-related diseases", due to their enhanced agonistic properties. These include increasing the stability of the ligand (e.g., interferon), protection from proteolysis and modification of the pharmacokinetic properties of the ligand (i.e., increasing the half-life of the ligand, while decreasing the clearance thereof).

Thus, the biomolecular sequences may be used to treat a number of diseases in which INR1 plays a favorable role. Examples of such diseases include, but are not limited to, cancer, such as, solid tumors (e.g., glioblastoma, renal cell carcinoma, melanoma) and hematological malignancies [e.g., chronic myelogenous leukemia (CML), multiple myeloma, non-Hodgkin's lymphoma and hairy cell leukemia], viral infections (e.g., hepatitis B/C, herpes and human papilloma virus) and autoimmune diseases such as multiple sclerosis.

As mentioned hereinabove, the polypeptide sequences of the present invention can be used in a number of therapeutic applications. In such applications it is highly desirable to employ the minimal and most efficacious peptide regions, which still exert inhibitory function. Identification of such peptide regions can be effected using various approaches, including, for example, display techniques.

Thus, according to still a further aspect of the present invention there is provided a display library comprising a plurality of display vehicles (such as phages, viruses or bacteria) each displaying at least 6, at least 7, at least 8, at least 9, at least 10, 10-15, 12-17, 15-20, 15-30 or 20-50 consecutive amino acids derived from the polypeptide sequences of the present invention.

Methods of constructing such display libraries are well known in the art. Such methods are described in, for example, Young AC, *et al.*, "The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes" J Mol Biol 1997 Dec 12;274(4):622-34; Giebel

LB *et al.* "Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities" Biochemistry 1995 Nov 28;34(47):15430-5; Davies EL *et al.*, "Selection of specific phage-display antibodies using libraries derived from chicken immunoglobulin genes" J Immunol Methods 1995 Oct 12;186(1):125-35; Jones C RT al. "Current trends in molecular recognition and bioseparation" J Chromatogr A 1995 Jul 14;707(1):3-22; Deng SJ *et al.* "Basis for selection of improved carbohydrate-binding single-chain antibodies from synthetic gene libraries" Proc Natl Acad Sci U S A 1995 May 23;92(11):4992-6; and Deng SJ *et al.* "Selection of antibody single-chain variable fragments with improved carbohydrate binding by phage display" J Biol Chem 1994 Apr 1;269(13):9533-8, which are incorporated herein by reference.

Peptide sequences which exhibit high therapeutic activity, such as by competing with wild type signaling proteins of the same signaling pathway, can be also uncovered using computational biology. Software programs useful for displaying three-dimensional structural models, such as RIBBONS (Carson, M., 1997. Methods in Enzymology 277, 25), O (Jones, TA. *et al.*, 1991. Acta Crystallogr. A47, 110), DINO (DINO: Visualizing Structural Biology (2001) http://www.dino3d.org); and QUANTA, INSIGHT, SYBYL, MACROMODE, ICM, MOLMOL, RASMOL and GRASP (reviewed in Kraulis, J., 1991. Appl Crystallogr. 24, 946) can be utilized to model interactions between the polypeptides of the present invention and prospective peptide sequences to thereby identify peptides which display the highest probability of binding for example to a respective ligand (e.g., IL-10). Computational modeling of protein-peptide interactions has been successfully used in rational drug design, for further detail, see Lam et al., 1994. Science 263, 380; Wlodawer et al., 1993. Ann Rev Biochem. 62, 543; Appelt, 1993. Perspectives in Drug Discovery and Design 1, 23; Erickson, 1993. Perspectives in Drug Discovery and Design 1, 109, and Mauro MJ. et al., 2002. J Clin Oncol. 20, 325–34.

It will be appreciated that peptides identified according to the teachings of the present invention may be degradation products, synthetic peptides or recombinant peptides as well as peptidomimetics, typically, synthetic peptides and peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into cells. Such modifications include, but are not limited to N terminus modification, C

terminus modification, peptide bond modification, including, but not limited to, CH2-NH, CH2-S, CH2-S=O, O=C-NH, CH2-O, CH2-CH2, S=C-NH, CH=CH or CF=CH, backbone modifications, and residue modification. Methods for preparing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, C.A. Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992), which is incorporated by reference as if fully set forth herein. Further details in this respect are provided hereinunder.

Peptide bonds (-CO-NH-) within the peptide may be substituted, for example, by N-methylated bonds (-N(CH3)-CO-), ester bonds (-C(R)H-C-O-O-C(R)-N-), ketomethylen bonds (-CO-CH2-), α-aza bonds (-NH-N(R)-CO-), wherein R is any alkyl, e.g., methyl, carba bonds (-CH2-NH-), hydroxyethylene bonds (-CH(OH)-CH2-), thioamide bonds (-CS-NH-), olefinic double bonds (-CH=CH-), retro amide bonds (-NH-CO-), peptide derivatives (-N(R)-CH2-CO-), wherein R is the "normal" side chain, naturally presented on the carbon atom.

These modifications can occur at any of the bonds along the peptide chain and even at several (2-3) at the same time.

Natural aromatic amino acids, Trp, Tyr and Phe, may be substituted for synthetic non-natural acid such as Phenylglycine, TIC, naphthylelanine (Nol), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr.

In addition to the above, the peptides of the present invention may also include one or more modified amino acids or one or more non-amino acid monomers (e.g. fatty acids, complex carbohydrates etc).

As used herein in the specification and in the claims section below the term "amino acid" or "amino acids" is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally *in vivo*, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acids including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. Furthermore, the term "amino acid" includes both D- and L-amino acids.

Tables 1 and 2 below list naturally occurring amino acids (Table 1) and non-conventional or modified amino acids (Table 2) which can be used with the present invention.

Table 1

Amino Acid	*hree-Letter Abbreviation*	*One-letter Symbol*
alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic Acid	Glu	E
glycine	Gly	G
Histidine	His	H
isoleucine	Iie	I
leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
tryptophan	Trp	W
tyrosine	Tyr	Y
Valine	Val	V
Any amino acid as above	Xaa	X

Table 2

Non-conventional amino acid	Code	Non-conventional amino acid	Code
α-aminobutyric acid	Abu	L-N-methylalanine	Nmala
α-amino-α-methylbutyrate	Mgabu	L-N-methylarginine	Nmarg
aminocyclopropane-carboxylate	Cpro	L-N-methylasparagine	Nmasn
		L-N-methylaspartic acid	Nmasp
aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
aminonorbornyl-carboxylate	Norb	L-N-methylglutamine	Nmgin
		L-N-methylglutamic acid	Nmglu
cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
cyclopentylalanine	Cpen	L-N-methylisolleucine	Nmile
D-alanine	Dal	L-N-methylleucine	Nmleu
D-arginine	Darg	L-N-methyllysine	Nmlys
D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
D-isoleucine	Dile	L-N-methylproline	Nmpro
D-leucine	Dleu	L-N-methylserine	Nmser
D-lysine	Dlys	L-N-methylthreonine	Nmthr
D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
D-phenylalanine	Dphe	L-N-methylvaline	Nmval
D-proline	Dpro	L-N-methylethylglycine	Nmetg
D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
D-threonine	Dthr	L-norleucine	Nle
D-tryptophan	Dtrp	L-norvaline	Nva
D-tyrosine	Dtyr	α-methyl-aminoisobutyrate	Maib
D-valine	Dval	α-methyl-γ-aminobutyrate	Mgabu
D-α-methylalanine	Dmala	α-methylcyclohexylalanine	Mchexa
D-α-methylarginine	Dmarg	α-methylcyclopentylalanine	Mcpen
D-α-methylasparagine	Dmasn	α-methyl-α-napthylalanine	Manap

D-α-methylaspartate	Dmasp	α- methylpenicillamine	Mpen
D-α-methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
D-α-methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
D-α-methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
D-α-methylisoleucine	Dmile	N- amino-α-methylbutyrate	Nmaabu
D-α-methylleucine	Dmleu	α-napthylalanine	Anap
D-α-methyllysine	Dmlys	N-benzylglycine	Nphe
D-α-methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
D-α-methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
D-α-methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
D-α-methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
D-α-methylserine	Dmser	N-cyclobutylglycine	Ncbut
D-α-methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
D-α-methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
D-α-methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
D-α-methylvaline	Dmval	N-cyclododeclglycine	Ncdod
D-α-methylalnine	Dnmala	N-cyclooctylglycine	Ncoct
D-α-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
D-α-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
D-α-methylasparatate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
D-α-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
D-N-methylleucine	Dnmleu	N-(3-indolylyethyl) glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl-γ-aminobutyrate	Nmgabu
N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nva
D-N-methyltyrosine	Dnmtyr	N-methyla-napthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
γ-aminobutyric acid	Gabu	N-(*p*-hydroxyphenyl)glycine	Nhtyr
L-*t*-butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe	L-α-methylalanine	Mala
L-α-methylarginine	Marg	L-α-methylasparagine	Masn
L-α-methylaspartate	Masp	L-α-methyl-*t*-butylglycine	Mtbug
L-α-methylcysteine	Mcys	L-methylethylglycine	Metg
L-α-methylglutamine	Mgln	L-α-methylglutamate	Mglu
L-α-methylhistidine	Mhis	L-α-methylhomo phenylalanine	Mhphe
L-α-methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
D-N-methyllysine	Dnmlys	N-methyl-γ-aminobutyrate	Nmgabu
N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe

N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
D-N-methyltyrosine	Dnmtyr	N-methyla-napthylalanine	Nmanap
D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
γ-aminobutyric acid	Gabu	N-(*p*-hydroxyphenyl)glycine	Nhtyr
L-*t*-butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
L-ethylglycine	Etg	penicillamine	Pen
L-homophenylalanine	Hphe	L-α-methylalanine	Mala
L-α-methylarginine	Marg	L-α-methylasparagine	Masn
L-α-methylaspartate	Masp	L-α-methyl-*t*-butylglycine	Mtbug
L-α-methylcysteine	Mcys	L-methylethylglycine	Metg
L-α-methylglutamine	Mgln	L-α-methylglutamate	Mglu
L-α-methylhistidine	Mhis	L-α-methylhomophenylalanine	Mhphe
L-α-methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
L-α-methylleucine	Mleu	L-α-methyllysine	Mlys
L-α-methylmethionine	Mmet	L-α-methylnorleucine	Mnle
L-α-methylnorvaline	Mnva	L-α-methylornithine	Morn
L-α-methylphenylalanine	Mphe	L-α-methylproline	Mpro
L-α-methylserine	mser	L-α-methylthreonine	Mthr
L-α-methylvaline	Mtrp	L-α-methyltyrosine	Mtyr
L-α-methylleucine	Mval Nnbhm	L-N-methylhomophenylalanine	Nmhphe
N-(N-(2,2-diphenylethyl)		N-(N-(3,3-diphenylpropyl)	
carbamylmethyl-glycine	Nnbhm	carbamylmethyl(1)glycine	Nnbhe
1-carboxy-1-(2,2-diphenyl ethylamino) cyclopropane	Nmbc		

Table 2 Cont.

Since the peptides of the present invention are preferably utilized in therapeutics which require the peptides to be in soluble form, the peptides of the present invention preferably include one or more non-natural or natural polar amino acids, including but not limited to serine and threonine which are capable of increasing peptide solubility due to their hydroxyl-containing side chain.

The peptides of the present invention are preferably utilized in a linear form, although it will be appreciated that in cases where cyclicization does not severely interfere with peptide characteristics, cyclic forms of the peptide can also be utilized.

The peptides of present invention can be biochemically synthesized such as by using standard solid phase techniques. These methods include exclusive solid phase synthesis, partial solid phase synthesis methods, fragment condensation, classical solution synthesis. These methods are preferably used when the peptide is relatively

short (i.e., 10 kDa) and/or when it cannot be produced by recombinant techniques (i.e., not encoded by a nucleic acid sequence) and therefore involves different chemistry.

Solid phase peptide synthesis procedures are well known in the art and further described by John Morrow Stewart and Janis Dillaha Young, Solid Phase Peptide Syntheses (2nd Ed., Pierce Chemical Company, 1984).

Synthetic peptides can be purified by preparative high performance liquid chromatography [Creighton T. (1983) Proteins, structures and molecular principles. WH Freeman and Co. N.Y.] and the composition of which can be confirmed via amino acid sequencing.

In cases where large amounts of the peptides of the present invention are desired, the peptides of the present invention can be generated using recombinant techniques such as described by Bitter et al., (1987) Methods in Enzymol. 153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89, Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987) EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986) Mol. Cell. Biol. 6:559-565 and Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463.

Briefly, polynucleotides encoding the polypeptides of the present invention are first cloned into an appropriate nucleic acid construct (i.e., vector).

To enable cellular expression of the proteins of the present invention, the nucleic acid construct of the present invention further includes at least one cis acting regulatory element. As used herein, the phrase "cis acting regulatory element" refers to a polynucleotide sequence, preferably a promoter, which binds a trans acting regulator and regulates the transcription of a coding sequence located downstream thereto.

Any available promoter can be used by the present methodology dependent on the host cell (e.g., eukaryotic, prokaryotic).

The nucleic acid construct of the present invention can further include an enhancer, which can be adjacent or distant to the promoter sequence and can function in up regulating the transcription therefrom.

The constructs of the present methodology preferably further include an appropriate selectable marker and/or an origin of replication. Preferably, the construct utilized is a shuttle vector, which can propagate both in *E. coli* (wherein the

construct comprises an appropriate selectable marker and origin of replication) and be compatible for propagation in cells, or integration in a gene and a tissue of choice. The construct according to the present invention can be, for example, a plasmid, a bacmid, a phagemid, a cosmid, a phage, a virus or an artificial chromosome.

Other then containing the necessary elements for the transcription and translation of the inserted coding sequence, the expression construct of the present invention can also include sequences engineered to enhance stability, production, purification, yield or toxicity of the expressed peptide. For example, the expression of a fusion protein or a cleavable fusion protein comprising Met variant of the present invention and a heterologous protein can be engineered. Such a fusion protein can be designed so that the fusion protein can be readily isolated by affinity chromatography; e.g., by immobilization on a column specific for the heterologous protein. Where a cleavage site is engineered between the Met moiety and the heterologous protein, the Met moiety can be released from the chromatographic column by treatment with an appropriate enzyme or agent that disrupts the cleavage site [e.g., see Booth et al. (1988) Immunol. Lett. 19:65-70; and Gardella et al., (1990) J. Biol. Chem. 265:15854-15859].

As mentioned hereinabove, a variety of prokaryotic or eukaryotic cells can be used as host-expression systems to express the polypeptides of the present invention. These include, but are not limited to, microorganisms, such as bacteria transformed with a recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vector containing the coding sequence; yeast transformed with recombinant yeast expression vectors containing the coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors, such as Ti plasmid, containing the coding sequence. Mammalian expression systems can also be used to express the polypeptides of the present invention.

Examples of bacterial constructs include the pET series of E. coli expression vectors [Studier et al. (1990) Methods in Enzymol. 185:60-89).

In yeast, a number of vectors containing constitutive or inducible promoters can be used, as disclosed in U.S. Pat. Application No: 5,932,447. Alternatively, vectors can be used which promote integration of foreign DNA sequences into the yeast chromosome.

In cases where plant expression vectors are used, the expression of the coding sequence can be driven by a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV [Brisson et al. (1984) Nature 310:511-514], or the coat protein promoter to TMV [Takamatsu et al. (1987) EMBO J. 6:307-311] can be used. Alternatively, plant promoters such as the small subunit of RUBISCO [Coruzzi et al. (1984) EMBO J. 3:1671-1680 and Brogli et al., (1984) Science 224:838-843] or heat shock promoters, e.g., soybean hsp17.5-E or hsp17.3-B [Gurley et al. (1986) Mol. Cell. Biol. 6:559-565] can be used. These constructs can be introduced into plant cells using Ti plasmid, Ri plasmid, plant viral vectors, direct DNA transformation, microinjection, electroporation and other techniques well known to the skilled artisan. See, for example, Weissbach & Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463.

Other expression systems such as insects and mammalian host cell systems which are well known in the art and are further described hereinbelow can also be used by the present invention.

Constructs encoding the polypeptides of the present invention are transformed into an appropriate host cell. Transformed cells are cultured under conditions, which allow for the expression of high amounts of recombinant polypeptide. Such conditions include, but are not limited to, media, bioreactor, temperature, pH and oxygen conditions that permit protein production. "Media" refers to any medium in which a cell is cultured to produce the recombinant polypeptide of the present invention. Such a medium typically includes an aqueous solution having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. Cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are well known to one of ordinary skill in the art.

Recovery of the recombinant polypeptide is effected following an appropriate time in culture. The phrase "recovering the recombinant polypeptide" refers to collecting the whole fermentation medium containing the polypeptide and need not imply additional steps of separation or purification. Not withstanding the above,

polypeptides of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization.

As mentioned hereinabove, the biomolecular sequences of the present invention can be used to treat subjects with the above-described diseases.

The subject according to the present invention is a mammal, preferably a human which is diagnosed with one of the diseases described hereinabove, or alternatively is predisposed to having one of the diseases described hereinabove.

As used herein the term "treating" refers to preventing, curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of the above-described diseases.

Treating, according to the present invention, can be effected by specifically upregulating the expression of at least one of the polypeptides of the present invention in the subject.

Upregulating expression of the polypeptides of the present invention in a subject may be effected via the administration of at least one of the exogenous polynucleotide sequences of the present invention (e.g., SEQ ID NOs: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39 or 43) ligated into a nucleic acid expression construct designed for expression of coding sequences in eukaryotic cells (e.g., mammalian cells). Accordingly, the exogenous polynucleotide sequence may be a DNA or RNA sequence encoding the variants of the present invention or active portions thereof.

It will be appreciated that the nucleic acid construct can be administered to the individual employing any suitable mode of administration, described hereinbelow (i.e., in-vivo gene therapy). Alternatively, the nucleic acid construct is introduced into a suitable cell via an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.) and an expression system as needed and then the modified cells are expanded in culture and returned to the individual (i.e., ex-vivo gene therapy).

Preferably, the promoter utilized by the nucleic acid construct of the present invention is active in the specific cell population transformed. Examples of cell type-specific and/or tissue-specific promoters include promoters, such as albumin that is

liver specific [Pinkert et al., (1987) Genes Dev. 1:268-277], lymphoid specific promoters [Calame et al., (1988) Adv. Immunol. 43:235-275]; in particular promoters of T-cell receptors [Winoto et al., (1989) EMBO J. 8:729-733] and immunoglobulins; [Banerji et al. (1983) Cell 33729-740], neuron-specific promoters such as the neurofilament promoter [Byrne et al. (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477], pancreas-specific promoters [Edlunch et al. (1985) Science 230:912-916] or mammary gland-specific promoters such as the milk whey promoter (U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166).

Examples of suitable constructs include, but are not limited to, pcDNA3, pcDNA3.1 (+/-), pGL3, PzeoSV2 (+/-), pDisplay, pEF/myc/cyto, pCMV/myc/cyto each of which is commercially available from Invitrogen Co. (www.invitrogen.com). Examples of retroviral vector and packaging systems are those sold by Clontech, San Diego, Calif., including Retro-X vectors pLNCX and pLXSN, which permit cloning into multiple cloning sites and the trasgene is transcribed from CMV promoter. Vectors derived from Mo-MuLV are also included such as pBabe, where the transgene will be transcribed from the 5'LTR promoter.

Currently preferred in vivo nucleic acid transfer techniques include transfection with viral or non-viral constructs, such as adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated virus (AAV) and lipid-based systems. Useful lipids for lipid-mediated transfer of the gene are, for example, DOTMA, DOPE, and DC-Chol [Tonkinson et al., Cancer Investigation, 14(1): 54-65 (1996)]. The most preferred constructs for use in gene therapy are viruses, most preferably adenoviruses, AAV, lentiviruses, or retroviruses. A viral construct such as a retroviral construct includes at least one transcriptional promoter/enhancer or locus-defining element(s), or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger. Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used, unless it is already present in the viral construct. In addition, such a construct typically includes a signal sequence for secretion of the peptide from a host cell in which it is placed. Preferably the signal sequence for this purpose is a mammalian signal sequence or the signal sequence of the polypeptide variants of the present invention. Optionally, the construct may also include a signal that directs

polyadenylation, as well as one or more restriction sites and a translation termination sequence. By way of example, such constructs will typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3' LTR or a portion thereof. Other vectors can be used that are non-viral, such as cationic lipids, polylysine, and dendrimers.

It will be appreciated that the present methodology may also be effected by specifically upregulating the expression of the splice variants of the present invention endogenously in the subject. Agents for upregulating endogenous expression of specific splice variants of a given gene include antisense oligonucleotides, which are directed at splice sites of interest, thereby altering the splicing pattern of the gene. This approach has been successfully used for shifting the balance of expression of the two isoforms of Bcl-x [Taylor (1999) Nat. Biotechnol. 17:1097-1100; and Mercatante (2001) J. Biol. Chem. 276:16411-16417]; IL-5R [Karras (2000) Mol. Pharmacol. 58:380-387]; and c-myc [Giles (1999) Antisense Acid Drug Dev. 9:213-220].

For example, interleukin 5 and its receptor play a critical role as regulators of hematopoiesis and as mediators in some inflammatory diseases such as allergy and asthma. Two alternatively spliced isoforms are generated from the IL-5R gene, which include (i.e., long form) or exclude (i.e., short form) exon 9. The long form encodes for the intact membrane-bound receptor, while the shorter form encodes for a secreted soluble non-functional receptor. Using 2'-O-MOE-oligonucleotides specific to regions of exon 9, Karras and co-workers (supra) were able to significantly decrease the expression of the wild type receptor and increase the expression of the shorter isoforms. Design and synthesis of oligonucleotides which can be used according to the present invention are described hereinbelow and by Sazani and Kole (2003) Progress in Moleclular and Subcellular Biology 31:217-239.

Alternatively or additionally, upregulation may be effected by administering to the subject at least one of the polypeptides of the present invention (e.g., recombinant or synthetic) or an active portion thereof, as described hereinabove. However, since the bioavailability of large polypeptides is relatively small due to high degradation rate and low penetration rate, administration of polypeptides is preferably confined to small peptide fragments (e.g., about 100 amino acids).

The agents of the present invention (e.g., polynucleotides, polypeptides, oligonucleotides) can be provided to the subject *per se*, or as part of a pharmaceutical composition where they are mixed with a pharmaceutically acceptable carrier.

As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

Herein the term "active ingredient" refers to the preparation accountable for the biological effect (e.g., polynucleotides, polypeptides, oligonucleotides of the present invention).

Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases. One of the ingredients included in the pharmaceutically acceptable carrier can be for example polyethylene glycol (PEG), a biocompatible polymer with a wide range of solubility in both organic and aqueous media (Mutter et al. (1979).

Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

Techniques for formulation and administration of drugs may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, inrtaperitoneal, intranasal, or intraocular injections. Alternately, one may administer a preparation in a local rather than systemic manner,

for example, via injection of the preparation directly into a specific region of a patient's body.

Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the active ingredients of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic,

talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical compositions, which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by nasal inhalation, the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The preparations described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame

oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

The preparation of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.

Determination of a therapeutically effective amount is well within the capability of those skilled in the art.

For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro assays. For example, a dose can be formulated in animal models and such information can be used to more accurately determine useful doses in humans.

Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures *in vitro*, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment

lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

Compositions including the preparation of the present invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

Pharmaceutical compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert.

It will be appreciated that treatment of the above-described diseases according to the present invention may be combined with other treatment methods known in the art (i.e., combination therapy). Thus, treatment of malignancies using the agents of the present invention may be combined with, for example, radiation therapy, antibody therapy and/or chemotherapy.

It will be appreciated that since abnormal expression (i.e., upregulation or downregulation as compared to normal state) of these biomolecular sequences may contribute to disease onset or progression or be present during the course of the disease, such biomolecular sequences can also be used as valuable diagnostic markers.

Thus, the present invention also envisages determining a level of a biomolecular sequence of the present invention (i.e., a polynucleotide or a polypeptide) in a biological sample obtained from the subject. Wherein the level determined can be correlated with predisposition to, or presence or absence of the

above-described corresponding disease, thereby diagnosing predisposition to, or presence of such disease in the subject.

As used herein the term "diagnosing" refers to classifying a disease or a symptom, determining a severity of the disease, monitoring disease progression and therapeutic treatment, forecasting an outcome of a disease and/or prospects of recovery.

As used herein, the term "level" refers to expression levels of RNA and/or protein or to DNA copy number of the variants of the present invention.

A level correlatable with predisposition to, or presence or absence of a disease can be a level of a variant of the present invention in a pathological sample which is different (i.e., increased or descreased) from the level of the same variant in a normal healthy sample obtained from a similar tissue or cellular origin.

As used herein "a biological sample" refers to a sample of tissue or fluid isolated from the subject, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs, and also samples of in vivo cell culture constituents.

Numerous well known tissue or fluid collection methods can be utilized to collect the biological sample from the subject in order to determine the level of DNA, RNA and/or polypeptide of the variants of the present invention in the subject.

Examples include, but are not limited to, fine needle biopsy, needle biopsy, core needle biopsy and surgical biopsy.

Regardless of the procedure employed, once a biopsy is obtained the level of the variants of the present invention can be determined and a diagnosis can thus be made.

Determining a level of the variants of the present invention can be effected using various biochemical and molecular approaches used in the art for determining gene amplification, and/or level of gene expression.

Determining the level of the variants of the present invention in normal tissues of the same origin is preferably effected along side to detect an elevated expression and/or amplification. Additionally or alternatively, determining the level of wild-type gene product (e.g., c-Met) is preferably effected along side.

Typically, detection of a nucleic acid of interest in a biological sample is effected by hybridization-based assays using an oligonucleotide probe.

The term "oligonucleotide" refers to a single stranded or double stranded oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring bases, sugars and covalent internucleoside linkages (e.g., backbone) as well as oligonucleotides having non-naturally-occurring portions which function similarly to respective naturally-occurring portions. For example, an oligonucleotide probe which can be utilized by the present invention is a single stranded polynucleotide which includes a sequence complementary to a unique sequence region of a variant of the present invention (e.g., SEQ ID NO: 4).

Oligonucleotides designed according to the teachings of the present invention can be generated according to any oligonucleotide synthesis method known in the art such as enzymatic synthesis or solid phase synthesis. Equipment and reagents for executing solid-phase synthesis are commercially available from, for example, Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the capabilities of one skilled in the art and can be accomplished via established methodologies as detailed in, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988) and "Oligonucleotide Synthesis" Gait, M. J., ed. (1984) utilizing solid phase chemistry, e.g. cyanoethyl phosphoramidite followed by deprotection, desalting and purification by for example, an automated trityl-on method or HPLC.

The oligonucleotide of the present invention is of at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 22, at least 25, at least 30 or at least 40; bases specifically hybridizable with the variants of the present invention.

The oligonucleotides of the present invention may comprise heterocylic nucleosides consisting of purines and the pyrimidines bases, bonded in a 3' to 5' phosphodiester linkage.

Preferably used oligonucleotides are those modified in either backbone, internucleoside linkages or bases, as is broadly described hereinunder. These can be efficiently used for in-vivo diagnosis procedures.

Specific examples of preferred oligonucleotides useful according to this aspect of the present invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone, as disclosed in U.S. Pat. NOs: 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466, 677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms can also be used.

Alternatively, modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH_2 component parts, as disclosed in U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240;

5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623, 070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439.

Other oligonucleotides which can be used according to the present invention, are those modified in both sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for complementation with the appropriate polynucleotide target. An example for such an oligonucleotide mimetic, includes peptide nucleic acid (PNA). A PNA oligonucleotide refers to an oligonucleotide where the sugar-backbone is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The bases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Other backbone modifications, which can be used in the present invention are disclosed in U.S. Pat. No: 6,303,374.

Oligonucleotides of the present invention may also include base modifications or substitutions. As used herein, "unmodified" or "natural" bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified bases include but are not limited to other synthetic and natural bases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further bases include those disclosed in U.S. Pat. No: 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302,

Crooke, S. T. and Lebleu, B. , ed., CRC Press, 1993. Such bases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 °C. [Sanghvi YS et al. (1993) Antisense Research and Applications, CRC Press, Boca Raton 276-278] and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

It will be appreciated that oligonucleotides of the present invention may include further modifications which increase bioavailability, therapeutic efficacy and reduce cytotoxicity. Such modifications are described in Younes (2002) Current Pharmaceutical Design 8:1451-1466.

Hybridization based assays which allow the detection of the variants of the present invention (i.e., DNA or RNA) in a biological sample rely on the use of oligonucleotide which can be 10, 15, 20, or 30 to 100 nucleotides long preferably from 10 to 50, more preferably from 40 to 50 nucleotides. It will be appreciated, though, that the length of the oligonucleotide of the present invention will greatly depend on the length and composition of the unique nucleic acid sequence region of the variant.

Hybridization of short nucleic acids (below 200 bp in length, e.g. 17-40 bp in length) can be effected using the following exemplary hybridization protocols which can be modified according to the desired stringency; *(i)* hybridization solution of 6 x SSC and 1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 µg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature of 1 - 1.5 °C below the T_m, final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS at 1 - 1.5 °C below the T_m; *(ii)* hybridization solution of 6 x SSC and 0.1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 µg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature of 2 - 2.5 °C below the T_m, final wash solution of 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS at 1 - 1.5 °C below the T_m, final wash solution of 6 x SSC, and final wash at 22 °C; *(iii)* hybridization

solution of 6 x SSC and 1 % SDS or 3 M TMACI, 0.01 M sodium phosphate (pH 6.8), 1 mM EDTA (pH 7.6), 0.5 % SDS, 100 μg/ml denatured salmon sperm DNA and 0.1 % nonfat dried milk, hybridization temperature.

The detection of hybrid duplexes can be carried out by a number of methods. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Such labels refer to radioactive, fluorescent, biological or enzymatic tags or labels of standard use in the art. A label can be conjugated to either the oligonucleotide probes or the nucleic acids derived from the biological sample (target).

For example, oligonucleotides of the present invention can be labeled subsequent to synthesis, by incorporating biotinylated dNTPs or rNTP, or some similar means (e.g., photo-cross-linking a psoralen derivative of biotin to RNAs), followed by addition of labeled streptavidin (e.g., phycoerythrin-conjugated streptavidin) or the equivalent. Alternatively, when fluorescently-labeled oligonucleotide probes are used, fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, FluorX (Amersham) and others [e.g., Kricka et al. (1992), Academic Press San Diego, Calif] can be attached to the oligonucleotides.

Traditional hybridization assays include PCR, RT-PCR, real-time PCR, RNase protection, in-situ hybridization, primer extension, Southern blot, Northern Blot and dot blot analysis.

Those skilled in the art will appreciate that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the oligonucleotide primers and probes.

It will be appreciated that a variety of controls may be usefully employed to improve accuracy of hybridization assays. For instance, samples may be hybridized to an irrelevant probe and treated with RNAse A prior to hybridization, to assess false hybridization.

It will be appreciated that antisense oligonucleotides may be employed to quantify expression of a splice isoform of interest. Such detection is effected at the pre-mRNA level. Essentially the ability to quantitate transcription from a splice site of interest can be effected based on splice site accessibility. Oligonucleotides may

compete with splicing factors for the splice site sequences. Thus, low activity of the antisense oligonucleotide is indicative of splicing activity [see Sazani and Kole (2003), supra].

Polymerase chain reaction (PCR)-based methods may be used to identify the presence of mRNAs of the variants of the present invention. For PCR-based methods a pair of oligonucleotides is used, which is specifically hybridizable with the polynucleotide sequences described hereinabove in an opposite orientation so as to direct exponential amplification of a portion thereof (including the hereinabove described sequence alteration) in a nucleic acid amplification reaction.

The polymerase chain reaction and other nucleic acid amplification reactions are well known in the art and require no further description herein. The pair of oligonucleotides according to this aspect of the present invention are preferably selected to have compatible melting temperatures (Tm), e.g., melting temperatures which differ by less than that 7 °C, preferably less than 5 °C, more preferably less than 4 °C, most preferably less than 3 °C, ideally between 3 °C and 0 °C.

Hybridization to oligonucleotide arrays may be also used to determine expression of the variants of the present invention. Such screening has been undertaken in the BRCA1 gene and in the protease gene of HIV-1 virus [see Hacia et al., (1996) Nat Genet 1996;14(4):441-447; Shoemaker et al., (1996) Nat Genet 1996;14(4):450-456; Kozal et al., (1996) Nat Med 1996;2(7):753-759].

The nucleic acid sample, which includes the candidate region to be analyzed is isolated, amplified and labeled with a reporter group. This reporter group can be a fluorescent group such as phycoerythrin. The labeled nucleic acid is then incubated with the probes immobilized on the chip using a fluidics station. For example, Manz et al. (1993) Adv in Chromatogr 1993; 33:1-66 describe the fabrication of fluidics devices and particularly microcapillary devices, in silicon and glass substrates.

Once the reaction is completed, the chip is inserted into a scanner and patterns of hybridization are detected. The hybridization data is collected, as a signal emitted from the reporter groups already incorporated into the nucleic acid, which is now bound to the probes attached to the chip. Since the sequence and position of each probe immobilized on the chip is known, the identity of the nucleic acid hybridized to a given probe can be determined.

It will be appreciated that when utilized along with automated equipment, the above described detection methods can be used to screen multiple samples for the above-mentioned diseases both rapidly and easily.

The presence of the variants of the present invention may also be detected at the protein level. Numerous protein detection assays are known in the art, examples include, but are not limited to, chromatography, electrophoresis, immunodetection assays such as ELISA and western blot analysis, immunohistochemistry and the like, which may be effected using antibodies specific to the variants of the present invention.

Preferably used are antibodies which specifically interact with the polypeptides of the present invention and not with the protein or other isoforms thereof, for example. Such antibodies are directed, for example, to the unique sequence portions of the polypeptide variants of the present invention (e.g., SEQ ID NOs: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42) or to unique sequences, which bridge the common portion, which is shared with the wild-type sequence, and the unique sequence regions.

Preferably, the antibody of this aspect of the present invention specifically binds at least one epitope of the polypeptide variants of the present invention. As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds.

Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

The term "antibody" as used in this invention includes intact molecules as well as functional fragments thereof, such as Fab, F(ab')2, and Fv that are capable of binding to macrophages. These functional antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab')2, the

fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab')2 is a dimer of two Fab' fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody ("SCA"), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference). It will be appreciated that the polypeptides of the present invention may be coupled with a carrier protein with high antigenicity, or the polypeptides are administrated together with a suitable adjuvant. Examples of carrier proteins include hemocyanin of Fissurellidae, keyhole limpet hemocyanin, bovine serum albumin, bovine thyroalbumin, or the like. Examples of adjuvants include Complete Freund's Adjuvant, hydroxylated aluminum gel, pertussis vaccine, or the like.

Antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby incorporated by reference in their entirety. See also Porter, R. R. [Biochem. J. 73: 119-126 (1959)]. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain

fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar *et al.* [Proc. Nat'l Acad. Sci. USA 69:2659-62 (19720]. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by [Whitlow and Filpula, Methods 2: 97-105 (1991); Bird *et al.*, Science 242:423-426 (1988); Pack *et al.*, Bio/Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry [Methods, 2: 106-10 (1991)].

Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are

found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature 332:323-327 (1988); Verhoeyen *et al.*, Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks *et al.*, J. Mol. Biol., 222:581 (1991)]. The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner *et al.*, J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including

gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks *et al.*, Bio/Technology 10,: 779-783 (1992); Lonberg *et al.*, Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild *et al.*, Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).

The diagnostic reagents described hereinabove can also be included in kits. For example a kit for diagnosing predisposition to, or presence of the above-described diseases in a subject can include an antibody directed at the unique amino acid sequence of the Met variant (SEQ ID NO: 2) in a one container and a solid phase for attaching multiple biological samples packaged in a second container with appropriate buffers and preservatives and used for diagnosis. It will be appreciated that such a kit can also include reagents which detect the level of the wild-type gene (e.g., c-Met).

As used herein the term "about" refers to ± 10 %.

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and

Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., Eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

EXAMPLE 1

Description of the methodology undertaken to uncover the biomolecular sequences of the present invention and uses therefor

Human ESTs and cDNAs were obtained from NCBI GenBank version 126 (Oct 15 2001, www.ncbi.nlm.nih.gov/dbEST) and aligned to the human genome (NCBI assembled genomic sequence from Oct. 2001) using the LEADS clustering

and assembly system as described in U.S. Pat. No. 6,625,545 and U.S. Pat. Appl. No. 10/426,002.

. Briefly, the software cleans the expressed sequences from repeats, vectors and immunoglobulins. It then aligns the expressed sequences to the genome taking alternatively splicing into account and clusters overlapping expressed sequences into "clusters" that represent genes or partial genes.

These were annotated using the GeneCarta (Compugen, Tel-Aviv, Israel) platform. The GeneCarta platform includes a rich pool of annotations, sequence information (particularly of spliced sequences), chromosomal information, alignments, and additional information such as SNPs, gene ontology terms, expression profiles, functional analyses, detailed domain structures, known and predicted proteins and detailed homology reports.

Brief description of the methodology used to obtain annotative sequence information is summarized infra (for detailed description see U.S. Pat. Appl. 10/426,002).

The ontological annotation approach - An ontology refers to the body of knowledge in a specific knowledge domain or discipline such as molecular biology, microbiology, immunology, virology, plant sciences, pharmaceutical chemistry, medicine, neurology, endocrinology, genetics, ecology, genomics, proteomics, cheminformatics, pharmacogenomics, bioinformatics, computer sciences, statistics, mathematics, chemistry, physics and artificial intelligence.

An ontology includes domain-specific concepts – referred to, herein, as sub-ontologies. A sub-ontology may be classified into smaller and narrower categories. The ontological annotation approach is effected as follows.

First, biomolecular (i.e., polynucleotide or polypeptide) sequences are computationally clustered according to a progressive homology range, thereby generating a plurality of clusters each being of a predetermined homology of the homology range.

Progressive homology is used to identify meaningful homologies among biomolecular sequences and to thereby assign new ontological annotations to sequences, which share requisite levels of homologies. Essentially, a biomolecular sequence is assigned to a specific cluster if displays a predetermined homology to at least one member of the cluster (i.e., single linkage). A "progressive homology

range" refers to a range of homology thresholds, which progress via predetermined increments from a low homology level (e.g. 35 %) to a high homology level (e.g. 99 %).

Following generation of clusters, one or more ontologies are assigned to each cluster. Ontologies are derived from an annotation preassociated with at least one biomolecular sequence of each cluster; and/or generated by analyzing (e.g., text-mining) at least one biomolecular sequence of each cluster thereby annotating biomolecular sequences.

The hierarchical annotation approach - "Hierarchical annotation" refers to any ontology and subontology, which can be hierarchically ordered, such as, a tissue expression hierarchy, a developmental expression hierarchy, a pathological expression hierarchy, a cellular expression hierarchy, an intracellular expression hierarchy, a taxonomical hierarchy, a functional hierarchy and so forth.

The hierarchical annotation approach is effected as follows.

First, a dendrogram representing the hierarchy of interest is computationally constructed. A "dendrogram" refers to a branching diagram containing multiple nodes and representing a hierarchy of categories based on degree of similarity or number of shared characteristics.

Each of the multiple nodes of the dendrogram is annotated by at least one keyword describing the node, and enabling literature and database text mining, such as by using publicly available text mining software. A list of keywords can be obtained from the GO Consortium (www.geneontlogy.org). However, measures are taken to include as many keywords, and to include keywords which might be out of date. For example, for tissue annotation, a hierarchy is built using all available tissue/libraries sources available in the GenBank, while considering the following parameters: ignoring GenBank synonyms, building anatomical hierarchies, enabling flexible distinction between tissue types (normal versus pathology) and tissue classification levels (organs, systems, cell types, etc.).

In a second step, each of the biomolecular sequences is assigned to at least one specific node of the dendrogram.

The biomolecular sequences can be annotated biomolecular sequences, unannotated biomolecular sequences or partially annotated biomolecular sequences.

Annotated biomolecular sequences can be retrieved from pre-existing annotated databases as described hereinabove.

For example, in GenBank, relevant annotational information is provided in the definition and keyword fields. In this case, classification of the annotated biomolecular sequences to the dendrogram nodes is directly effected. A search for suitable annotated biomolecular sequences is performed using a set of keywords which are designed to classify the biomolecular sequences to the hierarchy (i.e., same keywords that populate the dendrogram)

In cases where the biomolecular sequences are unannotated or partially annotated, extraction of additional annotational information is effected prior to classification to dendrogram nodes. This can be effected by sequence alignment, as described hereinabove. Alternatively, annotational information can be predicted from structural studies. Where needed, nucleic acid sequences can be transformed to amino acid sequences to thereby enable more accurate annotational prediction.

Finally, each of the assigned biomolecular sequences is recursively classified to nodes hierarchically higher than the specific nodes, such that the root node of the dendrogram encompasses the full biomolecular sequence set, which can be classified according to a certain hierarchy, while the offspring of any node represent a partitioning of the parent set.

For example, a biomolecular sequence found to be specifically expressed in "rhabdomyosarcoma", will be classified also to a higher hierarchy level, which is "sarcoma", and then to "Mesenchimal cell tumors" and finally to a highest hierarchy level "Tumor". In another example, a sequence found to be differentially expressed in endometrium cells, will be classified also to a higher hierarchy level, which is "uterus", and then to "women genital system" and to "genital system" and finally to a highest hierarchy level "genitourinary system". The retrieval can be performed according to each one of the requested levels.

Annotating gene expression according to relative abundance - Spatial and temporal gene annotations are also assigned by comparing relative abundance in libraries of different origins. This approach can be used to find genes, which are differentially expressed in tissues, pathologies and different developmental stages. In principal, the presentation of a contigue in at least two tissues of interest is determined and significant over or under representation of the contigue in one of the at least two

tissues is assessed to identify differential expression. Significant over or under representation is analyzed by statistical pairing.

Annotating spatial and temporal expression can also be effected on splice variants. This is effected as follows. First, a contigue which includes exonal sequence presentation of the at least two splice variants of the gene of interest is obtained. This contigue is assembled from a plurality of expressed sequences;

Then, at least one contigue sequence region, unique to a portion (i.e., at least one and not all) of the at least two splice variants of the gene of interest, is identified . Identification of such unique sequence region is effected using computer alignment software.

Finally, the number of the plurality of expressed sequences in the tissue having the at least one contigue sequence region is compared with the number of the plurality of expressed sequences not-having the at least one contigue sequence region, to thereby compare the expression level of the at least two splice variants of the gene of interest in the tissue.

Data concerining therapies, indications and possible pharmacological activities of the polypeptides of the present invention was obtained from PharmaProject (PJB Publications Ltd 2003 http://www.pjbpubs.com/cms.asp?pageid=340) and public databases, including LocusLink (http://www.genelynx.org/cgi-bin/resource?res=locuslink) and Swissprot (http://www.ebi.ac.uk/swissprot/index.html). Functional structural analysis of the polypeptides of the present invention was effected using Interpro domain analysis software (Interpro default parameters, the analyses that were run are HMMPfam, HMMSmart, ProfileScan, FprintScan, and BlastProdom). Subecllular localization was analysed using ProLoc software (Einat Hazkani-Covo, Erez Y. Levanon, Galit Rotman, Dan Graur, Amit Novik. Evolution of multicellularity in metazoa: comparative analysis of the subcellular localization of proteins in Saccharomyces, Drosophila and Caenorhabditis. Cell Biology International (in press).

EXAMPLE 2

Met- Hepatocyte growth factor receptor

The protein product of c-met oncogene (Swissprot Locus No. MET_HUMAN), is a tyrosine kinase receptor for hepatocyte growth factor (HGF,

Swissprot Locus No. HGF_HUMAN), also known as scatter factor (SF). HGF/SF was identified independently as both a growth factor for hepatocytes and as a fibroblast-derived cell motility factor, or scatter factor. The mature HGF is a disulfide-linked heterodimer composed of an α- chain and a β-chain deriving from a pre-pro HGF polypeptide that is proteolytically cleaved to yield the mature active HGF. HGF is produced predominantly by mesenchymal cells and acts primarily on Met-expressing ephithelial cells in an endocrine and/or paracrine fashion. The HGF/SF-Met complex induces a wide range of biological events, including proliferation, scattering, invasion, branching morphogenesis, transformation and angiogenesis. This wide array of biological processes is mediated by the HGF–Met signaling involving interactions between mesenchymal and epithelial cells. Such paracrine signaling is vital to embryogenesis and contributes to kidney and mammary gland formation, migration and development of muscle and neuronal precursors, and liver and placenta development.

Binding of HGF to the extracellular domain of Met triggers autophosphorylation of specific tyrosine residues in the intracellular region of Met. Specifically, phosphorylation of two tyrosine residues (Tyr1234 and Tyr1235) located within the activation loop of the tyrosine kinase domain activates the intrinsic kinase activity of the receptor, while phosphorylation of two tyrosine residues (Tyr1349 and Tyr1356) located in the C-terminus of Met activates a multisubstrate docking site, recruiting downstream signaling molecules and adaptor proteins thereby amplifying the cellular responses from HGF to multiple distinctive pathways.

While HGF/SF-Met signaling plays a key role during normal development (embryonic development, wound healing and tissue regeneration) this signaling pathway has been implicated in tumor development and progression. In particular, abnormal HGF-Met signaling was shown to play a significant role in promoting tumor cell invasion and metastasis. c-Met mutations have been described in hereditary and sporadic human papillary renal carcinomas and have been reported in ovarian cancer, childhood hepatocellular carcinoma, metastatic head and neck squamous cell carcinomas, and gastric cancer. c-Met is also over-expressed in both small cell lung cancer and non-small cell lung cancer. In view of its critical role in oncogenesis, various inhibition strategies have been employed to therapeutically target Met receptor tyrosine kinase.

Chromosomal location and structural information

The human Met gene, which includes 21 exons, is located on chromosome 7 band 7q21–q31 and spans more than 120 kb in length.

The primary Met transcript produces a 150 kDa polypeptide (1390 amino acids) that is partially glycosylated to produce a 170 kDa precursor protein. This 170 kDa precursor is further glycosylated and then cleaved into a 50 kDa α-chain and a 140 kDa β-chain which are disulfide-linked. The α-subunit of the mature Met heterodimer is highly glycosylated and is entirely extracellular, while the β-subunit contains a large extracellular region, a membrane spanning segment, and an intracellular tyrosine kinase domain.

Met is the prototypic member of a subfamily of heterodimeric receptor tyrosine kinases which include Met, Ron, and Sea. Members of the Met receptor subfamily have been shown to share homology with semaphorins and semaphorin receptors (plexin), which play a role in cell scattering. All semaphorins contain a conserved 500 amino acid extracellular domain (Sema domain) in which resides the cysteine-rich Met related sequence (MRS) which minimal consensus is C-X(5–6)-C-X(2)-C-X(6–8)-C-X(2)-C-X(3–5)-C. The extracellular portions of Met, Ron, and Sea contain a region of homology to semaphorins including the N-terminal Sema domain and the MRS. Other domains identified in the extracellular portion of Met are the PSI domain and the IPT/TIG repeat domain. The PSI domain is found in plexins, semaphorins and integrins while the IPT repeats (also known as TIG domains) are found within immunoglobulin, plexins and transcription factors. The C-terminus intracellular tyrosine kinase domain shares homology with Ron and Sea.

Biological function

1. Proliferation- Aside from hepatocytes, HGF is also an important growth factor for cells of various origins, including epithelial cells, neurons and placental cytotromphoblasts. The mitogenic effect of HGF is also crucial in regenerative processes following tissue injury.

2. Scattering- The process of cell scattering can be divided into three phases, essentially, cell spreading, cell–cell dissociation, and cell migration. As mentioned above, HGF was discovered as a secretory product of fibroblasts and smooth muscle cells that induces dissociation and motility of epithelial cells. HGF/SF

is able to induce cell dissociation and mutual repulsion in a similar manner to semaphorins.

3. Angiogenesis- HGF acts as a potent angiogenic molecule by directly acting on vascular endothelial cells. HGF stimulation of vascular endothelial cells promotes migration, proliferation, protease production, invasion, and organization into capillary-like tubes. HGF can also promote the expression of angiogenic factors by tumor cells. HGF induces a dose-dependent increase in the angiogenic cytokines IL-8 and vascular endothelial growth factor (VEGF) produced by head and neck squamous cell carcinoma cell lines.

4. Cell motility- The key events regulating cell motility are polymerization of actin, formation of actin stress fibers, and focal adhesion formation. Many studies have shown that HGF–Met signaling increases the motility of epithelial cells.

5. Morphogenesis- HGF has been shown to induce branching morphogenesis of kidney, mammary and bile ductular cells. In response to HGF, Met expressing cells form branches in three-dimensional matrigel or tubule-like structures in collagen gels. This process is mediated through changes in cell shape, asymmetric polarization of the cells in the direction of branching, branch elongation, cell-cell contact, cell-ECM communication, ECM remodeling, controlled proteolysis and cell motility.

6. Invasion and metastasis- HGF/SF–Met signaling has been strongly implicated in the promotion of the invasive/metastatic tumor phenotype. An HGF stimulated pathway involving MAPK1/2 signaling is important in the up-regulation of expression of the serine protease urokinase (uPA) and its receptor (uPAR), resulting in an increase of uPA on the cell surface. Certain components of the ECM can be directly degraded by uPA, and more importantly, uPA cleaves plasminogen into the broader-specificity protease plasmin, which is able to efficiently degrade several ECM and basement membrane (BM) components. Plasmin also activates metalloproteinases, which have potent ECM/BM degrading abilities. HGF has been reported to promote attachment of tumor cells to endothelium, an important step in the metastatic cascade. This activity may be mediated by HGF induced up-regulation of CD44 expression on endothelium cells, and an induced integrin expression on tumor cells.

Abnormal activity and/or expression of Met-HGF in cancer

Aberrant c-Met signaling has been described in a variety of human cancers (solid tumors and hematologic malignancies). Mutations in c-Met, over-expression of c-Met and/or HGF, and expression of c-Met and HGF by the same cell can all contribute to tumorigenesis. Cell lines with uncontrolled c-Met activation via one of these mechanisms are both highly invasive and metastatic. Increased c-Met and/or HGF expression by human tumor cells is often associated with high tumor grade and poor prognosis.

References:

Maulik et al. 2002. Cytokine and Growth Factor Reviews. 13:41-59.

Zhang et al. 2003. Journal of Cellular Biochemistry. 88:408-417.

Furge et al. 2000. Oncogene. 19:5582-5589.

To et al. 1998. Oncology Reports. 5:1013-1024.

Trusolino et al. 1998. The FASEB Journal. 12:1267-1280.

Comoglio et al. 2002. The Journal of Clinical Investigation. Vol. 109, No. 7, Pp. 857-862.

Danilkovitch-Miagkova et al. 2002. The Journal of Clinical Investigation. Vol. 109, No. 7, Pp. 863-867.

Wajih et al. 2002. Circulation Research. 90:46-52.

Mark et al. 1992. The Journal of Biological Chemistry. Vol 267, No. 36, Pp. 26166-26171.

Met splice variant-structure

The present inventors have uncovered a novel splice variant of Met (SEQ ID NOs: 1, 3, Figures 1a,b-4) by LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1). This splice variant results from alternative splicing of the c-Met gene, thereby causing an extension of exon 12 (the last exon before the transmembrane region encoding exon) leading to an insertion of a stop codon and the generation of a truncated Met protein which terminates just before the transmembrane domain. Met splice variant has an open reading frame (ORF) of 934 amino acids: 910 amino acids of the wild-type (w.t.) Met protein and a unique sequence of 24 amino acids at the C-terminus of the protein. It contains nearly the complete extracellular portion of Met (910 amino acids of 933 of the w.t protein) and therefore comprises all its structural domains (the Sema, PSI and TIG domains). It is

predicated to be a secreted protein since it retains the original N-terminal signal peptide (amino acids 1-24) and lacks the transmembrane domain (amino acids 933-955 of the w.t.).

Therapeutic and diagnostic applications for the Met splice variant of the present invention

Met splice variant of the present invention can serve as a antagonist (i.e., inhibitor) of Met-HGF interaction. It contains the extracellular region of Met, the HGF binding site, and therefore it is likely to bind HGF. Met extracellular region has been shown previously to bind HGF with a high affinity (comparable to the membrane bound receptor). Met splice variant can inhibit Met-HGF signaling by competing with the membrane-bound receptor for the ligand-HGF, thus preventing HGF binding to the cell surface receptor and as a consequence blocking Met activation and its signaling pathway.

Because of the overwhelming evidence favoring the role of aberrant HGF–Met signaling in the pathogenesis of various human cancers, endogenous and exogenous inhibitors of this signaling pathway such as Met splice variant may be used as valuable therapeutic tools in the treatment of cancers such as, hereditary and sporadic papillary renal carcinoma, breast cancer, ovarian cancer, childhood hepatocellular carcinoma, metastatic head and neck squamous cell carcinomas, lung cancer (e.g., non-small cell lung cancer, small cell lung cancer), prostate cancer, pancreatic cancer, gastric cancer and other diseases such as diabetic retinopathy.

In addition to its therapeutic potential, Met splice variant may be used for diagnosing cancer. Aberrant c-Met signaling, which results from mutations in the Met sequence or over-expression of c-Met, has been described in a variety of human cancers. Furthermore, increased c-Met expression by human tumor cells is often associated with high tumor grade and poor prognosis.

EXAMPLE 3

Interleukin-6 (IL-6)

Background

IL-6 (Swissprot Locus No. IL6_HUMAN) was originally identified as an antigen-nonspecific B-cell differentiation factor in culture media of mitogen- or

antigen-stimulated peripheral blood mononuclear cells that induced B cells to produce immunoglobulins and was named B-cell stimulatory factor 2 (BSF-2).

IL-6 is a pleiotropic cytokine with a wide range of biological activities in immune regulation, hematopoiesis, inflammation, and oncogenesis. The cytokine is produced by various types of lymphoid and nonlymphoid cells, such as T cells, B cells, monocytes, fibroblasts, keratinocytes, endothelial cells, mesangial cells, and several tumor cells. It induces growth of T cells and differentiation of cytotoxic T cells by augmenting the expression of IL-2 receptor and IL-2. IL-6 acts synergistically with IL-3 to support the formation of multilineage blast cell colonies in hematopoiesis. It also induces differentiation of macrophages, megakaryocytes and osteoclasts. In the acute-phase reaction, this cytokine stimulates hepatocytes to produce acute-phase proteins such as C-reactive protein (CRP), fibrinogen, α_1-antitrypsin and serum amyloid A and it simultaneously suppresses albumin production. It causes leukocytosis and fever when administered in vivo and also acts as a growth factor for renal mesangial cells, epidermal keratinocytes and various types of tumor cells, for example, in plasmacytoma, multiple myeloma and renal cell carcinoma.

Although IL-6 has pleiotropic effects on various target cells, some of these biological activities are also mediated by other cytokines, such as leukemia inhibitory factor (LIF) and oncostatin M (OSM). The pleiotropy and redundancy of IL-6 functions can be explained by the unique composition of its receptor signaling system. Two components of IL-6 receptor (IL-6R) were identified, an 80-kDa IL-6-binding protein (α chain) and a common 130-kDa signal transducer known as gp130 (β chain). The gp130 subunit is shared by receptors for other cytokines of the IL-6 superfamily, such as ciliary neurotrophic factor (CNTF), LIF, OSM, IL-11, and cardiotrophin-1 receptors. Although IL-6 cannot directly bind to gp130, it can bind to IL-6R to thereby generate the high-affinity complex of IL-6/IL-6R/gp130. Mutagenesis studies have identified three distinct regions on the surface of IL-6 which specifically interact with the respective receptors: site I interacts with IL-6Rα; site II, which is common to all IL-6-type cytokines, interacts with the cytokine-binding module of gp130 and site III interacts with the second signaling receptor (another gp130, in the case of IL-6). The signal transduction through gp130 is mediated by two pathways: the JAK–STAT

(Janus family tyrosine kinase–signal transducer and activator of transcription) pathway and the Ras mitogen-activated protein kinase (MAPK) pathway.

Clinical application

IL-6 have been shown to play key roles in various disease conditions, such as inflammatory, autoimmune, and malignant diseases. Uncontrolled IL-6 overproduction appears to be responsible for the clinical symptoms and abnormal laboratory findings in Rheumatoid arthritis (RA). The ability of IL-6 to induce differentiation of B-cells suggests that overproduction of IL-6 is responsible for the increase in serum γ-globulin and the emergence of rheumatoid factors in RA. As a hepatocyte-stimulating factor, IL-6 causes an increase in CRP, serum amyloid A, and erythrocyte sedimentation rate and a decrease in serum albumin. On the other hand, IL-6 as a megakaryocyte differentiation factor causes thrombocytosis. The ability of IL-6 in the presence of soluble IL-6R to induce bone absorption, suggests that IL-6 may be involved in the osteoporosis and destruction of bone and cartilage associated with RA. In fact, a large amount of IL-6 has been observed in both sera and synovial fluids from the affected joints of patients with RA. Blockade of the IL-6 signaling may thus constitute a new therapeutic strategy for RA. In addition to RA, IL-6 was found to be involved in various diseases such as Castleman's disease, Crohn's disease, multiple myeloma/plasmacytoma, mesangial proliferative glomerulonephritis, psoriasis and Kaposi's sarcoma. Thus RA and these other diseases could be targets for IL-6 inhibitors.

References

Simpson et al. 1997. Protein Science. 6:929-955.

Jones et al. 2001. The FASEB Journal. 15:43-58.

Hirano T. 1998. Intern. Rev. Immunol. Vol. 16, Pp. 249-284.

Heinrich et al. 2003. Biochemical Society. 374 :1-20.

Bihl et al. 2002. American Journal Of Respiratory Cell and Molecular Biology. Vol. 27, pp. 48-56.

Naka et al. 2002. Arthritis Research. Vol 4 Suppl 3:S233-S242.

IL-6 splice variant-structure

A novel splice variant of IL-6 (SEQ ID NOs: 5 and 7, Figures 5a-b-8) was uncovered by LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1). IL-6 splice variant results from alternative splicing

of the IL-6 gene, thus causing an extension of exon 4, leading to an insertion of a stop codon and the generation of a truncated protein. IL-6 splice variant encodes a 198 amino acids long protein which contains the N-terminal signal sequence (residues 1-29), most of the IL6/GCSF/MGF family domain and a unique sequence of 41 amino acids at the C-terminus of the protein.

Therapeutic applications for the IL-6 splice variant of the present invention

The IL-6 splice variant of the present invention contains the N-terminus 157 amino acids of the wild-type while lacking the last 50 amino acids of the protein. This splice variant may serve as an antagonist of IL-6 by several mechanisms. For example, it can bind only to IL-6Rα while abolishing the binding to gp130. Since gp130 is the signaling subunit of the IL-6R complex, such variant will not be able to activate the receptor. By binding to the receptor without activating it, IL-6 splice variant might have the potential to serve as an antagonist of IL-6 signaling.

Disregulation of IL-6 production has been implicated in the pathogenesis of a variety of diseases, including plasmacytoma/myeloma and several chronic inflammatory proliferative diseases. Blocking of IL-6 signaling by inhibitors such as this IL-6 splice variant can thus have an important therapeutic potential for the treatment of Rhematoid arthritis, Castleman's disease, Crohn's disease, multiple myeloma/plasmacytoma, mesangial proliferative glomerulonephritis, psoriasis and Kaposi's sarcoma.

EXAMPLE 4

Interleukin-7 (IL-7)

Background

The IL-7 cytokine (Swissprot Locus No. IL7_HUMAN) was originally identified as a growth factor for murine B cell progenitors and was isolated from bone marrow stromal cells. Subsequently, it was demonstrated that IL-7 plays a crucial role in normal B and T cell lymphopoiesis. It acts as a differentiation and proliferation factor of B cells and as a survival factor of activated T cells. Receptors for IL-7 have been found on cells of both the lymphoid and myeloid lineages. A heterodimeric IL-7R complex is composed of two subunits, a unique α subunit and a p64 γ subunit, which is common to the receptors for IL-2, IL-4, IL-9 and IL-15. While IL-7R expression is important for early pre-B and pro-B cell development, mature B cells

lack expression of high affinity receptor and demonstrate no proliferative response to IL-7. In addition to its expression on immature B cells, IL-7R has been identified also on thymocyte and on most mature T cells, wherein the receptor is transiently down-regulated upon activation. IL-7 signaling involves a number of nonreceptor tyrosine kinase pathways that associate with the cytoplasmic tail of the receptor. These include the Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway, phosphatidylinositol 3-kinase (PI3-kinase), and Src family tyrosine kinases.

Clinical applications

Due to the numerous effects of IL-7 on mature T cells it may modulate immune responses in infectious or cancerous disease. Systemic administration of IL-7 can be used as an anti-cancer therapy by enhancing the immune responses against tumor through a variety of mechanisms. In addition, IL-7 combined with other factors, such as GM-CSF, can enhance the generation of mature monocyte-derived dendritic cells. Furthermore, IL-7, along with other cytokines, may contribute to the induction of a type 1 immune response and LAK cells. Finally, by diminishing TGF-β production, IL-7 can potentially down-regulate one mechanism through which tumors suppress local immune responses. In contrast, IL-7 stimulates the growth of pre-B and T acute lymphoblastic leukemia cells in vitro. It also induces proliferation of chronic lymphocytic leukemia cells and acute myelogenous leukemia cells, as well as cells from patients with Sezary syndrome. IL-7R is expressed on the majority of neoplastic lymphoid cells and on a subset of myeloid neoplasms. The demonstration of IL-7 secretion by neoplastic B lymphocytes from patients with Burkitt's lymphoma, Sezary leukemia cells, Hodgkin's lymphoma cells and normal keratinocytes suggests the possibility of both autocrine and paracrine growth-stimulatory mechanisms for IL-7 in neoplastic diseases. Therefore inhibiting IL-7 signaling might have a therapeutic potential in cancer therapy.

References

Cosenza et al. 2000. Protein Science. 9:916-926.

VanderSpek et al. 2002. Cytokine. Vol. 17, No. 5, Pp. 227-233.

Gorgun et al. 2002. Cytokine. Vol. 20, No. 1, Pp 17-22.

Fry et al. 2002. Blood. Vol. 99, No. 11, Pp. 3892-3904.

Splice variant structure

The present inventors uncovered two novel splice variants of IL-7, variant T7 (SEQ ID NOs: 9, 11) and variant T8 (SEQ ID NO: 13, 15) by applying LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1).

IL-7 splice variant T7 (see Figures 9a-b-12) results from alternative splicing of the IL-7 gene, involving the skipping of exon 6 (the last exon of wild-type IL-7) into a new last exon and 3' UTR, and the generation of a protein with a different C-terminus. IL-7 splice variant T7 encodes a 167 amino acids long protein which contains the N-terminal signal sequence (residues 1-27), an almost the complete IL-7/IL-9 family domain and a unique sequence of 29 amino acids at the C-terminus.

IL-7 splice variant T8 (see Figures 9c-d-12) results from alternative splicing of the IL-7 gene, involving the skipping of exon 6 (the last exon of wild-type IL-7) into a new last exon and 3' UTR, and the generation of a protein with a different C-terminus. IL-7 splice variant T8 encodes a 157 amino acids long protein which contains the N-terminal signal sequence (residues 1-27), most of the IL-7/IL-9 family domain and a unique sequence of 19 amino acids at the C-terminus.

Therapeutic applications for the IL-7 splice variants of the present invention

IL-7 splice variants contain the N-terminus 138 amino acids of the wild-type IL-7 and a unique sequences at the C terminus of the proteins. These splice variants can modulate IL-7 signaling and therefore may be used as valuable therapeutic tools in the treatment of cancers, such as acute and chronic lymphocytic leukemia, acute myelogenous leukemia, Sezary's syndome, Burkitt's lymphoma and Hodgkin's disease, and in constructing a spectrum of lymphoid cell types following radiotherapy or chemotherapy.

EXAMPLE 5

Tumor necrosis factor receptor-9/ 4-1BBR

Background

T cells receiving signals via the Ag-specific TCR require a second, costimulatory signal to stabilize cytokine mRNA and induce the expression of anti-apoptotic proteins. The most well-studied costimulatory pathway involves the binding of two members of the Ig supergene family B7-1 (CD80) and B7-2 (CD86), present

on APCs, to T cell counter receptors CD28, and CTLA-4(CD152). Similarly, members of the nerve growth factor/TNF superfamily can function as costimulatory molecules. These include 4-1BB receptor (CDw137), CD30, OX40, and CD40 ligand (CD154). The 4-1BB receptor (Swissprot Locus No. TNR9_HUMAN) is an inducible type I membrane protein expressed on activated cytolytic and helper T cells as well as NK cells.

The ligand for 4-1BB receptor is 4-1BB ligand (4-1BBL), which is expressed on activated APCs including activated B cells, activated macrophages and mature dendritic cells. This expression pattern suggested that pairing of 4-1BBR and 4-1BBL is important for interactions between APCs and T cells, which play a role in the process of antigen presentation. Signals delivered by the 4-1BB receptor can induce T cells to produce IL-2, proliferate and differentiate, as well as protect T cells from activation-induced cell death. Despite the expression of 4-1BBR on both CD4+ and CD8+ T cells, 4-1BBR has been reported to predominantly affect CD8+ T cell responses. 4-1BBR was shown to regulate both clonal expansion and survival of CD8+ T cells. As is the case for other TNFR superfamily members, 4-1BBR uses adaptor molecules called tumor necrosis factor receptor-associated factors (TRAFs) to transduce a downstream signal. The cytoplasmic domain of 4-1BBR is able to associate specifically with TRAF1, TRAF2, and TRAF3. Accumulating evidence indicates that there exists a signal transduction pathway via the 4-1BB ligand as well as via the 4-1BB receptor. 4-1BBR is able to replace CD28 in stimulating high-level IL-2 production by resting T cells in the absence of CD28. Since 4-1BBR must be up-regulated before providing costimulatory signals for T cells, in contrast to CD28 which is expressed constitutively, 4-1BBR may play a major role in the later stages of the immune response. Thus, it is plausible to hypothesize that CD28 and 4-1BBR play sequentially differential roles in the stages of the immune response: CD28 is more important in the induction stages of the immune response while 4-1BBR is more important in perpetuating the immune response. This task of 4-1BBR may be achieved by providing a survival signal as well as a costimulatory signal for T cells.

Clinical applications

Administration of agonistic anti-4-1BBR antibodies has been shown to eradicate established large tumors in mice. Interestingly, anti-4-1BBR-mediated tumor elimination is a complex process which requires CD4 + T cells and NK cells as

well as CD8 + T cells. Thus, it seems that the immune response induced by anti-4-1BB antibodies augment tumor-specific cytotoxic activity of CD8 + T cells, which is regulated by CD4 + T cells and NK cells. Similarly, the introduction of 4-1BBL into tumor cells confers full immunogenicity and thus enhances the amplification of an anti-tumor immune response. Although 4-1BB was shown to effect CD8+ cells preferentially, there is accumulating evidence that 4-1BBR is implicated in immune responses mediated by CD4+ T cells, including alloimmune responses and inflammation. As with CD8+ T cells, signaling through 4-1BBR appears to promote cell proliferation and survival of CD4+ T cells. This suggested that intervention in the 4-1BBR costimulatory pathway could provide an immunotherapeutic approach to the treatment of inflammatory diseases. It has been shown that in vivo blocking of 4-1BB/4-1BBL interactions, by administration of anti 4-1BBL monoclonal antibody, significantly decrease the myocardial inflammation, induced by coxackievirus B3, and prevented the herpetic stromal keratitis (HSK) induced by HSV-1. Contrary to these observations, administration of agonistic anti-4-1BBR monoclonal antibody blocked the disease progression of spontaneous systemic lupos erythematosus (SLE). In general, it was suggested that agonistic anti 4-1BBR monoclonal antibody may be a valid therapeutic approach to treat Th2-mediated autoimmune diseases such as SLE, RA, ulcerative colitis, whereas tools to block the 4-1BBR costimulatory pathway such as anti 4-1BBL monoclonal antibody may provide immuno-therapy to treat Th1-mediated inflammatory diseases such as MS and Crohn's disease and to prevent rejection of organ transplant. Agonistic anti 4-1BBR monoclonal antibody may also be used as an immunotherapeutic agent to eradicate tumor or viral infection.

References

Blazar et al. 2001. The Journal of Immunology. 166:3174-3183.

Seo et al. 2003. The Journal of Immunology. 171:576-583.

Croft M. 2003. Cytokine and Growth Factor Reviews. 14:265-273.

Vinay et al. 1998. Seminars in Immunology. 10:481-489.

Croft M. 2003. Nature Reviews Immunology. 3:609-620.

Aggarwal B.B. 2003. Nature Reviews Immunology. 3:745-755.

Kwon et al. 2003. Experimental and Molecular Medicine. Vol. 35, No. 1 Pp. 8-16.

Kwon et al. 2000. Molecules and Cells. Vol. 10, No. 2, Pp. 119-126.

TNR9-splice variant structure

The present inventors uncovered novel splice variants of TNR9 (SEQ ID NOs: 17, 19, Figures 13a-b-16) by applying LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1).

This TNR9 (4-1BBR) splice variant results from alternative splicing of the TNR9 gene, thus introducing a new exon 5a (between exons 5 and 6) and a 3' UTR, leading to an insertion of a stop codon and the generation of a truncated protein. TNR9 splice variant encodes a 153 amino acids long protein which contains the N-terminal signal sequence (residues 1-17), one of the TNFR cys rich repeats (residues 47-86) and a unique sequence of 15 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it lacks the transmembrane domain.

Therapeutic applications for the TNR9 splice variants of the present invention

TNR9 splice variant can serve as a antagonist of TNR9 (4-1-BBR)/4-1BBL interaction. It contains part of the extracellular region of TNR9, thus may be capable of inhibiting TNR9 signaling by competing with the membrane-bound receptor for the ligand-4-1BBL, thus preventing its binding to the cell surface receptor and as a consequence blocking TNR9 activation and its signaling pathway.

Inhibitors of TNR9 signaling pathway, such as this TNR9 splice variant, could have an important therapeutic potential for the treatment of inflammatory diseases such as MS and Crohn's disease, myocardial inflammation, induced by coxackievirus B3, herpetic stromal keratitis (HSK) induced by HSV-1 and to prevent rejection of organ transplant and graft-vs-host disease.

EXAMPLE 6

Interleukin-4 receptor (IL-4R)

Background

IL-4 is a pleiotropic and multifunctional cytokine produced by activated T cells, mast cells and basophils. IL-4 plays a critical role in regulating the outcome of an immune response by facilitating Th2 cell differentiation and suppressing the differentiation of IFN-γ-producing CD4 + T cells, thereby favoring humoral immune responses. The other important function of IL-4 is the regulation of immunoglobulin

class-switching. It induces class-switching to IgE and IgG4 in humanB cells, suggesting a preeminent role of IL-4 in the regulation of allergic conditions. IL-4 also exerts a wide variety of other effects on hematopoietic and nonhematopoietic cells. It enhances the expression of CD23 and class II MHC molecules in B cells and upregulates surface expression of the receptor complex for IL-4. On vascular endothelial cells, IL-4 together with TNF induces the expression of VCAM-1 (vascular cell adhesion molecule 1) and downregulates the expression of E-selectin, thereby changing the adhesive characteristics of endothelial cells and facilitating tissue infiltration by allergic inflammatory cells, such as eosinophils. IL-4 receptors are expressed on hematopoietic cells and a range of nonhematopoietic cells including epithelial, endothelial, muscle, fibroblast and liver cells. On hematopoietic cells, the receptor complex for IL-4 is composed of a 140 kDa high-affinity ligand-binding chain, the IL-4-receptor α chain (IL-4Rα) and the so-called common γ chain (γC) that is shared by IL-2, IL-7, IL-9 and IL-15. In contrast, IL-13Rα1 is the predominant accessory chain of the receptor complex for IL-4 in non-hematopoietic cells. Furthermore, the receptor complex for IL-13 consists of various combinations of the IL-4Rα, IL-13Rα1 and IL-13Rα2. This may explain the redundancy in biological responses mediated by IL-4 and IL-13. Both IL-4 and IL-13 have been implicated in allergic diseases, probably through redundant and independent pathways. Although homodimerized IL-4Rα can generate biological signals within the cell, physiologic signaling requires heterodimerization of IL-4Rα and the accessory chain (γC). Neither IL-4Rα nor γC contains intrinsic kinase activities; rather the IL-4R requires receptor-associated kinases for the initiation of signal transduction. Three members of the Janus kinase (Jak) family- Jak-1, Jak-2 and Jak-3 have been shown to be activated in response to IL-4R engagement and to associate with the components of the receptor complex for IL-4. Jak-1 has been proposed to bind IL-4Rα whereas Jak-3 associates with the γC chain. IL-4-IL-4R engagement results in tyrosine phosphorylation of Jak-1 and Jak-3, leading to tyrosine phosphorylation of IL-4Rα itself, a process that occurs immediately after IL-4R engagement. Five conserved tyrosine residues (Tyr497, Tyr575, Tyr603, Tyr631 and Tyr713) that can potentially be phosphorylated are present in the cytoplasmic domain of IL-4Rα. After tyrosine phosphorylation, these conserved tyrosine residues become potential docking sites for downstream

signaling molecules containing Src-homology-domain 2 (SH2) or phosphotyrosine-binding domains.

References

Mueller et al. 2002. Biochimica et Biophysica Acta. 1592:237-250.

Nelms et al. 1999. Annu. Rev. Immunol. 17:701-738.

Pan et al. 1999. Current Opinion in Immunology. 11:615-620.

Gessner et al. 1999/2000. Immunobiology. 201, 285-307.

IL-4R splice variants-structure

The present inventors uncovered novel isoforms of IL-4R as further described hereinbelow, by applying LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1).

IL-4R splice variant T4 (SEQ ID NO: 21, 23, Figures 17a-b-20) results from alternative splicing of the IL-4R gene, introducing a novel exon 4a (between exons 4 and 5), leading to an insertion of a stop codon and the generation of a truncated protein. IL-4R splice variant T4 encodes a 131 amino acids long protein which contains the N-terminal signal sequence (residues 1-25), the complete CRIA domain of IL-4R and a unique sequence of 10 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it has lost its transmembrane domain.

IL-4R splice variant T11 (SEQ ID NOs: 25, 27, Figures 17c, 18-20) results from alternative splicing of the IL-4R gene, thus causing the extension of exon 6 (the last exon before the exon that encodes the transmembrane domain), leading to an insertion of a stop codon and the generation of a truncated IL4R which ends just before the transmembrane domain. IL-4R splice variant T11 encodes a 229 amino acids long protein which contains the N-terminal signal sequence (residues 1-25), the complete CRIA domain of IL-4R and a unique sequence of 6 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it has lost its transmembrane domain.

Therapeutic applications for the IL-4R splice variants of the present invention

Since IL-4Rα is an independent high affinity IL-4 binding subunit, IL-4Rα splice variants, which are secreted forms of the receptor can serve as antagonists of IL-4/IL-4R interaction. They all contain the complete CRIA domain of IL-4Rα while

T11 splice variant even contains the whole extracellular region of IL-4Rα and therefore they can inhibit IL-4/IL4R signaling by competing with the membrane-bound receptor for the ligand, thus preventing IL-4R activation. It has been previously reported that the recombinant extracellular domain of IL-4R blocks IL-4 functions in vitro and in vivo, first shown in a murine model of allotransplantation.

IL-4-IL4R signaling pathways play a major role in the pathogenesis of allergic diseases. Moreover, naturally occurring mutations of the IL-4Rα chain have been identified and implicated in a genetic predisposition for atopic asthma. Blocking of IL-4 signaling could therefore have an important therapeutic potential for the treatment of asthma and other allergic disorders. In addition to its role in allergic disorders, IL-4R signaling was shown to be involved in autoimmune diseases and in organ transplantation. Recently, it has been shown that IL-4 may serve multiples roles in the development of lupus. Evidence for a novel role for IL-4 in the development of lupus nephritis comes from recent studies, which suggest that IL-4 may directly promote extracellular matrix deposition in the glomeruli. Blockage of IL-4 signaling may ameliorate glomerulosclerosis and prevent the development of end-stage renal disease and in general might have a therapeutic potential in the treatment of lupus. Thus, in addition to their therapeutic potential in the treatment of asthma and other allergic disorders, IL-4Rα splice variants may be used in the treatment of autoimmunity diseases such as lupus, in organ transplant rejection and graft-vs-host diseases.

EXAMPLE 7

Transforming growth factor β receptor type II (TGF- β-R/TGR2)

Background

TGF-β belongs to a large family of growth and differentiation factors. It is a potent growth inhibitor of all epithelial and hematopoietic cells and can also induce apoptosis. Three isoforms of TGF-β, designated TGF-β_{1-3}, with about 70% amino acid sequence identity have been identified in mammals. TGF-β signals through two related transmembrane ser/thr kinase receptors, the type I and type II receptors (TGR1 and TGR2). Signaling is initiated when TGF-β binds to the type II receptor (TGR2, Swissprot Locus No. TGR2_HUMAN) which is followed by recruitment of the type I receptor into a heteromeric complex. Within the complex the type II receptor

transphosphorylates and activates the type I receptor kinase which targets downstream signaling components of the pathway. Proteins belong to the SMAD family of intracellular mediators are the only downstream substrates of the type I receptor kinase. Two member of the SMAD family, namely, Smad 2 and Smad 3, are directly phosphorylated by the type I receptor, leading to association of these receptor-regulated SMADs and Smad 4, followed by translocation of the heteromeric complex to the nucleus. In the nucleus, these complexes of SMADs can interact with DNA and with specific DNA binding transcription factors to elicit gene response to TGF-β. In addition to the SMADs, the activated receptor complex can signal through phosphatidylinositol 3-kinase (PI3K), protein phosphatase 2A/p70 S6 kinase (PP2A/p70S6K), and various mitogen-activated protein kinase (MAPK) pathways. Since TGF-β inhibits cell growth, escape from the growth inhibition by TGF-β results in uncontrolled cell growth. Mutations in the extracellular domain of the type II receptor were identified in hereditary non-polyposis colon cancer (HNPCC) and in several transformed cells. In addition to defects in the type II receptor, alterations in the type I receptor have been found in prostate, colon and gastric cancer cells, which are insensitive to TGF-β.

Clinical applications

Although TGF-β can be tumor suppressive, there is increasing evidence that TGF-β secretion by tumor cells and/or stromal cells within the peritumoral microenviroment can contribute to tumor maintenance and progression. The effect of TGF-β is considered to be biphasic: It acts early as a tumor suppressor, probably by inhibiting the proliferation of nontransformed cells and it acts later as tumor promoter, by downregulating cellular adhesion molecules, elevating the expression of metallo-proteases, increasing motility and angiogenesis and causing local and systemic immunosuppression, all of which contribute to tumor progression and metastasis. In support of this view, elevated levels of TGF-β are often observed in advanced carcinomas and have been correlated with diseases progression. The potential tumor promoting effects of TGF-β provide novel molecular targets for interventions. Several approaches have been proposed, including the use of blocking antibodies against TGF-β1, TGF-β2, and TGF-β3, using the extracellular domains of the type II and III TGF-β receptors, which would sequester TGF-β isoforms at tumor sites and prevent

binding to cognate receptors and, using adenovirus encoding inhibitors of TGF-β signaling.

References

Dumont et al. 2000. Breast Cancer Res. 2:125-132.

Miyazono K. 1997. International Journal of Hematology. 65:97-104.

Brattain et al. 1996. Current Opinion in Oncology. 8:49-53.

Wrana J.L. 1998. Mineral and Electrolyte Metabolism. 24:120-130.

Moustakas et al. 2001. Journal of Cell Science 114:4359-4369.

Akhurst R.J. 2002. The Journal of Clinical Investigation. Vol. 109, No. 12, Pp. 1533-1536.

Attisano et al. 2002. Science. 296:1646-1647.

Splice variant structure

The present inventors uncovered a novel isoform of TGR2 (SEQ ID NOs: 29 and 31, Figures 21a-b-24) by applying LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1).

This TGR2 splice variant results from alternative splicing of the TGR2 gene, thus causing the extension of exon 3 (the last exon before the exon that encodes the transmembrane domain) leading to an insertion of a stop codon and the generation of a truncated TGR2 protein which ends just before the transmembrane domain. TGR2 splice variant encodes a 176 amino acids long protein which contains the N-terminal signal sequence (residues 1-23), the complete TGF-βR/ activinR domain and a unique sequence of 25 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it retains the original N-terminal signal peptide and lacks the transmembrane domain.

Therapeutic applications for the TGR2 splice variant of the present invention

Since TGR2 splice variant encodes a soluble receptor which contains the complete TGF-βR/ activinR domain, it is expected to bind TGF-β and thus can inhibit TGF-β/TGR2 signaling by competing with the membrane-bound receptor on the ligand, thus preventing TGF-β from binding to the cell surface receptor and activating it. A soluble form of TGR2 has been previously shown to bind TGF-β and to inhibit its signaling in vitro and in vivo. A chimeric Fc:TGR2 protein was shown to be very attractive because of its high affinity for TGF-β and its effectiveness in a number of

animal models. Fc:TGR2 was efficient in reducing tumor metastasis in models of brest cancer and melanoma, whether delivered genetically (transgenic mice) or administered as an injectable circulating drug. Similarly, TGR2 splice variant may be efficient in cancer therapy. In addition to cancer, TGR2 may be used for the treatment of other diseases including organ remodeling diseases/fibrotic diseases, such as chronic renal disease or pulmonary fibrosis, scleroderma and eye's scarring following glaucoma surgery.

EXAMPLE 8

Integrin α-V - ITAV

Background

The integrin family is composed of 15 α and 8 β subunits that form over twenty different αβ heterodimeric combinations on cell surfaces. Integrins recognize extracellular matrix (ECM) proteins and cell surface immunoglobulin family molecules through short peptide sequences. Several integrins (e.g., $\alpha_v\beta_3$, $\alpha_5\beta_1$, $\alpha_{IIb}\beta_3$) interact strongly with the tripeptide Arg-Gly-Asp (RGD) sequence within the context of specific ECM or cell surface proteins. While some integrins recognize only a single ECM protein ligand (e.g. $\alpha_5\beta_1$ recognizes only fibronectin), others can bind several ligands (e.g., $\alpha_v\beta_3$ binds vitronectin, fibronectin, osteopontin, fibrinogen, denatured or proteolysed collagen and other matrix proteins). The integrin-mediated adhesion of cells to the ECM leads to bi-directional intracellular signaling events that can regulate cell survival, proliferation and migration. In contrast, inhibition of integrin-ligands interactions suppresses cellular growth or induces apoptotic cell death. Integrin $\alpha_v\beta_3$, the most promiscuous member of the integrin family, is not widely expressed in normal tissue. It is not generally expressed on ephithelial cells and is expressed only at low levels on resting vascular and uterine smooth muscle as well as endothelium and on certain activated leukocytes, macrophages and osteoclasts. Although $\alpha_v\beta_3$ is not highly expressed on normal cells, it is expressed on tumor cells including late-stage glioblastomas, ovarian carcinoma and melanomas. It contributes to the progression of melanoma by regulating melanoma cell proliferation, survival and metastases. The $\alpha_v\beta_3$ on endothelium cells can take part in the angiogenic process in several ways. It regulates cell adhesion to the matrix, transmit signals to the nucleus of the cell and is pro-angiogenic by co-operating with VEGFR-2, a pro-angiogenic

receptor through the activation of cell signalling and the regulation of cell cycle gene expression. The two β chains identified with α_v and angiogenesis are β_3 and β_5. These subunits share 53% homology, however their ligand specificities are different. $\alpha_v\beta_3$ prefers to bind to osteopontin while $\alpha_v\beta_5$ prefers vitronectin. Two different cytokine-dependent pathways participate in the activation of these two integrins. The $\alpha_v\beta_3$ pathway involves basic FGF (FGF-2) or TNF-α, whereas $\alpha_v\beta_5$ uses VEGF, TGF-α, or PMA. Since the integrin α_v subunit is widely expressed on most cell types and associates with several different β subunits, the expression of $\alpha_v\beta_3$ is likely to be regulated by β transcription. There are additional α_v integrin complexes associated with angiogenesis and blood vessels. They include $\alpha_v\beta_1$ associated with brain blood vessels and with squamous cell carcinoma cell migration; $\alpha_v\beta_8$, identified on tumor cells; and $\alpha_v\beta_6$ which induces secretion of MMP-2 in colon cancer and is important in the progression of this disease.

Clinical applications

The role of integrins in pathological processes in both acute and chronic diseases include ocular, cancer (primary tumors and metastasis), cardiovascular (stroke and heart failure) and inflammatory conditions (rheumatoid arthritis). The α_v integrin has been found to be associated with multiple tumor types, including melanoma, breast, renal, cervical, colon, prostate, bladder, and lung carcinoma. Antibodies to α_v prevent human melanoma tumor formation in nude mice and antagonists of $\alpha_v\beta_3$ potentially inhibit angiogenesis in a number of animal models. Thus, blocking the α_v integrin serves as an important therapeutic strategy in cancer therapy. Inhibitors of integrin function include blocking monoclonal antibody and peptide antagonist, which mimics the RGD ligand recognition domain common to α_v integrin ligands, are in phase II clinical trials.

References

Kerr et al. 2000. Exp.Opin. Invest. Drugs 9(6) :1271-1279.

Tucker G.C. 2003. Current Opinion in Investigational Drugs. 4(6):722-731.

Mould et al. 2000. The Journal of Biological Chemistry. Vol. 275, No. 27, Pp. 20324-20336.

ITAV- splice variant structure

The present inventors uncovered a novel isoform of ITAV (SEQ ID NOs: 33 and 35, Figures 25a-b-28) by applying LEADS clustering and assembly algorithm and the annotation process, as described above (Example 1).

The ITAV splice variant T3 results from alternative splicing of the ITAV gene, causing an extension of exon 24, leading to the insertion of a stop codon and the generation of a truncated ITAV protein which ends before the transmembrane domain. ITAV splice variant T3 has an ORF of 815 amino acids: 811 amino acids of the wild-type protein and a unique sequence of 4 amino acids at the C-terminus. It contains most of the extracellular region of ITAV (811 amino acids out of 993 of the wild-type), including the five integrin alpha repeats. It is predicated to be a secreted protein due to the fact that it retains the original N-terminal signal peptide (amino acids 1-30) and lacks the transmembrane domain (amino acids 993-1016 of the wild-type).

Therapeutic applications for the ITAV splice variant of the present invention

ITAV splice variant T3 can serve as an antagonist of a variety of integrin interactions. It contains most of the extracellular region of ITAV and therefore is likely to bind the ligands. This splice variant can inhibit integrin signaling by competing with the membrane-bound receptor for the different ligands, thus preventing their binding to the cell surface receptor and as a consequence block integrin activation and signaling pathway. Alternatively, it can compete with the wild-type membrane ITAV for binding of the β subunit, thus preventing the heterodimerization of α_v with the β subunit and the subsequent signaling.

Because of the overwhelming evidence favoring the role of α_v integrin in the pathogenesis of a wide array of diseases as cancer, cardiovascular and inflammation, inhibitors of this molecule, such as the ITAV splice variant of the present invention, may have an important therapeutic potential. ITAV splice variant can play a critical role in the treatment of the following pathological conditions: cancer (in general, but in particular colon and melanoma); cardiovascular diseases, such as atherosclerosis, restenosis, ischemia and reperfusion injury; immunological related diseases such as immunodeficiency, allergies, asthma, psoriasis, RA and inflammatory bowl diseases/chrone's disease; metabolism related diseases, such as diabetes and diabetes related retinopathy; osteoporosis, sepsis and wound healing.

EXAMPLE 9

Interleukin-10 receptor β chain

Background

IL-10 was first described as a cytokine that is produced by T helper 2 (Th2) cells that inhibits interferon (IFN)-γ synthesis in Th1 cells. It is a homodimer, produced mainly by macrophages, which has a crucial role in immunoregulation. Its expression is regulated by several endogenous and exogenous factors such as endotoxin, tumor necrosis factor (TNF)-α, catecholamines, and cAMP-elevating agents. IL-10 activity is mediated by its specific cell surface receptor complex, which is expressed on a variety of cells, in particular immune cells. The IL-10 receptor is composed of two different chains, α and β (CRFB4), both members of the class II cytokine receptor family. These receptors are transmembrane glycoproteins whose extracellular domains consist of about 210 amino acids comprising two tandem fibronectin type III domains and having several conserved amino acid important for the secondary structure. The interaction of IL-10R with IL-10 seems to be highly complex. The IL-10Rβ chain (Swissprot Locus No. I10S_HUMAN) is essential for IL-10-mediated effects as CRFB4-deficient mice display the same phenotype as IL-10 deficient mice.

Interestingly, in cells which express IL-10Rβ exclusively, no IL-10/IL-10R complexes are formed, suggesting that only IL-10/IL-10Rα complexes interact with the β-chain. However in cells expressing both the IL-10Rα and β chains the characteristic STAT transcription factor activation pattern for IL-10 signaling is observed. . The IL-10/IL-10R interaction activates the tyrosine kinases Jak1 and Tyk2, which are associated with the IL-10Rα and IL-10Rβ2, respectively. The receptor engagement and tyrosine phosphorylation activates the cytoplasmically localized inactive transcription factors STAT 1, 3, and 5, resulting in their translocation to the nucleus and downstream gene activation. IL-10 signaling results in the inhibition of immune functions. It controls inflammatory processes by suppressing the expression of proinflammatory cytokines, chemokines, adhesion molecules, as well as antigen-presenting and costimulatory molecules in monocytes/ macrophages, neutrophils, and T cells. As all of these inflammatory proteins are transcriptionally controlled by NF-κB it wasn't surprising to find out that IL-10 exerts a significant part of its anti-inflammatory properties by inhibiting this

transcription factor. Antigen-presenting cells and lymphocytes are the primary targets of IL-10. Direct effects on these populations explains the major immunological impact of this cytokine, including the regulation of the Th1/Th2 balance. IL-10 reverses the Th1 cytokine pattern present. It promotes the development of a type 2 cytokine pattern by inhibiting the IFN-γ production of T lymphocytes particularly via the suppression of IL-12 synthesis in accessory cells. According to this, IL-10 costimulates the proliferation and differentiation of B cells, which is important in the adequate defense against intestinal parasites, neutralization of bacterial toxins, and in local mucosa defense. Moreover, IL-10 suppresses the production of proinflammatory cytokines as IL-1β, IL-6,IL-8,G-CSF, GM-CSF, TNFα while enhances the production of anti-inflammatory mediators such as IL-1RA and soluble TNFα receptors. In addition it inhibits the capacity of monocytes/macrophages and dendritic cells to present antigen to T cells. This is realized by down-regulation of cell surface levels of MHC class II, of costimulatory molecules such as CD86 and of some adhesion molecules such as CD58.

Clinical applications

Its considerable anti-inflammatory effects and ability to act as a main suppressor of cellular immunity raises the question of the IL-10 expression under pathophysiological conditions. Both overexpression (e.g., in lymphoma, melanoma, carcinoma) as well as IL-10 deficency were found (e.g., in inflammatory bowel disease, psoriasis) and seems to have a pathophysiological significance. IL-10 overexpression in different malignancies might contribute to tumor development, in particular, by suppressing the antitumor immune response. Moreover, IL-10 might even be a tumor cell growth factor in certain tumors such as B cell lymphoma and melanoma. In contrast to several malignancies, where there is an overexpression of IL-10, a relative deficiency is considered to be of pathophysiological relevance in chronic inflammatory disorders characterized by the predominance of a type1 cytokine pattern. These included psoriasis, inflammatory bowel disease such as Crohn's diseases, multiple sclerosis, rheumatoid arthritis, transplant rejection, and allergic contact dermatitis. The immunomodulatory properties of IL-10 and the promising results from IL-10 delivery on the course of several inflammatory diseases in experimental models induced the interest on clinical application of IL-10. So far human recombined IL-10 (ilodecakin/Tenovil; Schering-Plough Research,Kenilworth,

NJ) has been tested in healthy volunteers, patients with Crohn's disease, rheumatoid arthritis, psoriasis, hepatitis C infection, HIV infection, and for the inhibition of therapy associated cytokine releases in organ transplantation and Jarisch-Herxheimer reaction. Application of IL-10 in humans seems to be safe and immunologically active. The clinical effects of recombinant IL-10, however, have been quite heterogeneous in different entities. Whereas almost no effect was seen in rheumatoid arthritis and CD, significant response was observed in psoriasis.

References

Asadullah et al. 2003. Pharmacol Rev. 55:241-269.

Kotenko S.V. 2002. Cytokine & Growth Factor Reviews. 13:223-240.

Walter M.R. 2002. Immunologic Research. 26/1-3:303-308.

Moore et al. 2001. Annu. Rev. Immunol. 19:683-765.

IL-10-Rβ- splice variant structure

The present inventors uncovered a novel isoform of IL-10Rβ (SEQ ID Nos. 37 and 39, Figures 29a-b-32). IL-10-Rβ splice variant results from alternative splicing of the IL-10-Rβ gene, thus causing the skipping of exon 6 (the exon which encodes the transmembrane domain), leading to the insertion of a stop codon and the generation of a truncated protein. IL-10-Rβ splice variant encodes a 222 amino acids long protein which contains the N-terminal signal sequence (residues 1-17), the complete 2 fibronectin type III domains and a unique sequence of 7 amino acids at the C-terminus of the protein. It is predicated to be a secreted protein due to the fact that it has lost its transmembrane domain.

Therapeutic applications for the IL-10-Rβ splice variant of the present invention

IL-10 exhibits low in-vivo half life. Therefore extension its half life has a therapeutic advantage. Soluble receptors have been shown to exhibit agonistic properties including, increasing the molecular internal stability of the ligand, protection from proteolysis and modification of the pharmacokinetic properties of the ligand, namely, increasing its in vivo half-life while decreasing its clearance. IL-10-Rβ splice variant which encodes a soluble receptor might serve as an agonist, increaseing IL-10 half-life in vivo and therefore enhancing its biological effect. Thus, this splice variant may have an important therapeutic potential for the treatment of the following pathological conditions: inflammatory diseases, such as, psoriasis,

inflammatory bowel diseases (Crohn's disease), colitis ulcerative, multiple sclerosis, RA, transplant rejection and allergic contact dermatitis; hepatitis C infection; HIV infection and atherosclerosis.

EXAMPLE 10

Interferon-α/β-receptor-1- IFNAR1-INR1

Background

Type I interferons (IFNs), initially identified for their ability to protect cells from viral infections, are truly pleiotropic cytokines. They are also implicated in both normal and neoplastic cell growth regulation and in modulating both innate and adaptive immune responses to microbial challenge. All type I IFNs, IFN-αs, IFN-β, IFN-ω,

IFN-κ, and IFN-τ, are functionally active as monomers and activate a specific receptor complex composed of two major subunits, IFNAR-1/INR1 and IFNAR-2/INR2. The high affinity interaction between IFN-α/β and its specific cell surface receptor leads to receptor aggregation and the activation of receptor-associated cytoplasmic tyrosine kinases of the Jak family- Jak1 and Tyk2. These in turn phosphorylate intracellular tyrosine residues of the IFNAR-1 and IFNAR-2 chains, that serve as recruitment sites for the signal transducers and activators of transcription (STAT) proteins, Stat 1-5. Once associated with the activated receptor, the STAT become phosphorylated, then form both homodimers and heterodimers, which translocate to the nucleus and bind specific DNA sequences within the promoter regions of IFN-sensitive genes (ISG). The Jak-Stat pathway is an essential signaling pathway for the transcription of many ISGs, whose protein products mediate specific IFN-dependent biologic responses. IFNs mediate a critical role in innate cellular defense against viral infection. Mice deficient in IFN-β or in IFNAR-1 are highly susceptible to viral infections. The antiviral activity of INFs include inhibition of viral replication and protein synthesis and the induction of viral mRNA degradation. In addition to their antiviral activity, IFNs exhibit growth inhibitory activity, either by mediating cell death (through caspases) or by modulating the expression of proteins regulating cell cycle entry and exit, hence mediating growth arrest. IFNs are also involved in the regulation of immune response towards viral or tumor challenge. A well-characterized function of IFNs is their ability to upregulate MHC class I

expression and consequently promote CD8+ T cell responses. Moreover, IFNs can regulate the expression of key cytokines that influence T cell responses, namely, IL-12, IL-15 and IFN-γ and of CC- chemokines. IFNs-α/β regulate the functions of immune cells from different lineages including NK cells, dentritic cells and B/T lymphocytes.

Clinical application

Due to their growth inhibitory activity and the modulation of immune responses, type I interferons have been used as therapeutic agents against a variety of solid tumors and hematological malignancies. IFN-α has been approved for the treatment of chronic myelogenous leukemia (CML), multiple myeloma and hairy cell leukemia.

At this time, IFN-α is the treatment of choice for CML patients not eligible for allogeneic bone marrow transplantation. In addition, it may have the potential therapeutic value in the treatment of several lymphomas. Apart from the widespread therapeutic indications for IFNs in the treatment of neoplasias, their efficacy as therapeutic agents for the treatment of viral infections and autoimmune diseases has been proved. IFN-α is the treatment of choice for hepatitis B and C infections and accumulating evidence supports the use of IFN-β for the treatment of multiple sclerosis.

References

Deonarain et al. 2002. Current Pharmaceutical Design. Vol. 8, No. 24, Pp. 2131-2137.

Brierley et al. 2002. Journal of Interferon and Cytokine Research. 22:835-845.

INR1-splice variant structure

The present inventors uncovered a novel isoform of INR1 (SEQ ID NOs: 41 and 43, Figures 33a-b-35). INR1 splice variant 11 results from alternative splicing of the INR1 gene, thus causing an extension of exon 9, leading to an insertion of a stop codon and the generation of a truncated protein. INR1 splice variant T11 encodes a 441 amino acids long protein which contains the N-terminal signal sequence (residues 1-27), the complete extracellular portion of the wild-type INR1 (up to amino acid 427), including the four fibronectin type III-like domains and a unique sequence of 10 amino acids at the C-terminus of the protein. It is predicted to be a secreted protein since it does not contain the transmembrane domain (residues 437-457).

Therapeutic applications for the INR1 splice variant of the present invention

Although the activity and specificity of function make the IFNs potentially therapeutic agents, they are not ideal drugs, exhibiting low stability in vivo. Thus, there is an intense interest in developing alternative or improved molecules that demonstrate IFNs function but have superior pharmacological properties. For example, PEGylation of type I IFNs extends the serum half-life and duration of therapeutic activity. PEGylation of IFN-α and IFN-β increased their serum half-life by 6 and 5 fold, respectively, however the PEGylated form of IFN-β exhibited less efficient systemic distribution with some evidence of induction of neutralizing antibodies. As opposed to their well-characterized function as competitive inhibitors (antagonists), soluble receptors have been shown to exhibit agonistic properties. These include increasing the molecular internal stability of the ligand, protection from proteolysis and modification of the pharmacokinetic properties of the ligand, namely, increasing its in vivo half-life while decreasing its clearance.

INR1 splice variants which encode soluble receptors might serve as agonists, increaseing IFNs half-life in vivo and therefore enhancing their biological effect. Thus, this splice variant may have an important therapeutic potential for the treatment of the following pathological conditions: cancer, such as, solid tumors (e.g., glioblastoma, renal cell carcinoma, melanoma) and hematological malignancies (e.g., chronic myelogenous leukemia (CML), multiple myeloma, non-Hodgkin's lymphomaand hairy cell leukemia), viral infections (e.g., hepatitis B/C, herpes and human papilloma virus) and autoimmune diseases such as multiple sclerosis.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad

scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

2. The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 3.

3. The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 4.

4. The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 1.

5. The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 2.

6. An isolated polynucleotide as set forth in SEQ ID NO: 4.

7. An isolated polynucleotide as set forth in SEQ ID NO: 3.

8. An isolated polypeptide as set forth in SEQ ID NO: 1.

9. An isolated polypeptide as set forth in SEQ ID NO: 2.

10. A nucleic acid construct comprising the isolated polynucleotide of claim 1.

11. The nucleic acid construct of claim 10, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

12. The nucleic acid construct of claim 10, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

13. A host cell comprising the nucleic acid construct of claim 10.

14. An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

15. An antibody or an antibody fragment being capable of specifically binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

16. An oligonucleotide specifically hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

17. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

18. A method of treating Met-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters, thereby treating the Met-related disease in a subject.

19. The method of claim 18, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

20. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

21. The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 8.

22. The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 7.

23. The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 5.

24. The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 6.

25. An isolated polynucleotide as set forth in SEQ ID NO: 8.

26. An isolated polynucleotide as set forth in SEQ ID NO: 7.

27. An isolated polypeptide as set forth in SEQ ID NO: 5.

28. An isolated polypeptide as set forth in SEQ ID NO: 6.

29. A nucleic acid construct comprising the isolated polynucleotide of claim 20.

30. The nucleic acid construct of claim 29, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

31. The nucleic acid construct of claim 29, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

32. A host cell comprising the nucleic acid construct of claim 29.

33. An isolated polypeptide comprising an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

34. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

35. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

36. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

37. A method of treating an IL-6-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5 as determined using the

LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters, thereby treating the IL-6-related disease in the subject.

38. The Method of claim 37, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

39. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

40. The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 11.

41. The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 12.

42. The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 9.

43. The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 10.

44. An isolated polynucleotide as set forth in SEQ ID NO: 11.

45. An isolated polynucleotide as set forth in SEQ ID NO: 12.

46. An isolated polypeptide as set forth in SEQ ID NO: 10.

47. An isolated polypeptide as set forth in SEQ ID NO: 9.

48. A nucleic acid construct comprising the isolated polynucleotide of claim 39.

49. The nucleic acid construct of claim 48, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

50. The nucleic acid construct of claim 48, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

51. A host cell comprising the nucleic acid construct of claim 48.

52. An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

53. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

54. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

55. A pharmaceutical composition comprising a therapeutically effective amount of a IL-7 polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

56. A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

57. The method of claim 56, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

58. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

59. The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 15.

60. The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 16.

61. The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 13.

62. The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 14.

63. An isolated polynucleotide as set forth in SEQ ID NO: 15.

64. An isolated polynucleotide as set forth in SEQ ID NO: 16.

65. An isolated polypeptide as set forth in SEQ ID NO: 13.

66. An isolated polypeptide as set forth in SEQ ID NO: 14.

67. A nucleic acid construct comprising the isolated polynucleotide of claim 58.

68. The nucleic acid construct of claim 67, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

69. The nucleic acid construct of claim 67, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

70. A host cell comprising the nucleic acid construct of claim 67.

71. An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

72. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

73. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

74. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 85 % identical to

SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

75. A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

76. The method of claim 75, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

77. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

78. The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 19.

79. The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 20.

80. The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 17.

81. The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 18.

82. An isolated polynucleotide as set forth in SEQ ID NO: 19.

83. An isolated polynucleotide as set forth in SEQ ID NO: 20.

84. An isolated polypeptide as set forth in SEQ ID NO: 17.

85. An isolated polypeptide as set forth in SEQ ID NO: 18.

86. A nucleic acid construct comprising the isolated polynucleotide of claim 77.

87. The nucleic acid construct of claim 86, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

88. The nucleic acid construct of claim 86, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

89. A host cell comprising the nucleic acid construct of claim 86.

90. An isolated polypeptide comprising an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

91. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

92. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 60 % identical to SEQ ID NO: 17, as

determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

93. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

94. A method of treating TNFR9-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

95. The method of claim 94, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

96. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

97. The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 27.

98. The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 28.

99. The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 25.

100. The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 26.

101. An isolated polynucleotide as set forth in SEQ ID NO: 27.

102. An isolated polynucleotide as set forth in SEQ ID NO: 28.

103. An isolated polypeptide as set forth in SEQ ID NO: 25.

104. An isolated polypeptide as set forth in SEQ ID NO: 26.

105. A nucleic acid construct comprising the isolated polynucleotide of claim 96.

106. The nucleic acid construct of claim 105, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

107. The nucleic acid construct of claim 105, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

108. A host cell comprising the nucleic acid construct of claim 105.

109. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

110. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25,

as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

111. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

112. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

113. A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

114. The method of claim 113, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or ,

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

115. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

116. The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 24.

117. The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 23.

118. The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 21.

119. The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 22.

120. An isolated polynucleotide as set forth in SEQ ID NO: 23.

121. An isolated polynucleotide as set forth in SEQ ID NO: 24.

122. An isolated polypeptide as set forth in SEQ ID NO: 21.

123. An isolated polypeptide as set forth in SEQ ID NO: 22.

124. A nucleic acid construct comprising the isolated polynucleotide of claim 115.

125. The nucleic acid construct of claim 124, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

126. The nucleic acid construct of claim 124, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

127. A host cell comprising the nucleic acid construct of claim 124.

128. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

129. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

130. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

131. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

132. A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

133. The method of claim 132, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

134. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

135. The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 31.

136. The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 32.

137. The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 29.

138. The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 30.

139. An isolated polynucleotide as set forth in SEQ ID NO: 31.

140. An isolated polynucleotide as set forth in SEQ ID NO: 32.

141. An isolated polypeptide as set forth in SEQ ID NO: 29.

142. An isolated polypeptide as set forth in SEQ ID NO: 30.

143. A nucleic acid construct comprising the isolated polynucleotide of claim 134.

144. The nucleic acid construct of claim 143, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

145. The nucleic acid construct of claim 143, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

146. A host cell comprising the nucleic acid construct of claim 143.

147. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

148. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

149. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

150. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

151. A method of treating TGR2-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

152. The method of claim 151, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

153. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

154. The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 35.

155. The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 36.

156. The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 33.

157. The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 34.

158. An isolated polynucleotide as set forth in SEQ ID NO: 35.

159. An isolated polynucleotide as set forth in SEQ ID NO: 36.

160. An isolated polypeptide as set forth in SEQ ID NO: 33.

161. An isolated polypeptide as set forth in SEQ ID NO: 34.

162. A nucleic acid construct comprising the isolated polynucleotide of claim 153.

163. The nucleic acid construct of claim 162, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

164. The nucleic acid construct of claim 162, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

165. A host cell comprising the nucleic acid construct of claim 162.

166. An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

167. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

168. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

169. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

170. A method of treating ITAV-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

171. The method of claim 170, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

172. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

173. The isolated polynucleotide of claim 172, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 39.

174. The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 37.

175. The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 38.

176. An isolated polynucleotide as set forth in SEQ ID NO: 39.

177. An isolated polypeptide as set forth in SEQ ID NO: 37.

178. An isolated polypeptide as set forth in SEQ ID NO: 38.

179. A nucleic acid construct comprising the isolated polynucleotide of claim 172.

180. The nucleic acid construct of claim 179, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

181. The nucleic acid construct of claim 179, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

182. A host cell comprising the nucleic acid construct of claim 179.

183. An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

184. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

185. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

186. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

187. A method of treating IL10-R-B-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

188. The method of claim 187, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

189. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

190. The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 43.

191. The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 40.

192. The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 41.

193. The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 42.

194. An isolated polynucleotide as set forth in SEQ ID NO: 43.

195. An isolated polynucleotide as set forth in SEQ ID NO: 40.

196. An isolated polypeptide as set forth in SEQ ID NO: 41.

197. An isolated polypeptide as set forth in SEQ ID NO: 42.

198. A nucleic acid construct comprising the isolated polynucleotide of claim 189.

199. The nucleic acid construct of claim 189, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

200. The nucleic acid construct of claim 189, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

201. A host cell comprising the nucleic acid construct of claim 198.

202. An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

203. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

204. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

205. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

206. A method of treating INR1-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41 as determined using the

LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

207. The method of claim 206, wherein said upregulating expression of said polypeptide is effected by:

(i) administering said polypeptide to the subject; and/or

(ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

MET_T9 (SEQ ID NO: 3)

gaattccgccctcgccgcccgcggcgccccgagcgctttgtgagcagatgcggagccgag
tggagggcgcgagccagatgcggggcgacagctgacttgctgagaggaggcggggaggcg
cggagcgcgcgtgtggtccttgcgccgctgacttctccactggttcctgggcaccgaaag
ataaacctctcataATGaaggcccccgctgtgcttgcacctggcatcctcgtgctcctgt
ttaccttggtgcagaggagcaatggggagtgtaaagaggcactagcaaagtccgagatga
atgtgaatatgaagtatcagcttcccaacttcaccgcggaaacacccatccagaatgtca
ttctacatgagcatcacattttccttggtgccactaactacatttatgttttaaatgagg
aagaccttcagaaggttgctgagtacaagactgggcctgtgctggaacacccagattgtt
tcccatgtcaggactgcagcagcaaagccaatttatcaggaggtgtttggaaagataaca
tcaacatggctctagttgtcgacacctactatgatgatcaactcattagctgtggcagcg
tcaacagagggacctgccagcgacatgtctttccccacaatcatactgctgacatacagt
cggaggttcactgcatattctccccacagatagaagagcccagccagtgtcctgactgtg
tggtgagcgccctgggagccaaagtcctttcatctgtaaaggaccggttcatcaacttct
ttgtaggcaataccataaattcttcttatttcccagatcatccattgcattcgatatcag
tgagaaggctaaaggaaacgaaagatggttttatgtttttgacggaccagtcctacattg
atgttttacctgagttcagagattcttaccccattaagtatgtccatgcctttgaaagca
acaattttatttacttcttgacggtccaaagggaaactctagatgctcagacttttcaca
caagaataatcaggttctgttccataaactctggattgcattcctacatggaaatgcctc
tggagtgtattctcacagaaaagagaaaaaagagatccacaaagaaggaagtgtttaata
tacttcaggctgcgtatgtcagcaagcctggggcccagcttgctagacaaataggagcca
gcctgaatgatgacattcttttcggggtgttcgcacaaagcaagccagattctgccgaac
caatggatcgatctgccatgtgtgcattccctatcaaatatgtcaacgacttcttcaaca
agatcgtcaacaaaaacaatgtgagatgtctccagcatttttacggacccaatcatgagc
actgctttaataggacacttctgagaaattcatcaggctgtgaagcgcgccgtgatgaat
atcgaacagagtttaccacagctttgcagcgcgttgacttattcatgggtcaattcagcg
aagtcctcttaacatctatatccaccttcattaaaggagacctcaccatagctaatcttg
ggacatcagagggtcgcttcatgcaggttgtggtttctcgatcaggaccatcaacccctc
atgtgaattttctcctggactcccatccagtgtctccagaagtgattgtggagcatacat
taaaccaaaatggctacacactggttatcactgggaagaagatcacgaagatcccattga
atggcttgggctgcagacatttccagtcctgcagtcaatgcctctctgccccacccttg
ttcagtgtggctggtgccacgacaaatgtgtgcgatcggaggaatgcctgagcgggacat
ggactcaacagatctgtctgcctgcaatctacaaggttttcccaaatagtgcacccctg
aaggagggacaaggctgaccatatgtggctgggactttggatttcggaggaataataaat
ttgatttaaagaaaactagagttctccttggaaatgagagctgcaccttgactttaagtg
agagcacgatgaatacattgaaatgcacagttggtcctgccatgaataagcatttcaata
tgtccataattatttcaaatggccacgggacaacacaatacagtacattctcctatgtgg
atcctgtaataacaagtatttcgccgaaatacggtcctatggctggtggcactttactta
ctttaactggaaattacctaaacagtgggaattctagacacatttcaattggtggaaaaa
catgtactttaaaaagtgtgtcaaacagtattcttgaatgttataccccagcccaaacca
tttcaactgagtttgctgttaaattgaaaattgacttagccaaccgagagacaagcatct
tcagttaccgtgaagatcccattgtctatgaaattcatccaaccaaatcttttattagtg
gtgggagcacaataacaggtgttgggaaaaacctgaattcagttagtgtcccgagaatgg
tcataaatgtgcatgaagcaggaaggaactttacagtggcatgtcaacatcgctctaatt
cagagataatctgttgtaccactccttccctgcaacagctgaatctgcaactcccctga
aaaccaaagccttttcatgttagatgggatcctttccaaatactttgatctcatttatg
tacataatcctgtgtttaagccttttgaaaagccagtgatgatctcaatgggcaatgaaa
atgtactggaaattaagggaaatgatattgaccctgaagcagttaaaggtgaagtgttaa
aagttggaaataagagctgtgagaatatacacttacattctgaagccgttttatgcacgg
tccccaatgacctgctgaaattgaacagcgagctaaatatagaggtgggattcctgcatt
cctctcatgatgtaaataaggaagccagtgtaattatgttattctcaggcttaaaaTAAa
tcattaaagctcatttatgtgtgggttttggctcatcaactc

Fig. 1a

MET T9 (SEQ ID NO: 1)

MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHE
HHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINM
ALVVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVV
SALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYID
VLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMP
LECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSA
EPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARR
DEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGP
STPHVNFLLDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLS
APPFVQCGWCHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGF
RRNNKFDLKKTRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQY
STFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILE
CYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNL
NSVSVPRMVINVHEAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGI
LSKYFDLIYVHNPVFKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENI
HLHSEAVLCTVPNDLLKLNSELNIEVGFLHSSHDVNKEASVIMLFSGLK

Fig. 1b


Met-Hepatocyte growth factor receptor-
ESTs supporting the new variant
Novel Transcript

Fig. 2

hsu08818_t9.pfs

Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:MET_HUMAN

Sequence documentation:
Hepatocyte growth factor receptor precursor (EC 2.7.1.112) (Met proto-oncogene tyrosine kinase) (c-met) (HGF receptor) (HGF-SF receptor).
Homo sapiens (Human). P08581; O60366; Q9UPL8;

Alignment of: HSU08818_T9 x MET_HUMAN ..

```
       .         .         .         .         .
   1 MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAET 50
     ||||||||||||||||||||||||||||||||||||||||||||||||||
   1 MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAET 50
       .         .         .         .         .
  51 PIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQD 100
     ||||||||||||||||||||||||||||||||||||||||||||||||||
  51 PIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQD 100
       .         .         .         .         .
 101 CSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNH 150
     ||||||||||||||||||||||||||||||||||||||||||||||||||
 101 CSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNH 150
       .         .         .         .         .
 151 TADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNT 200
     ||||||||||||||||||||||||||||||||||||||||||||||||||
 151 TADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNT 200
       .         .         .         .         .
 201 INSSYFPDHPLHISISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYV 250
     ||||||||||||||||||||||||||||||||||||||||||||||||||
 201 INSSYFPDHPLHISISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYV 250
       .         .         .         .         .
 251 HAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECIL 300
     ||||||||||||||||||||||||||||||||||||||||||||||||||
 251 HAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECIL 300
       .         .         .         .         .
 301 TEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSK 350
     ||||||||||||||||||||||||||||||||||||||||||||||||||
 301 TEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSK 350
       .         .         .         .         .
 351 PDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNR 400
     ||||||||||||||||||||||||||||||||||||||||||||||||||
 351 PDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNR 400
       .         .         .         .         .
 401 TLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDL 450
     ||||||||||||||||||||||||||||||||||||||||||||||||||
 401 TLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDL 450
       .         .         .         .         .
 451 TIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNG 500
     ||||||||||||||||||||||||||||||||||||||||||||||||||
 451 TIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNG 500
       .         .         .         .         .
 501 YTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEE 550
     ||||||||||||||||||||||||||||||||||||||||||||||||||
 501 YTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEE 550
       .         .         .         .         .
 551 CLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKK 600
           .         .         .         .         .
```

Fig. 3

```
601 TRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYS 650
    ||||||||||||||||||||||||||||||||||||||||||||||||||
601 TRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYS 650
651 TFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLK 700
    ||||||||||||||||||||||||||||||||||||||||||||||||||
651 TFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLK 700
701 SVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPT 750
    ||||||||||||||||||||||||||||||||||||||||||||||||||
701 SVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPT 750
751 KSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQHRSNSEIIC 800
    ||||||||||||||||||||||||||||||||||||||||||||||||||
751 KSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQHRSNSEIIC 800
801 CTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFKPFEKPVMI 850
    ||||||||||||||||||||||||||||||||||||||||||||||||||
801 CTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFKPFEKPVMI 850
851 SMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDL 900
    ||||||||||||||||||||||||||||||||||||||||||||||||||
851 SMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDL 900
901 LKLNSELNIEVGFLHSSHDVNKEASVIMLFSGLK                 934
    ||||||||||
901 LKLNSELNIE.....                                   910
```

Fig. 3 (Cont.)


MET structure
W.T
SP
1-24
Sema Domain
55-500
PSI
519-562
TIG
563-655
TIG
657-739
TIG
742-836
TM
933-955
pkinase
1078-1339
SV
SP
1-24
Sema Domain
55-500
PSI
519-562
TIG
563-655
TIG
657-739
TIG
742-836
24 a.a

Fig. 4

IL6 T6 (SEQ ID NO: 7)

ccatgtttggtaaataagtgttttggtgttgtgcaagggtctggtttcagcctgaagcca
tctcagagctgtctgggtctctggagactggagggacaacctagtctagagcccatttgc
atgagaccaaggatcctcctgcaagagacaccatcctgagggaagagggcttctgaacca
gcttgacccaataagaaattcttgggtgccgacgcggaagcagattcagagcctagagcc
gtgcctgcgtccgtagtttccttctagcttcttttgatttcaaatcaagacttacaggga
gagggagcgataaacacaaactctgcaagatgccacaaggtcctcctttgacatccccaa
caaagaggactggagatgtctgaggctcattctgccctcgagcccaccgggaacgaaaga
gaagctctatctcccctccaggagcccagctATGaactccttctccacaagcgccttcgg
tccagttgccttctccctggggctgctcctggtgttgcctgctgccttccctgccccagt
acccccaggagaagattccaaagatgtagccgccccacacagacagccactcacctcttc
agaacgaattgacaaacaaattcggtacatcctcgacggcatctcagccctgagaaagga
gacatgtaacaagagtaacatgtgtgaaagcagcaaagaggcactggcagaaaacaacct
gaaccttccaaagatggctgaaaaagatggatgcttccaatctggattcaatgaggagac
ttgcctggtgaaaatcatcactggtcttttggagtttgaggtatacctagagtacctcca
gaacagatttgagagtagtgaggaacaagccagagctgtgcagatgagtacaaaagtcct
gatccagttcctgcagaaaaaggtgggtgtgtcctcattccctcaacttggtgtgggggga
agacaggctcaaagacagtgtcctggacaactcagggatgcaatgccacttccaaaagag
aaggctacacgtaaacaaaagagtcTGAgaaatagtttctgattgttattgttaaatctt
tttttgtttgtttggttggttggctctcttctgcaaaggacatcaa

Fig. 5a

IL-6 T6 (SEQ ID NO: 5)

MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYI
LDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLL
EFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKKVGVSSFPQLGVGEDRLKDSVLDN
SGMQCHFQKRRLHVNKRV

Fig. 5b

Interleukin 6



Fig. 6

```
s56892_p6(t6).pfs

Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:IL6_HUMAN

Sequence documentation:
Interleukin-6 precursor (IL-6) (B-cell stimulatory factor 2) (BSF-2)
(Interferon beta-2) (Hybridoma growth factor) (CTL differentiation
factor) (CDF).  Homo sapiens (Human).  P05231; Q9UCU2; Q9UCU3; Q9UCU4;

Alignment of: S56892_P6 x IL6_HUMAN   ..
                .         .         .         .         .
       1 MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS 50
         ||||||||||||||||||||||||||||||||||||||||||||||||||
       1 MNSFSTSAFGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS 50
                .         .         .         .         .
      51 ERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDG 100
         ||||||||||||||||||||||||||||||||||||||||||||||||||
      51 ERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDG 100
                .         .         .         .         .
     101 CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVL 150
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     101 CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVL 150
                .         .         .         .
     151 IQFLQKKVGVSSFPQLGVGEDRLKDSVLDNSGMQCHFQKRRLHVNKRV   198
         |||||||
     151 IQFLQKK.....................................   157
```

Fig. 7



Fig. 8

IL-7 T7 (SEQ ID NO: 11)

aagacgaatagtttgatttattagccaattcagataaatgtgcacgtggaagtcatagtt
aaatattatcgtcagtttccacgtcctgcgtttaatttggggtttgattttccaaataca
acacttaccagattaggtggacccacaggattatttttccttgaggtctcacctgagcag
gtgcatgtacagcagacggagcagaaagagactgattagagaggttggagtggtagaggg
cgtgaccctcttaatcattcttcacttccttttttaaaagacgacttggcatcgtccacc
acatccgcggcaacgcctccttggtgtcgtccgcttccaataacccagcttgcgtcctgc
acacttgtggcttccgtgcacacattaacaactcatggttctagctcccagtcgccaagc
gttgccaaggcgttgagagatcatctgggaagtcttttacccagaattgctttgattcag
gccagctggtttttcctgcggtgattcggaaattcgcgaattcctctggtcctcatccag
gtgcgcgggaagcaggtgcccaggagagaggggataatgaagattccatgctgatgatcc
caaagattgaacctgcagaccaagcgcaaagtagaaactgaaagtacactgctggcggat
cctacggaagttatggaaaaggcaaagcgcagagccacgccgtagtgtgtgccgcccccc
ttgggatggatgaaactgcagtcgcggcgtgggtaagaggaaccagctgcagagatcacc
ctgcccaacacagactcggcaactccgcggaagaccagggtcctgggagtgactatgggc
ggtgagagcttgctcctgctccagttgcggtcatcatgactacgcccgcctcccgcagac
cATGttccatgtttcttttaggtatatctttggacttcctcccctgatccttgttctgtt
gccagtagcatcatctgattgtgatattgaaggtaaagatggcaaacaatatgagagtgt
tctaatggtcagcatcgatcaattattggacagcatgaaagaaattggtagcaattgcct
gaataatgaatttaacttttttaaaagacatatctgtgatgctaataaggaaggtatgtt
tttattccgtgctgctcgcaagttgaggcaatttcttaaaatgaatagcactggtgattt
tgatctccacttattaaaagtttcagaaggcacaacaatactgttgaactgcactggcca
ggttaaaggaagaaaaccagctgccctgggtgaagcccaaccaacaaagagtttgtcctc
aggactacagaagcagttcacattttacagatcaaacggacgacacacacattctttcca
ctgcaaattgtcctttctccacTAGaaggtatcagtttctccaaataaattgtatcaact
tgagggcagacacttaattacatcttattatctcgatccccatcattgcatatccagaaa
gagcacataaagcgtttttcaatgcttattttagttgatggactatttgtttctttgttt
tgaccaataagactgaataaagataactgaggggaaaaaaattaacaactaatcaggaaa
taaacttttttcggatttatgaaataatttgttgacatgctctacaggagtgaccttaac
atacctaatggtaactaaaactgttctctttaattacaaaattcccagcatctatcctac
tatgatactatctgaagataggcaccaataatacaaatgtttatccaaa

Fig. 9a

IL-7 T7 (SEQ ID NO: 9)

MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCL
NNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQ
VKGRKPAALGEAQPTKSLSSGLQKQFTFYRSNGRHTHSFHCKLSFLH

Fig. 9b

IL7-T8 (SEQ ID NO: 15)

aagacgaatagtttgatttattagccaattcagataaatgtgcacgtggaagtcatagtt
aaatattatcgtcagtttccacgtcctgcgtttaatttggggtttgattttccaaataca
acacttaccagattaggtggacccacaggattatttttccttgaggtctcacctgagcag
gtgcatgtacagcagacggagcagaaagagactgattagagaggttggagtggtagaggg
cgtgaccctcttaatcattcttcacttccttttttaaaagacgacttggcatcgtccacc
acatccgcggcaacgcctccttggtgtcgtccgcttccaataacccagcttgcgtcctgc
acacttgtggcttccgtgcacacattaacaactcatggttctagctcccagtcgccaagc
gttgccaaggcgttgagagatcatctgggaagtcttttacccagaattgctttgattcag
gccagctggtttttcctgcggtgattcggaaattcgcgaattcctctggtcctcatccag
gtgcgcgggaagcaggtgcccaggagagaggggataatgaagattccatgctgatgatcc
caaagattgaacctgcagaccaagcgcaaagtagaaactgaaagtacactgctggcggat
cctacggaagttatggaaaaggcaaagcgcagagccacgccgtagtgtgtgccgcccccc
ttgggatggatgaaactgcagtcgcggcgtgggtaagaggaaccagctgcagagatcacc
ctgcccaacacagactcggcaactccgcggaagaccagggtcctgggagtgactatgggc
ggtgagagcttgctcctgctccagttgcggtcatcatgactacgcccgcctcccgcagac
cATGttccatgtttcttttaggtatatctttggacttcctcccctgatccttgttctgtt
gccagtagcatcatctgattgtgatattgaaggtaaagatggcaaacaatatgagagtgt
tctaatggtcagcatcgatcaattattggacagcatgaaagaaattggtagcaattgcct
gaataatgaatttaacttttttaaaagacatatctgtgatgctaataaggaaggtatgtt
tttattccgtgctgctcgcaagttgaggcaatttcttaaaatgaatagcactggtgattt
tgatctccacttattaaaagtttcagaaggcacaacaatactgttgaactgcactggcca
ggttaaaggaagaaaaccagctgccctgggtgaagcccaaccaacaaagagtttggtgga
actgatcattccttcatgtatgcctccactgctcagctcaacaagtaactctTAAtaacc
taccacctgttatctctgggagagggacatatgtttgccaatttctatcttcaatgctta
tcacaaattttcttatatttgaaataatctgattcaaatgagaactttaacctaaaactt
taattggaaagacaatcttataaaaatcttataacatattc

Fig. 9c

IL7 T8 (SEQ ID NO: 13)

MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLDSMKEIGSNCL
NNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDFDLHLLKVSEGTTILLNCTGQ
VKGRKPAALGEAQPTKSLVELIIPSCMPPLLSSTSNS

Fig. 9d


Interleukin 7
Novel Transcripts
EST supporting new variant (T8)
EST supporting new variant (T7)

Fig. 10

```
humil7a_p4(t7).pfs

Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:IL7_HUMAN

Sequence documentation:
Interleukin-7 precursor (IL-7).  Homo sapiens (Human).  P13232;

Alignment of: HUMIL7A_P4 x IL7_HUMAN    ..

       1 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLD 50
         ||||||||||||||||||||||||||||||||||||||||||||||||||
       1 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLD 50

      51 SMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDF 100
         ||||||||||||||||||||||||||||||||||||||||||||||||||
      51 SMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDF 100

     101 DLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLSSGLQKQFTFYR 150
         ||||||||||||||||||||||||||||||||||
     101 DLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSL..... 138

     151 SNGRHTHSFHCKLSFLH                              167

     138 .................                              138
```

Fig. 11a

```
humil7a_p5 (t8).pfs

Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:IL7_HUMAN

Sequence documentation:
Interleukin-7 precursor (IL-7).  Homo sapiens (Human).  P13232;

Alignment of: HUMIL7A_P5 x IL7_HUMAN    ..

       1 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLD 50
         ||||||||||||||||||||||||||||||||||||||||||||||||||
       1 MFHVSFRYIFGLPPLILVLLPVASSDCDIEGKDGKQYESVLMVSIDQLLD 50

      51 SMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDF 100
         ||||||||||||||||||||||||||||||||||||||||||||||||||
      51 SMKEIGSNCLNNEFNFFKRHICDANKEGMFLFRAARKLRQFLKMNSTGDF 100

     101 DLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSLVELIIPSCMPPL 150
         ||||||||||||||||||||||||||||||||||
     101 DLHLLKVSEGTTILLNCTGQVKGRKPAALGEAQPTKSL..... 138

     151 LSSTSNS                                       157

     138 .......                                        138
```

Fig. 11b


IL-7 structure
W.T
SP
IL7/IL9 family
1-27
28-173
T7
SP
IL7/IL9 family
U
1-27
28-166 (28 unique)
29 a.a
T8
SP
IL7/IL9 family
U
1-27
28-153 (15 unique)
19 a.a

Fig. 12

TNFR9 T4 (SEQ ID NO: 19)

gagaccaaggagtggaaagttctccggcagccctgagatctcaagagtga
catttgtgagaccagctaatttgattaaaattctcttggaatcagctttgctagtatcat
acctgtgccagatttcatcATGggaaacagctgttacaacatagtagccactctgttgct
ggtcctcaactttgagaggacaagatcattgcaggatccttgtagtaactgcccagctgg
tacattctgtgataataacaggaatcagatttgcagtccctgtcctccaaatagtttctc
cagcgcaggtggacaaaggacctgtgacatatgcaggcagtgtaaaggtgttttcaggac
caggaaggagtgttcctccaccagcaatgcagagtgtgactgcactccagggtttcactg
cctgggggcaggatgcagcatgtgtgaacaggattgtaaacaaggtcaagaactgacaaa
aaaaggttgtaaagactgttgctttgggacatttaacgatcagaaacgtggcatctgtcg
accctggacaaacatcagagtggctgacgaatggaatcatgattcacaagaaaagtatTG
Actatttctcggacttagctgaattctgtctttggaaagtggctttttaaaaagctgt
tctttggatggaaagtctgtgcttgtgaatgggacgaaggagagggacgtggtctgtgga
ccatctccagccgacctctctccgggagcatcctctgtgaccccgcctgcccctgcgaga
gagccaggacactctccgcagatcatctccttctttcttgcgctgacgtcgactgcgttg
ctcttcctgctgttcttcctcacgctccgtttctctgttgttaaacggggcagaaagaaa
ctcctgtatatattcaaacaacgtaagattaacataatcatattacagctctggca

Fig. 13a

TNFR9 T4 (SEQ ID NO: 17)

MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQR
TCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQGQELTKKGCKDC
CFGTFNDQKRGICRPWTNIRVADEWNHDSQEKY

Fig. 13b


Tumor necrosis factor receptor-9/ 4-1BB
Novel Transcript
EST supporting new variant

Fig. 14

```
hsu03397_p4 (T4).pfs

Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:TNR9_HUMAN

Sequence documentation:
Tumor necrosis factor receptor superfamily member 9 precursor (4-1BB
ligand receptor) (T-cell antigen 4-1BB homolog) (T-cell antigen ILA)
(CD137 antigen).  Homo sapiens (Human).  Q07011;

Alignment of: HSU03397_P4 x TNR9_HUMAN    ..
                .         .         .         .         .
       1 MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPP 50
         ||||||||||||||||||||||||||||||||||||||||||||||||||
       1 MGNSCYNIVATLLLVLNFERTRSLQDPCSNCPAGTFCDNNRNQICSPCPP 50
                .         .         .         .         .
      51 NSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCS 100
         ||||||||||||||||||||||||||||||||||||||||||||||||||
      51 NSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCS 100
                .         .         .         .         .
     101 MCEQDCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNIRVADEWNHDSQ 150
         ||||||||||||||||||||||||||||||||||
     101 MCEQDCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTN..........  138

     151 EKY                                               153

     138 ...                                               138
```

Fig. 15

TNFR 9- structure



Fig. 16

IL-4R T4 (SEQ ID NO: 23)

tgcagtgcccgacagattgtactagttactgattgaagggctgttttactatccaaatgtggctggagtaggagttgggt
aaacatttattgaagaatgtgcaaccactctcacttggaagccgggctgttaggaaggggaggaggattccagtcgccca
gccctcccccaccaaacgcaactgccccggcgcaaaagaggccgcggaggccaggcaggagcaggtcctggaggcctggt
cggcgtgggcgttttattccgagaccaaggggatccactgcagagttctccgctgggcgtgacctcgggctacggcgtgg
gaggaagcgcgcggcaagacacccagcgaggtgctggggtcgcccccaggagaggacggcggctcggactgtccggcggc
ggcggcggggacagcgacaggggcgcgaggtggccgggacccgggccgggcgcgccgggcggggcggcgcatgcaaatct
gccgggcgccgggcggggagcaggaagccggggcgggctgggtctccgcgcccaggaaagccccgcgcggcgcgggcca
gggaagggccacccaggggtcccccacttcccgcttgggcgcccggacggcgaatggagcaggggcgcgcagataattaa
agatttacacacagctggaagaaatcatagagaagccgggcgtggtggctcatgcctataatcccagcacttttggaggc
tgaggcgggcagatcacttgagatcaggagttcgagaccagcctggtgccttggcatctcccaATGgggtggctttgctc
tgggctcctgttccctgtgagctgcctggtcctgctgcaggtggcaagctctgggaacatgaaggtcttgcaggagccca
cctgcgtctccgactacatgagcatctctacttgcgagtggaagatgaatggtcccaccaattgcagcaccgagctccgc
ctgttgtaccagctggtttttctgctctccgaagcccacacgtgtatccctgagaacaacggaggcgcggggtgcgtgtg
ccacctgctcatggatgacgtggtcagtgcggataactatacactggacctgtgggctgggcagcagctgctgtggaagg
gctccttcaagcccagcgagcatgtcctcccacctttgaaacggagctggtcgcagTAGaccaccaagccccttcagcc
cagctgtttccacccctgaacttaagtgcccaggaaggcgtattgagatgaggtgtgcttgctggaaggcatgcctgctg
ctgattgaaaaccgaactgggaacagtccttccattctgtgtccactggtcagctgctgcggctttggatggtcttgacc
gtggaaggctgaccttcttctggtacccggagtccctgcaggaatcccccttgagcttgctgggctgtggtgacaggagt
ttaaaacatgcgttgtattccagtgatgcatgatatgacatgcatcacaggaataaaaacctgaggtctcatggatatga
ttgcttcaaaggagaccaagttttaaaacagatgaatcaaaataaagaaaaatactcagtaaatcatcataaagtacaga
gatgtggccaaaggtgtgaaggatgcagctgtaaaagctgaagtttgaggccgggtgtggtggttcatgcctataatccc
agcactttgggaggccgagcccagcggatcaccggaggtcaggagttcgagaccagcctggacaacatgtgaaacccagg
gccccaggaaacctgacagttcacaccaatgtctccgacactctgctgctgacctggagcaacccgtatccccctgacaa
ttacctgtataatcatctcacctatgcagtcaacatttggagtgaaaacgacccggcagatttcagaatctataacgtga
cctacctagaaccctccctccgcatcgcagccagcaccctgaagtctgggatttcctacagggcacgggtgagggcctgg
gctcagtgctataacaccacctggagtgagtggagccccagcaccaagtggcacaactcctacagggagcccttcgagca
gcacctcctgctgggcgtcagcgtttcctgcattgtcatcctggccgtctgcctgttgtgctatgtcagcatcaccaaga
ttaagaaagaatggtgggatcagattcccaacccagcccgcagccgcctcgtggctataataatccaggatgctcagggg
tcacagtgggagaagcggtcccgaggccaggaaccagccaagtgcccacactggaagaattgtcttaccaagctcttgcc
ctgttttctggagcacaacatgaaaagggatgaagatcctcacaaggctgccaaagagatgcctttccagggctctggaa
aatcagcatggtgcccagtggagatcagcaagacagtcctctggccagagagcatcagcgtggtgcgatgtgtggagttg
tttgaggccccggtggagtgtgaggaggaggaggaggtagaggaagaaaaagggagcttctgtgcatcgcctgagagcag
cagggatgacttccaggagggaagggagggcattgtggcccggctaacagagagcctgttcctggacctgctcggagagg
agaatgggggcttttgccagcaggacatgggggagtcatgccttcttccaccttcgggaagtacgagtgctcacatgccc
tgggatgagttcccaagtgcagggcccaaggaggcacctccctggggcaaggagcagcctctccacctggagccaagtcc
tcctgccagcccgacccagagtccagacaacctgacttgcacagagacgcccctcgtcatcgcaggcaaccctgcttacc
gcagcttcagcaactccctgagccagtcaccgtgtcccagagagctgggtccagacccactgctggccagacacctggag
gaagtagaacccgagatgccctgtgtccccagctctctgagccaaccactgtgccccaacctgagccagaaacctggga
gcagatcctccgccgaaatgtcctccagcatggggcagctgcagccccgtctcggcccccaccagtggctatcaggagt
ttgtacatgcggtggagcagggtggcacccaggccagtgcggtggtgggcttgggtccccaggagaggctggttacaag
gccttctcaagcctgcttgccagcagtgctgtgtccccagagaaatgtgggtttggggctagcagtggggaagaggggta
taagcctttccaagacctcattcctggctgccctggggaccctgccccagtccctgtcccctttgttcacctttggactgg
acagggagccacctcgcagtccgcagagctcacatctcccaagcagctccccagagcacctgggtctggagccgggggaa
aaggtagaggacatgccaaagcccccacttccccaggagcaggccacagacccccttgtggacagcctgggcagtggcat
tgtctactcagccccttacctgccacctgtgcggccacctgaaacagtgtcatggccaggaggatggtggccagaccccct
gtcatggccagtccttgctgtggctgctgctgtggagacaggtcctcgcccccctacaaccccccctgagggccccagaccc
ctctccaggtggggttccactggaggccagtctgtgtccggcctccctggcaccctcgggcatctcagagaagagtaaat
cctcatcatccttccatcctgcccctggcaatgctcagagctcaagccagacccccaaaatcgtgaactttgtctccgtg
ggacccacatacatgagggtctcttaggtgcatgtcctcttgttgctgagtctgcagatgaggactagggcttatccatg
cctgggaaatgccacctcctggaaggcagccaggctggcagatttccaaaagacttgaagaaccatggtatgaaggtgat
tggccccactgacgttggcctaacactgggctgcagagactggaccccgcccagcattgggctgggctcgccacatccca
tgagagtagagggcactgggtcgccgtgccccacggcaggcccctgcaggaaaactgaggcccttgggcacctcgacttg
tgaacgagttgttggctgctccctccacagcttctgcagcagactgtccctgttgtaactgcccaaggcatgttttgccc
accagatcatggcccacatggaggcccacctgcctctgtctcactgaactagaagccgagcctagaaactaacacagcca
tcaagggaatgacttgggcggccttgggaaatcgatgagaaattgaacttcagggagggtggtcattgcctagaggtgct
cattcatttaacagagcttccttaggttgatgctggaggcagaatcccggctgtcaaggggtgttcagttaaggggagca
acagaggacatgaaaaattgctgtgactaaagcagggacaatttgctgccaaacacccatgcccagctgtatggctgggg
gctcctcgtatgcatggaacccccagaataaatatgctcagccaccctgtgggccgggcaatccagacagcaggcataag
gcaccagttaccctgcatgttggcccagacctcaggtgctagggaaggcgggaaccttgggttgagtaatgctcgtctgt
gtgttttagtttcatcacctgttatctgtgtttgctgaggagagtggaacagaaggggtggagttttgtataaataaagt
ttctttgtctctttaaaaattatgtattaaccaaacatacctccagac

Fig. 17a

IL-4R T4 (SEQ ID NO: 21)

MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELR
LLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPS
EHVLPPLKRSWSQ

Fig. 17b

IL-4R T11 (SEQ ID NO: 27)

tgcagtgcccgacagattgtactagttactgattgaagggctgttttactatccaaatgtggctggagtaggagttgggt
aaacatttattgaagaatgtgcaaccactctcacttggaagccgggctgttaggaaggggaggaggattccagtcgccca
gccctccccaccaaacgcaactgccccggcgcaaaagaggccgcggaggccaggcaggagcaggtcctggaggcctggt
cggcgtgggcgttttattccgagaccaaggggatccactgcagagttctccgctgggcgtgacctcgggctacggcgtgg
gaggaagcgcgcggcaagacacccagcgaggtgctggggtcgccccaggagaggacggcggctcggactgtccggcggc
ggcggcggggacagcgacaggggcgcgaggtggccgggacccgggccgggcgcgccgggcggggcggcgcatgcaaatct
gccgggcgccggggcggggagcaggaagccggggcgggctgggtctccgcgcccaggaaagccccgcgcggcgcgggcca
gggaagggccacccaggggtcccccacttcccgcttgggcgcccggacggcgaatggagcaggggcgcgcagataattaa
agatttacacacagctggaagaaatcatagagaagccgggcgtggtggctcatgcctataatcccagcacttttggaggc
tgaggcgggcagatcacttgagatcaggagttcgagaccagcctggtgccttggcatctcccaATGgggtggctttgctc
tgggctcctgttccctgtgagctgcctggtcctgctgcaggtggcaagctctgggaacatgaaggtcttgcaggagccca
cctgcgtctccgactacatgagcatctctacttgcgagtggaagatgaatggtcccaccaattgcagcaccgagctccgc
ctgttgtaccagctggtttttctgctctccgaagcccacacgtgtatccctgagaacaacggaggcgcggggtgcgtgtg
ccacctgctcatggatgacgtggtcagtgcggataactatacactggacctgtgggctgggcagcagctgctgtggaagg
gctccttcaagcccagcgagcatgtgaaacccagggccccaggaaacctgacagttcacaccaatgtctccgacactctg
ctgctgacctggagcaacccgtatccccctgacaattacctgtataatcatctcacctatgcagtcaacatttggagtga
aaacgacccggcagatttcagaatctataacgtgacctacctagaaccctccctccgcatcgcagccagcaccctgaagt
ctgggatttcctacagggcacgggtgagggcctgggctcagtgctataacaccacctggagtgagtggagccccagcacc
aagtggcacaactgtgagtatcaagaggccTAAgcaatggtaatctccactctccattcttcccctgtggccagacactt
ccctggctgagtctctgggc

Fig. 17c

IL-4R T11 (SEQ ID NO: 25)

MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNGPTNCSTELR
LLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYTLDLWAGQQLLWKGSFKPS
EHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPDNYLYNHLTYAVNIWSENDPADFRIYNV
TYLEPSLRIAASTLKSGISYRARVRAWAQCYNTTWSEWSPSTKWHNCEYQEA

Fig. 18

```
cds-2_hsil4r_t4.pfs
Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:IL4R_HUMAN

Sequence documentation:
Interleukin-4 receptor alpha chain precursor (IL-4R-alpha) (CD124
antigen).  Homo sapiens (Human).  P24394; Q96P01;

Alignment of: CDS-2_HSIL4R_T4 x IL4R_HUMAN    ..
                .         .         .         .         .
        1 MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNG 50
          ||||||||||||||||||||||||||||||||||||||||||||||||||
        1 MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNG 50
                .         .         .         .         .
       51 PTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYT 100
          ||||||||||||||||||||||||||||||||||||||||||||||||||
       51 PTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYT 100
                .         .         .
      101 LDLWAGQQLLWKGSFKPSEHVLPPLKRSWSQ                    131
          |||||||||||||||||||
      101 LDLWAGQQLLWKGSFKPSEHV.........                    121
```

Fig. 19a

```
cds-2_hsil4r_t11.pfs
Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:IL4R_HUMAN

Sequence documentation:
Interleukin-4 receptor alpha chain precursor (IL-4R-alpha) (CD124
antigen).  Homo sapiens (Human).  P24394; Q96P01;

Alignment of: CDS-2_HSIL4R_T11 x IL4R_HUMAN    ..
                .         .         .         .         .
        1 MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNG 50
          ||||||||||||||||||||||||||||||||||||||||||||||||||
        1 MGWLCSGLLFPVSCLVLLQVASSGNMKVLQEPTCVSDYMSISTCEWKMNG 50
                .         .         .         .         .
       51 PTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYT 100
          ||||||||||||||||||||||||||||||||||||||||||||||||||
       51 PTNCSTELRLLYQLVFLLSEAHTCIPENNGGAGCVCHLLMDDVVSADNYT 100
                .         .         .         .         .
      101 LDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPD 150
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      101 LDLWAGQQLLWKGSFKPSEHVKPRAPGNLTVHTNVSDTLLLTWSNPYPPD 150
                .         .         .         .         .
      151 NYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRAR 200
          ||||||||||||||||||||||||||||||||||||||||||||||||||
      151 NYLYNHLTYAVNIWSENDPADFRIYNVTYLEPSLRIAASTLKSGISYRAR 200
                .         .
      201 VRAWAQCYNTTWSEWSPSTKWHNCEYQEA                      229
          |||||||||||||||||||||||
      201 VRAWAQCYNTTWSEWSPSTKWHN......                     223
```

Fig. 19b


IL4R structure
Cytoplasmic
TM
CRIA
SP
257-825
233-256
28-123
1-25
W.T
10 a.a
T4
5 a.a
T11

Fig. 20

TGR2 T7 (SEQ ID NO: 31)

acctaaagaaaaacattttacaacttgacagtgtatgcacatacatacatgcatatagac
acaactgaagcacaaatttaatgaagtagaatttaccgttactatttttatttgggaaaga
aatgtgctcgcgactcaatagattggagtattcactcctggatctcaacttgcaatttga
aaacgcatctctaaagcacctaggagcaatctgaagaaagctgaggggaggcggcagatg
ttctgatctactagggaaaacgtggacgttttctgttgttactttgtgaactgtgtgcac
ttagtcattcttgagtaaatacttggagcgaggaactcctgagtggtgtgggagggcggt
gaggggcagctgaaagtcggccaaagctctcggaggggctggtctaggaaacatgattgg
cagctacgagagagctaggggctggacgtcgaggagagggagaaggctctcgggcggaga
gaggtcctgcccagctgttggcgaggagtttcctgtttcccccgcagcgctgagttgaag
ttgagtgagtcactcgcgcgcacggagcgacgacacccccgcgcgtgcacccgctcggga
caggagccggactcctgtgcagcttccctcggccgccgggggcctccccgcgcctcgccg
gcctccaggcccccctcctggctggcgagcgggcgccacatctggcccgcacatctgcgct
gccggcccggcgcggggtccggagagggcgcggcgcggaggcgcagccaggggtccggga
aggcgccgtccgctgcgctgggggctcggtctatgacgagcagcggggtctgccATGggt
cgggggctgctcaggggcctgtggccgctgcacatcgtcctgtggacgcgtatcgccagc
acgatcccaccgcacgttcagaagtcggttaataacgacatgatagtcactgacaacaac
ggtgcagtcaagtttccacaactgtgtaaattttgtgatgtgagattttccacctgtgac
aaccagaaatcctgcatgagcaactgcagcatcacctccatctgtgagaagccacaggaa
gtctgtgtggctgtatggagaaagaatgacgagaacataacactagagacagtttgccat
gaccccaagctcccctaccatgactttattctggaagatgctgcttctccaaagtgcatt
atgaaggaaaaaaaaaagcctggtgagactttcttcatgtgttcctgtagctctgatgag
tgcaatgacaacatcatcttctcagaaggtgagttttcttctcttaagggtgtgggacct
gagatctgtgccaatttttttgtatccttggtctgcagtgtcaTAGagcacattcctcctg
tggtggattgcatacagtggattaggagctcattcagctggtggaaagaggggcttgggg
agtagcagggtttgttctggttctcatcaaatatggttgactggggcaaacattattatt
tgtctttgacaaatagtttctttcacctagagcagtgtttctcaaagtgcggccccttga
gcagccagcatcagtatcacctgggaacctgttataaatgcagattctcaggccccacta
aatgagaaacatagagggtgaaccccagctatctgtattttaacaagccctcccagtaat
tctgtgcagctaaaatttggtaactattgttctaaagatttggatggggttgtttaatct
tggaggaggactttctttataactgatgttgtttcttgtacatagtcccaggatttgtct
ttagggtacttgtcatcgatcccatttgagagacactttgcaatacagag

Fig. 21a

TGR2 T7 (SEQ ID NO: 29)

MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFST
CDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPK
CIMKEKKKPGETFFMCSCSSDECNDNIIFSEGEFSSLKGVGPEICANFLYPWSAVS

Fig. 21b


Transforming growth factor β receptor type II (TGF-β-R)
Novel Transcript
ESTs supporting new variant

Fig. 22

z21887_p6(t7).pfs

Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:TGR2_HUMAN

Sequence documentation:
TGF-beta receptor type II precursor (EC 2.7.1.37) (TGFR-2) (TGF-beta type II receptor). Homo sapiens (Human). P37173; Q99474;

Alignment of: Z21887_P6 x TGR2_HUMAN ..

```
          .         .         .         .         .
      1 MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQL 50
        ||||||||||||||||||||||||||||||||||||||||||||||||||
      1 MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQL 50
          .         .         .         .         .
     51 CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV 100
        ||||||||||||||||||||||||||||||||||||||||||||||||||
     51 CKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETV 100
          .         .         .         .         .
    101 CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS 150
        ||||||||||||||||||||||||||||||||||||||||||||||||||
    101 CHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFS 150
          .         .
    151 EGEFSSLKGVGPEICANFLYPWSAVS                         176
        |
    151 E.........................                        151
```

Fig. 23


TGR2 structure
W.T
SP
1-23
TGFβR/actininR
77-147
TM
167-187
Protein kinase
244-538
SY
SP
1-23
TGFβR/actininR
77-147
25 a.a

Fig. 24

ITAV_T3 (SEQ ID NO: 35)

gataaaaagctttcctcatttttaaacaacagtcgcacggaagttcccggcgggacaagg
gaacgtgggtgcccttgctactcccgtggacgcgggtagattgggacgctggaccgtatc
tccccgcccccgcccccacgcctcctcaggtgctcagcctgaggccttcgtccaggagcg
ctgccgctgacccaggctcaggagctgggggcccctgcacagacgcccaggtctcgggac
aggcggcgactgcactcacggaagtacgctgagctctcccctgtagaagggcgcctctcc
tcccccacttcctcctccagctccacagcagcctcccgggccggctcctcctccttccag
gtctcctcccagtgccgccgcggctctcaggcctgaggtgcggcgctcaccccggcagtc
cccagcctcagacgctgcgtggagcggcggagccggagggaagcaaaggaccgtctgcgc
tgctgtccccgccccgcgcgctctgcgcccctcgtccctggcggtcgctccgaagctcag
ccctcttgcctgccccggagctgtcccgggctagccgagaagagagcggccggcaagttt
gggcgcgcgcaggcggcgggccgcgggcactgggcgcctcgctggggcgggggaggtgg
ctaccgctcccggcttggcgtcccgcgcgcacttcggcg**ATG**gcttttccgccgcggcga
cggctgcgcctcggtccccgcggcctcccgcttcttctctcgggactcctgctacctctg
tgccgcgccttcaacctagacgtggacagtcctgccgagtactctggccccgagggaagt
tacttcggcttcgccgtggatttcttcgtgcccagcgcgtcttcccggatgtttcttctc
gtgggagctcccaaagcaaacaccacccagcctgggattgtggaaggagggcaggtcctc
aaatgtgactggtcttctacccgccggtgccagccaattgaatttgatgcaacaggcaat
agagattatgccaaggatgatccattggaatttaagtcccatcagtggtttggagcatct
gtgaggtcgaaacaggataaaattttggcctgtgccccattgtaccattggagaactgag
atgaaacaggagcgagagcctgttggaacatgctttcttcaagatggaacaaagactgtt
gagtatgctccatgtagatcacaagatattgatgctgatggacagggattttgtcaagga
ggattcagcattgattttactaaagctgacagagtacttcttggtggtcctggtagcttt
tattggcaaggtcagcttatttcggatcaagtggcagaaatcgtatctaaatacgacccc
aatgtttacagcatcaagtataataaccaattagcaactcggactgcacaagctattttt
gatgacagctatttgggttattctgtggctgtcggagatttcaatggtgatggcatagat
gactttgtttcaggagttccaagagcagcaaggactttgggaatggtttatatttatgat
gggaagaacatgtcctccttatacaattttactggcgagcagatggctgcatatttcgga
ttttctgtagctgccactgacattaatggagatgattatgcagatgtgtttattggagca
cctctcttcatggatcgtggctctgatggcaaactccaagaggtggggcaggtctcagtg
tctctacagagagcttcaggagacttccagacgacaaagctgaatggatttgaggtcttt
gcacggtttggcagtgccatagctcctttgggagatctggaccaggatggtttcaatgat
attgcaattgctgctccatatgggggtgaagataaaaaaggaattgtttatatcttcaat
ggaagatcaacaggcttgaacgcagtcccatctcaaatccttgaagggcagtgggctgct
cgaagcatgccaccaagctttggctattcaatgaaaggagccacagatatagacaaaaat
ggatatccagacttaattgtaggagcttttggtgtagatcgagctatcttatacagggcc
agaccagttatcactgtaaatgctggtcttgaagtgtaccctagcattttaaatcaagac
aataaaacctgctcactgcctggaacagctctcaaagtttcctgttttaatgttaggttc
tgcttaaaggcagatggcaaaggagtacttcccaggaaacttaatttccaggtggaactt
cttttggataaactcaagcaaaagggagcaattcgacgagcactgtttctctacagcagg
tccccaagtcactccaagaacatgactatttcaaggggggactgatgcagtgtgaggaa
ttgatagcgtatctgcgggatgaatctgaatttagagacaaactcactccaattactatt
tttatggaatatcggttggattatagaacagctgctgatacaacaggcttgcaacccatt
cttaaccagttcacgcctgctaacattagtcgacaggctcacattctacttgactgtggt
gaagacaatgtctgtaaacccaagctggaagtttctgtagatagtgatcaaaagaagatc
tatattggggatgacaaccctctgacattgattgttaaggctcagaatcaaggagaaggt
gcctacgaagctgagctcatcgtttccattccactgcaggctgatttcatcggggttgtc
cgaaacaatgaagccttagcaagactttcctgtgcatttaagacagaaaaccaaactcgc
caggtggtatgtgaccttggaaacccaatgaaggctggaactcaactcttagctggtctt
cgtttcagtgtgcaccagcagtcagagatggatacttctgtgaaatttgacttacaaatc
caaagctcaaatctatttgacaaagtaagcccagttgtatctcacaaagttgatcttgct
gttttagctgcagttgagataagaggagtctcgagtcctgatcatatctttcttccgatt
ccaaactgggagcacaaggagaaccctgagactgaagaagatgttgggccagttgttcag
cacatctatgaggtttgcagttgt**TAG**attttactcaaacctcgtgagcaagccaacgaa
gagaggaacaactaagctactttaaaaaaaaaattctatgtaatttttatgtaaactcta
cattggttaagtatgtgtcagagatttctttgaatattttccctatacataaattcattt

Fig. 25a

ITAV T3 (SEQ ID NO: 33)

MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSA
SSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKS
HQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDAD
GQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLAT
RTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE
QMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTK
LNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQI
LEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVY
PSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRR
ALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD
TTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVK
AQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAG
TQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSP
DHIFLPIPNWEHKENPETEEDVGPVVQHIYEVCSC

Fig. 25b


Integrin alpha-V
Novel Transcripts
EST supporting new variant (T5)
EST supporting new variant (T3)

Fig. 26

humvtnr_p3(t3).pfs 29/39

Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:ITAV_HUMAN

Sequence documentation:
Integrin alpha-V precursor (Vitronectin receptor alpha subunit) (CD51 antigen). Homo sapiens (Human). P06756;

Alignment of: *HUMVTNR_P3* x *ITAV_HUMAN* ..

```
       1 MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFG 50
         ||||||||||||||||||||||||||||||||||||||||||||||||||
       1 MAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFG 50

      51 FAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPI 100
         ||||||||||||||||||||||||||||||||||||||||||||||||||
      51 FAVDFFVPSASSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPI 100

     101 EFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQ 150
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     101 EFDATGNRDYAKDDPLEFKSHQWFGASVRSKQDKILACAPLYHWRTEMKQ 150

     151 EREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVL 200
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     151 EREPVGTCFLQDGTKTVEYAPCRSQDIDADGQGFCQGGFSIDFTKADRVL 200

     201 LGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDS 250
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     201 LGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLATRTAQAIFDDS 250

     251 YLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE 300
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     251 YLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE 300

     301 QMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQ 350
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     301 QMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQ 350

     351 RASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKK 400
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     351 RASGDFQTTKLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKK 400

     401 GIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYP 450
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     401 GIVYIFNGRSTGLNAVPSQILEGQWAARSMPPSFGYSMKGATDIDKNGYP 450

     451 DLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKV 500
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     451 DLIVGAFGVDRAILYRARPVITVNAGLEVYPSILNQDNKTCSLPGTALKV 500

     501 SCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPS 550
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     501 SCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRRALFLYSRSPS 550

     551 HSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD 600
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     551 HSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD 600
```

Fig. 27

```
601 TTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIG 650
    ||||||||||||||||||||||||||||||||||||||||||||||||||||
601 TTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIG 650
          .         .         .         .         .
651 DDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAF 700
    ||||||||||||||||||||||||||||||||||||||||||||||||||||
651 DDNPLTLIVKAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAF 700
          .         .         .         .         .
701 KTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSS 750
    ||||||||||||||||||||||||||||||||||||||||||||||||||||
701 KTENQTRQVVCDLGNPMKAGTQLLAGLRFSVHQQSEMDTSVKFDLQIQSS 750
          .         .         .         .         .
751 NLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHIFLPIPNWEHKENPETEE 800
    ||||||||||||||||||||||||||||||||||||||||||||||||||||
751 NLFDKVSPVVSHKVDLAVLAAVEIRGVSSPDHIFLPIPNWEHKENPETEE 800
          .
801 DVGPVVQHIYEVCSC                                    815
    ||||||||||||
801 DVGPVVQHIYE....                                     811
```

Fig. 27 (Cont.)


ITAV structure
W.T
SP
Int α
Int α
Int α
Int α
TM
Int-c
1-30
46-108
249-302
303-362
367-427
432-483
993-1016
1017-1031
T3
SP
Int α
Int α
Int α
Int α
4 a.a
1-30
46-108
249-302
303-362
367-427
432-483

Fig. 28

IL-10-R-β T1 (SEQ ID NO: 39)

cccgcccatctccgctggttcccggaagccgccgcggacaagctctcccgggcgcgggcg
ggggtcgtgtgcttggaggaagccgcggaacccccagcgtccgtccATGgcgtggagcct
tgggagctggctgggtggctgcctgctggtgtcagcattgggaatggtaccacctcccga
aaatgtcagaatgaattctgttaatttcaagaacattctacagtgggagtcacctgcttt
tgccaaagggaacctgactttcacagctcagtacctaagttataggatattccaagataa
atgcatgaatactaccttgacggaatgtgatttctcaagtctttccaagtatggtgacca
caccttgagagtcagggctgaatttgcagatgagcattcagactgggtaaacatcacctt
ctgtcctgtggatgacaccattattggacccccctggaatgcaagtagaagtacttgctga
ttctttacatatgcgtttcttagcccctaaaattgagaatgaatacgaaacttggactat
gaagaatgtgtataactcatggacttataatgtgcaatactggaaaaacggtactgatga
aaagtttcaaattactccccagtatgactttgaggtcctcagaaacctggagccatggac
aacttattgtgttcaagttcgagggtttcttcctgatcggaacaaagctggggaatggag
tgagcctgtctgtgagcaaacaacccatgaCGtttttgggccatcctcatcaTAAcacac
ttctgtttttctcctttccattgtcggatgagaatgatgtttttgacaagctaagtgtca
ttgcagaagactctgagagcggcaagcagaatcctggtgacagctgcagcctcgggaccc
cgcctgggcaggggccccaaagctaggctctgagaaggaaacacactcggctgggcacag
tgacgtactccatctcacatctgcctcagtgagggatcagggcagcaaacaagggccaag
accatctgagccagccccacatctagaactcccagaccctggacttagccaccagagagc
tacatttaaaggctgtcttggcaaaaatactccatttgggaactcactgccttataaag
gctttcatgatgttttcagaagttggccactgagagtgtaattttcagccttttatatca
ctaaaataagatcatgttttaattgtgagaaacagggccgagcacagtggctcacgcctg
taataccagcaccttagaggtcgaggcaggcggatcacttgaggtcaggagttcaagacc
agcctggccaatatggtgaaacccagtctctactaaaaatacaaaaattagctaggcatg
atggcgcatgcctataatcccagctactcgagtgcctgaggcaggagaattgcatgaacc
cgggaggaggaggaggaggttgcagtgagccgagatagcggcactgcactccagcctggg
tgacaaagtgagactccatctcaaaaaaaaaaaaaaaaaattgtgagaaacagaaatact
taaaatgaggaataagaatggagatgttacatctggtagatgtaacattctaccagatta
tggatggactgatctgaaaatcaacctcaactcaagggtggtcagctcaatgctacacag
agcacggacttttggattctttgcagtactttgaatttatttttctacctatatatgttt
tatatgctgctggtgctccattaaagttttactctgtgttgcactatatgtgttcatgat
aaaaaa

Fig. 29a

IL-10-R-β T1 (SEQ ID NO: 37)

MAWSLGSWLGGCLLVSALGMVPPPENVRMNSVNFKNILQWESPAFAKGNLTFTAQYLSYR
IFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDWVNITFCPVDDTIIGPPGMQV
EVLADSLHMRFLAPKIENEYETWTMKNVYNSWTYNVQYWKNGTDEKFQITPQYDFEVLRN
LEPWTTYCVQVRGFLPDRNKAGEWSEPVCEQTTHDVFGPSSS

Fig. 29b

Interleukin-10 receptor β chain



Fig. 30

t48767_p2(t1).pfs

Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:I10S_HUMAN

Sequence documentation:
Interleukin-10 receptor beta chain precursor (IL-10R-B) (IL-10R2)
(Cytokine receptor class-II CRF2-4). Homo sapiens (Human). Q08334;

Alignment of: T48767_P2 x I10S_HUMAN ..

```
          .         .         .         .         .
    1 MAWSLGSWLGGCLLVSALGMVPPPENVRMNSVNFKNILQWESPAFAKGNL 50
      ||||||||||||||||||||||||||||||||||||||||||||||||||
    1 MAWSLGSWLGGCLLVSALGMVPPPENVRMNSVNFKNILQWESPAFAKGNL 50
          .         .         .         .         .
   51 TFTAQYLSYRIFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDW 100
      ||||||||||||||||||||||||||||||||||||||||||||||||||
   51 TFTAQYLSYRIFQDKCMNTTLTECDFSSLSKYGDHTLRVRAEFADEHSDW 100
          .         .         .         .         .
  101 VNITFCPVDDTIIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYN 150
      ||||||||||||||||||||||||||||||||||||||||||||||||||
  101 VNITFCPVDDTIIGPPGMQVEVLADSLHMRFLAPKIENEYETWTMKNVYN 150
          .         .         .         .         .
  151 SWTYNVQYWKNGTDEKFQITPQYDFEVLRNLEPWTTYCVQVRGFLPDRNK 200
      ||||||||||||||||||||||||||||||||||||||||||||||||||
  151 SWTYNVQYWKNGTDEKFQITPQYDFEVLRNLEPWTTYCVQVRGFLPDRNK 200
          .         .
  201 AGEWSEPVCEQTTHDVFGPSSS                             222
      ||||||||||||||
  201 AGEWSEPVCEQTTHD.......                             215
```

Fig. 31


IL10-R-β-chain structure
W.T
SP
Fibronectin type III
Fibronectin type III
TM
Cytoplasmic
1-19
21-98
112-202
221-242
243-325
SV
SP
Fibronectin type III
Fibronectin type III
1-19
21-98
112-202
7 a.a

Fig. 32

INR1_T11 (SEQ ID NO: 43)

agaagaggcggcgcgtgcgtagaggggcggtgagagctaagaggggcagcgcgtgtgcag
aggggcggtgtgacttaggacggggcgatggcggctgagaggagctgcgcgtgcgcgaac
atgtaactggtgggatctgcggcggctcccagatgATGgtcgtcctcctgggcgcgacga
ccctagtgctcgtcgccgtggcgccatgggtgttgtccgcagccgcaggtggaaaaaatc
taaaatctcctcaaaaagtagaggtcgacatcatagatgacaactttatcctgaggtgga
acaggagcgatgagtctgtcgggaatgtgacttttcattcgattatcaaaaaactggga
tggataattggataaaattgtctgggtgtcagaatattactagtaccaaatgcaacttt
cttcactcaagctgaatgtttatgaagaaattaaattgcgtataagagcagaaaaagaaa
acacttcttcatggtatgaggttgactcatttacaccatttcgcaaagctcagattggtc
ctccagaagtacatttagaagctgaagataaggcaatagtgatacacatctctcctggaa
caaaagatagtgttatgtgggctttggatggtttaagctttacatatagcttagttatct
ggaaaaactcttcaggtgtagaagaaaggattgaaaatatttattccagacataaaattt
ataaactctcaccagagactacttattgtctaaaagttaaagcagcactacttacgtcat
ggaaaattggtgtctatagtccagtacattgtataaagaccacagttgaaaatgaactac
ctccaccagaaaatatagaagtcagtgtccaaaatcagaactatgttcttaaatgggatt
atacatatgcaaacatgacctttcaagttcagtggctccacgccttttaaaaaggaatc
ctggaaaccatttgtataaatggaaacaaatacctgactgtgaaaatgtcaaaactaccc
agtgtgtctttcctcaaaacgttttccaaaaaggaatttaccttctccgcgtacaagcat
ctgatggaaataacacatctttttggtctgaagagataaagtttgatactgaaatacaag
ctttcctacttcctccagtctttaacattagatcccttagtgattcattccatatctata
tcggtgctccaaaacagtctggaaacacgcctgtgatccaggattatccactgatttatg
aaattatttttgggaaaacacttcaaatgctgagagaaaaattatcgagaaaaaaactg
atgttacagttcctaatttgaaaccactgactgtatattgtgtgaaagccagagcacaca
ccatggatgaaaagctgaataaaagcagtgtttttagtgacgctgtatgtgagaaaacaa
aaccaggtcagaatctttattgtctttttaaaaatgTAGctagacataataaaagtaa
ttctatactgta

Fig. 33a

INR1_T11 (SEQ ID NO: 41)

MVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVTF
SFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSFT
PFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERIE
NIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQN
QNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQKG
IYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTPV
IQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSVF
SDAVCEKTKPGQNLLLSFLKM

Fig. 33b


Interferon-α/β-receptor-1-INR1
Novel Transcripts
ESTs supporting new variant (T12)
ESTs supporting new variant (T11)

Fig. 34

```
t07758_p5(t11).pfs

Sequence name: /dir/tp/CGC/DATA/analysis_db/sw.fasta:INR1_HUMAN

Sequence documentation:
Interferon-alpha/beta receptor alpha chain precursor (IFN-alpha-REC).
Homo sapiens (Human).  P17181;

Alignment of: T07758_P5 x INR1_HUMAN   ..
                .         .         .         .         .
       1 MVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRW 48
         |||||||||||||||| |||||||||||||||||||||||||||||||
       2 MVVLLGATTLVLVAVGPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRW 49
                .         .         .         .         .
      49 NRSDESVGNVTFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEE 98
         ||||||||||||||||||||||||||||||||||||||||||||||||||
      50 NRSDESVGNVTFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEE 99
                .         .         .         .         .
      99 IKLRIRAEKENTSSWYEVDSFTPFRKAQIGPPEVHLEAEDKAIVIHISPG 148
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     100 IKLRIRAEKENTSSWYEVDSFTPFRKAQIGPPEVHLEAEDKAIVIHISPG 149
                .         .         .         .         .
     149 TKDSVMWALDGLSFTYSLVIWKNSSGVEERIENIYSRHKIYKLSPETTY 197
         |||||||||||||||| |||||||||||||||||||||||||||||||||
     150 TKDSVMWALDGLSFTYSLLIWKNSSGVEERIENIYSRHKIYKLSPETTY 198
                .         .         .         .         .
     198 CLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQNQNYVLKW 247
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     199 CLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQNQNYVLKW 248
                .         .         .         .         .
     248 DYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVF 297
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     249 DYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVF 298
                .         .         .         .         .
     298 QKGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHI 347
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     299 QKGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHI 348
                .         .         .         .         .
     348 YIGAPKQSGNTPVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKP 397
         ||||||||||||||||||||||||||||||||||||||||||||||||||
     349 YIGAPKQSGNTPVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKP 398
                .         .         .         .
     398 LTVYCVKARAHTMDEKLNKSSVFSDAVCEKTKPGQNLLLSFLKM       441
         |||||||||||||||||||||||||||||||
     399 LTVYCVKARAHTMDEKLNKSSVFSDAVCEKTKPG.........       432
```

Fig. 35


INR1 structure
W.T
SP
FN III-like
FN III-like
FN III-like
TM
Cytoplasmic
1-27
30-127
129-230
230-330
334-427
437-457
458-557
T11
SP
FN III-like
FN III-like
FN III-like
1-27
30-127
129-230
230-330
334-427
10 a.a

Fig. 36

SEQUENCE LISTING

<110> Ayalon, Michal
Pollock, Sarah
Diber, Alex
Levine, Zurit
Nemzer, Sergey
Dahary, Dvir
Sorek, Rotem
Levanon, Erez
Rotman, Galit
Savitsky, Kineret
Chermesh, Chen
Mintz, Liat
Freilich, Shiri
Beck, Nili
Zhu, Wei-Yong
Wasserman, Alon
Azar, Idit
Bernstein, Jeanne

<120> NOVEL POLYNUCLEOTIDES ENCODING SOLUBLE POLYPEPTIDES AND METHODS USING SAME

<130> 27253

<160> 43

<170> PatentIn version 3.2

<210> 1
<211> 934
<212> PRT
<213> Homo sapiens

<400> 1

Met Lys Ala Pro Ala Val Leu Ala Pro Gly Ile Leu Val Leu Leu Phe
1 5 10 15

Thr Leu Val Gln Arg Ser Asn Gly Glu Cys Lys Glu Ala Leu Ala Lys
20 25 30

Ser Glu Met Asn Val Asn Met Lys Tyr Gln Leu Pro Asn Phe Thr Ala
35 40 45

Glu Thr Pro Ile Gln Asn Val Ile Leu His Glu His His Ile Phe Leu
50 55 60

Gly Ala Thr Asn Tyr Ile Tyr Val Leu Asn Glu Glu Asp Leu Gln Lys
65 70 75 80

Val Ala Glu Tyr Lys Thr Gly Pro Val Leu Glu His Pro Asp Cys Phe
85 90 95

Pro Cys Gln Asp Cys Ser Ser Lys Ala Asn Leu Ser Gly Gly Val Trp
100 105 110

Lys Asp Asn Ile Asn Met Ala Leu Val Val Asp Thr Tyr Tyr Asp Asp
115 120 125

```
Gln Leu Ile Ser Cys Gly Ser Val Asn Arg Gly Thr Cys Gln Arg His
    130                 135                 140

Val Phe Pro His Asn His Thr Ala Asp Ile Gln Ser Glu Val His Cys
145                 150                 155                 160

Ile Phe Ser Pro Gln Ile Glu Glu Pro Ser Gln Cys Pro Asp Cys Val
                165                 170                 175

Val Ser Ala Leu Gly Ala Lys Val Leu Ser Ser Val Lys Asp Arg Phe
            180                 185                 190

Ile Asn Phe Phe Val Gly Asn Thr Ile Asn Ser Ser Tyr Phe Pro Asp
        195                 200                 205

His Pro Leu His Ser Ile Ser Val Arg Arg Leu Lys Glu Thr Lys Asp
    210                 215                 220

Gly Phe Met Phe Leu Thr Asp Gln Ser Tyr Ile Asp Val Leu Pro Glu
225                 230                 235                 240

Phe Arg Asp Ser Tyr Pro Ile Lys Tyr Val His Ala Phe Glu Ser Asn
                245                 250                 255

Asn Phe Ile Tyr Phe Leu Thr Val Gln Arg Glu Thr Leu Asp Ala Gln
            260                 265                 270

Thr Phe His Thr Arg Ile Ile Arg Phe Cys Ser Ile Asn Ser Gly Leu
        275                 280                 285

His Ser Tyr Met Glu Met Pro Leu Glu Cys Ile Leu Thr Glu Lys Arg
    290                 295                 300

Lys Lys Arg Ser Thr Lys Lys Glu Val Phe Asn Ile Leu Gln Ala Ala
305                 310                 315                 320

Tyr Val Ser Lys Pro Gly Ala Gln Leu Ala Arg Gln Ile Gly Ala Ser
                325                 330                 335

Leu Asn Asp Asp Ile Leu Phe Gly Val Phe Ala Gln Ser Lys Pro Asp
            340                 345                 350

Ser Ala Glu Pro Met Asp Arg Ser Ala Met Cys Ala Phe Pro Ile Lys
        355                 360                 365

Tyr Val Asn Asp Phe Phe Asn Lys Ile Val Asn Lys Asn Asn Val Arg
    370                 375                 380

Cys Leu Gln His Phe Tyr Gly Pro Asn His Glu His Cys Phe Asn Arg
```

385 390 395 400

Thr Leu Leu Arg Asn Ser Ser Gly Cys Glu Ala Arg Arg Asp Glu Tyr
405 410 415

Arg Thr Glu Phe Thr Thr Ala Leu Gln Arg Val Asp Leu Phe Met Gly
420 425 430

Gln Phe Ser Glu Val Leu Leu Thr Ser Ile Ser Thr Phe Ile Lys Gly
435 440 445

Asp Leu Thr Ile Ala Asn Leu Gly Thr Ser Glu Gly Arg Phe Met Gln
450 455 460

Val Val Val Ser Arg Ser Gly Pro Ser Thr Pro His Val Asn Phe Leu
465 470 475 480

Leu Asp Ser His Pro Val Ser Pro Glu Val Ile Val Glu His Thr Leu
485 490 495

Asn Gln Asn Gly Tyr Thr Leu Val Ile Thr Gly Lys Lys Ile Thr Lys
500 505 510

Ile Pro Leu Asn Gly Leu Gly Cys Arg His Phe Gln Ser Cys Ser Gln
515 520 525

Cys Leu Ser Ala Pro Pro Phe Val Gln Cys Gly Trp Cys His Asp Lys
530 535 540

Cys Val Arg Ser Glu Glu Cys Leu Ser Gly Thr Trp Thr Gln Gln Ile
545 550 555 560

Cys Leu Pro Ala Ile Tyr Lys Val Phe Pro Asn Ser Ala Pro Leu Glu
565 570 575

Gly Gly Thr Arg Leu Thr Ile Cys Gly Trp Asp Phe Gly Phe Arg Arg
580 585 590

Asn Asn Lys Phe Asp Leu Lys Lys Thr Arg Val Leu Leu Gly Asn Glu
595 600 605

Ser Cys Thr Leu Thr Leu Ser Glu Ser Thr Met Asn Thr Leu Lys Cys
610 615 620

Thr Val Gly Pro Ala Met Asn Lys His Phe Asn Met Ser Ile Ile Ile
625 630 635 640

Ser Asn Gly His Gly Thr Thr Gln Tyr Ser Thr Phe Ser Tyr Val Asp
645 650 655

Pro Val Ile Thr Ser Ile Ser Pro Lys Tyr Gly Pro Met Ala Gly Gly
660 665 670

Thr Leu Leu Thr Leu Thr Gly Asn Tyr Leu Asn Ser Gly Asn Ser Arg
675 680 685

His Ile Ser Ile Gly Gly Lys Thr Cys Thr Leu Lys Ser Val Ser Asn
690 695 700

Ser Ile Leu Glu Cys Tyr Thr Pro Ala Gln Thr Ile Ser Thr Glu Phe
705 710 715 720

Ala Val Lys Leu Lys Ile Asp Leu Ala Asn Arg Glu Thr Ser Ile Phe
725 730 735

Ser Tyr Arg Glu Asp Pro Ile Val Tyr Glu Ile His Pro Thr Lys Ser
740 745 750

Phe Ile Ser Gly Gly Ser Thr Ile Thr Gly Val Gly Lys Asn Leu Asn
755 760 765

Ser Val Ser Val Pro Arg Met Val Ile Asn Val His Glu Ala Gly Arg
770 775 780

Asn Phe Thr Val Ala Cys Gln His Arg Ser Asn Ser Glu Ile Ile Cys
785 790 795 800

Cys Thr Thr Pro Ser Leu Gln Gln Leu Asn Leu Gln Leu Pro Leu Lys
805 810 815

Thr Lys Ala Phe Phe Met Leu Asp Gly Ile Leu Ser Lys Tyr Phe Asp
820 825 830

Leu Ile Tyr Val His Asn Pro Val Phe Lys Pro Phe Glu Lys Pro Val
835 840 845

Met Ile Ser Met Gly Asn Glu Asn Val Leu Glu Ile Lys Gly Asn Asp
850 855 860

Ile Asp Pro Glu Ala Val Lys Gly Glu Val Leu Lys Val Gly Asn Lys
865 870 875 880

Ser Cys Glu Asn Ile His Leu His Ser Glu Ala Val Leu Cys Thr Val
885 890 895

Pro Asn Asp Leu Leu Lys Leu Asn Ser Glu Leu Asn Ile Glu Val Gly
900 905 910

Phe Leu His Ser Ser His Asp Val Asn Lys Glu Ala Ser Val Ile Met
915 920 925

Leu Phe Ser Gly Leu Lys
930

<210> 2
<211> 24
<212> PRT
<213> Homo sapiens

<400> 2

Val Gly Phe Leu His Ser Ser His Asp Val Asn Lys Glu Ala Ser Val
1 5 10 15

Ile Met Leu Phe Ser Gly Leu Lys
20

<210> 3
<211> 3042
<212> DNA
<213> Homo sapiens

<400> 3
gaattccgcc ctcgccgccc gcggcgcccc gagcgctttg tgagcagatg cggagccgag 60

tggagggcgc gagccagatg cggggcgaca gctgacttgc tgagaggagg cggggaggcg 120

cggagcgcgc gtgtggtcct tgcgccgctg acttctccac tggttcctgg gcaccgaaag 180

ataaacctct cataatgaag gcccccgctg tgcttgcacc tggcatcctc gtgctcctgt 240

ttaccttggt gcagaggagc aatggggagt gtaaagaggc actagcaaag tccgagatga 300

atgtgaatat gaagtatcag cttcccaact tcaccgcgga aacacccatc cagaatgtca 360

ttctacatga gcatcacatt ttccttggtg ccactaacta catttatgtt ttaaatgagg 420

aagaccttca gaaggttgct gagtacaaga ctgggcctgt gctggaacac ccagattgtt 480

tcccatgtca ggactgcagc agcaaagcca atttatcagg aggtgtttgg aaagataaca 540

tcaacatggc tctagttgtc gacacctact atgatgatca actcattagc tgtggcagcg 600

tcaacagagg gacctgccag cgacatgtct ttccccacaa tcatactgct gacatacagt 660

cggaggttca ctgcatattc tccccacaga tagaagagcc cagccagtgt cctgactgtg 720

tggtgagcgc cctgggagcc aaagtccttt catctgtaaa ggaccggttc atcaacttct 780

ttgtaggcaa taccataaat tcttcttatt tcccagatca tccattgcat tcgatatcag 840

tgagaaggct aaaggaaacg aaagatggtt ttatgttttt gacggaccag tcctacattg 900

atgttttacc tgagttcaga gattcttacc ccattaagta tgtccatgcc tttgaaagca 960

acaattttat ttacttcttg acggtccaaa gggaaactct agatgctcag acttttcaca 1020

caagaataat caggttctgt tccataaact ctggattgca ttcctacatg gaaatgcctc 1080

tggagtgtat tctcacagaa aagagaaaaa agagatccac aaagaaggaa gtgtttaata 1140

tacttcaggc tgcgtatgtc agcaagcctg gggcccagct tgctagacaa ataggagcca 1200

gcctgaatga tgacattctt ttcggggtgt tcgcacaaag caagccagat tctgccgaac 1260

caatggatcg atctgccatg tgtgcattcc ctatcaaata tgtcaacgac ttcttcaaca 1320

agatcgtcaa caaaaacaat gtgagatgtc tccagcattt ttacggaccc aatcatgagc 1380

actgctttaa taggacactt ctgagaaatt catcaggctg tgaagcgcgc cgtgatgaat 1440

atcgaacaga gtttaccaca gctttgcagc gcgttgactt attcatgggt caattcagcg 1500

aagtcctctt aacatctata tccaccttca ttaaaggaga cctcaccata gctaatcttg 1560

ggacatcaga gggtcgcttc atgcaggttg tggtttctcg atcaggacca tcaacccctc 1620

atgtgaattt tctcctggac tcccatccag tgtctccaga agtgattgtg gagcatacat 1680

taaaccaaaa tggctacaca ctggttatca ctgggaagaa gatcacgaag atcccattga 1740

atggcttggg ctgcagacat ttccagtcct gcagtcaatg cctctctgcc ccacccttg 1800

ttcagtgtgg ctggtgccac gacaaatgtg tgcgatcgga ggaatgcctg agcgggacat 1860

ggactcaaca gatctgtctg cctgcaatct acaaggtttt cccaaatagt gcacccctg 1920

aaggagggac aaggctgacc atatgtggct gggactttgg atttcggagg aataataaat 1980

ttgatttaaa gaaaactaga gttctccttg gaaatgagag ctgcaccttg actttaagtg 2040

agagcacgat gaatacattg aaatgcacag ttggtcctgc catgaataag catttcaata 2100

tgtccataat tatttcaaat ggccacggga caacacaata cagtacattc tcctatgtgg 2160

atcctgtaat aacaagtatt tcgccgaaat acggtcctat ggctggtggc actttactta 2220

ctttaactgg aaattaccta aacagtggga attctagaca catttcaatt ggtggaaaaa 2280

catgtacttt aaaaagtgtg tcaaacagta ttcttgaatg ttatacccca gcccaaacca 2340

tttcaactga gtttgctgtt aaattgaaaa ttgacttagc caaccgagag acaagcatct 2400

tcagttaccg tgaagatccc attgtctatg aaattcatcc aaccaaatct tttattagtg 2460

gtgggagcac aataacaggt gttgggaaaa acctgaattc agttagtgtc ccgagaatgg 2520

tcataaatgt gcatgaagca ggaaggaact ttacagtggc atgtcaacat cgctctaatt 2580

cagagataat ctgttgtacc actccttccc tgcaacagct gaatctgcaa ctccccctga 2640

aaaccaaagc ctttttcatg ttagatggga tcctttccaa atactttgat ctcatttatg 2700

tacataatcc tgtgtttaag ccttttgaaa agccagtgat gatctcaatg ggcaatgaaa 2760

atgtactgga aattaaggga aatgatattg accctgaagc agttaaaggt gaagtgttaa 2820

aagttggaaa taagagctgt gagaatatac acttacattc tgaagccgtt ttatgcacgg 2880

tccccaatga cctgctgaaa ttgaacagcg agctaaatat agaggtggga ttcctgcatt 2940

cctctcatga tgtaaataag gaagccagtg taattatgtt attctcaggc ttaaaataaa 3000

tcattaaagc tcatttatgt gtgggttttg gctcatcaac tc 3042

<210> 4
<211> 118
<212> DNA
<213> Homo sapiens

<400> 4
gtgggattcc tgcattcctc tcatgatgta aataaggaag ccagtgtaat tatgttattc 60

tcaggcttaa aataaatcat taaagctcat ttatgtgtgg gttttggctc atcaactc 118

<210> 5
<211> 198
<212> PRT
<213> Homo sapiens

<400> 5

Met Asn Ser Phe Ser Thr Ser Ala Phe Gly Pro Val Ala Phe Ser Leu
1 5 10 15

Gly Leu Leu Leu Val Leu Pro Ala Ala Phe Pro Ala Pro Val Pro Pro
20 25 30

Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg Gln Pro Leu Thr
35 40 45

Ser Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr Ile Leu Asp Gly Ile
50 55 60

Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn Met Cys Glu Ser
65 70 75 80

Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro Lys Met Ala
85 90 95

Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn Glu Glu Thr Cys Leu
100 105 110

Val Lys Ile Ile Thr Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr
115 120 125

Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu Gln Ala Arg Ala Val Gln
130 135 140

Met Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Val Gly Val
145 150 155 160

Ser Ser Phe Pro Gln Leu Gly Val Gly Glu Asp Arg Leu Lys Asp Ser
165 170 175

Val Leu Asp Asn Ser Gly Met Gln Cys His Phe Gln Lys Arg Arg Leu
180 185 190

His Val Asn Lys Arg Val
195

<210> 6
<211> 41

<212> PRT
<213> Homo sapiens

<400> 6

Val Gly Val Ser Ser Phe Pro Gln Leu Gly Val Gly Glu Asp Arg Leu
1 5 10 15

Lys Asp Ser Val Leu Asp Asn Ser Gly Met Gln Cys His Phe Gln Lys
20 25 30

Arg Arg Leu His Val Asn Lys Arg Val
35 40

<210> 7
<211> 1126
<212> DNA
<213> Homo sapiens

<400> 7
ccatgtttgg taaataagtg ttttggtgtt gtgcaagggt ctggtttcag cctgaagcca 60

tctcagagct gtctgggtct ctggagactg gagggacaac ctagtctaga gcccatttgc 120

atgagaccaa ggatcctcct gcaagagaca ccatcctgag ggaagagggc ttctgaacca 180

gcttgaccca ataagaaatt cttgggtgcc gacgcggaag cagattcaga gcctagagcc 240

gtgcctgcgt ccgtagtttc cttctagctt cttttgattt caaatcaaga cttacaggga 300

gagggagcga taaacacaaa ctctgcaaga tgccacaagg tcctcctttg acatccccaa 360

caaagaggac tggagatgtc tgaggctcat tctgccctcg agcccaccgg gaacgaaaga 420

gaagctctat ctcccctcca ggagcccagc tatgaactcc ttctccacaa gcgccttcgg 480

tccagttgcc ttctccctgg ggctgctcct ggtgttgcct gctgccttcc ctgccccagt 540

acccccagga gaagattcca aagatgtagc cgccccacac agacagccac tcacctcttc 600

agaacgaatt gacaaacaaa ttcggtacat cctcgacggc atctcagccc tgagaaagga 660

gacatgtaac aagagtaaca tgtgtgaaag cagcaaagag gcactggcag aaaacaacct 720

gaaccttcca aagatggctg aaaaagatgg atgcttccaa tctggattca atgaggagac 780

ttgcctggtg aaaatcatca ctggtctttt ggagtttgag gtatacctag agtacctcca 840

gaacagattt gagagtagtg aggaacaagc cagagctgtg cagatgagta caaaagtcct 900

gatccagttc ctgcagaaaa aggtgggtgt gtcctcattc cctcaacttg gtgtgggggа 960

agacaggctc aaagacagtg tcctggacaa ctcagggatg caatgccact tccaaaagag 1020

aaggctacac gtaaacaaaa gagtctgaga aatagtttct gattgttatt gttaaatctt 1080

tttttgtttg tttggttggt tggctctctt ctgcaaagga catcaa 1126

<210> 8
<211> 185
<212> DNA
<213> Homo sapiens

<400> 8
tgggtgtgtc ctcattccct caacttggtg tgggggaaga caggctcaaa gacagtgtcc 60

tggacaactc agggatgcaa tgccacttcc aaaagagaag gctacacgta aacaaaagag 120

tctgagaaat agtttctgat tgttattgtt aaatcttttt ttgtttgttt ggttggttgg 180

ctctc 185

<210> 9
<211> 167
<212> PRT
<213> Homo sapiens

<400> 9

Met Phe His Val Ser Phe Arg Tyr Ile Phe Gly Leu Pro Pro Leu Ile
1 5 10 15

Leu Val Leu Leu Pro Val Ala Ser Ser Asp Cys Asp Ile Glu Gly Lys
20 25 30

Asp Gly Lys Gln Tyr Glu Ser Val Leu Met Val Ser Ile Asp Gln Leu
35 40 45

Leu Asp Ser Met Lys Glu Ile Gly Ser Asn Cys Leu Asn Asn Glu Phe
50 55 60

Asn Phe Phe Lys Arg His Ile Cys Asp Ala Asn Lys Glu Gly Met Phe
65 70 75 80

Leu Phe Arg Ala Ala Arg Lys Leu Arg Gln Phe Leu Lys Met Asn Ser
85 90 95

Thr Gly Asp Phe Asp Leu His Leu Leu Lys Val Ser Glu Gly Thr Thr
100 105 110

Ile Leu Leu Asn Cys Thr Gly Gln Val Lys Gly Arg Lys Pro Ala Ala
115 120 125

Leu Gly Glu Ala Gln Pro Thr Lys Ser Leu Ser Ser Gly Leu Gln Lys
130 135 140

Gln Phe Thr Phe Tyr Arg Ser Asn Gly Arg His Thr His Ser Phe His
145 150 155 160

Cys Lys Leu Ser Phe Leu His
165

<210> 10
<211> 29
<212> PRT
<213> Homo sapiens

<400> 10

Ser Ser Gly Leu Gln Lys Gln Phe Thr Phe Tyr Arg Ser Asn Gly Arg
1 5 10 15

His Thr His Ser Phe His Cys Lys Leu Ser Phe Leu His
20 25

<210> 11
<211> 1789
<212> DNA
<213> Homo sapiens

<400> 11
aagacgaata gtttgattta ttagccaatt cagataaatg tgcacgtgga agtcatagtt 60

aaatattatc gtcagtttcc acgtcctgcg tttaatttgg ggtttgattt tccaaataca 120

acacttacca gattaggtgg acccacagga ttatttttcc ttgaggtctc acctgagcag 180

gtgcatgtac agcagacgga gcagaaagag actgattaga gaggttggag tggtagaggg 240

cgtgaccctc ttaatcattc ttcacttcct tttttaaaag acgacttggc atcgtccacc 300

acatccgcgg caacgcctcc ttggtgtcgt ccgcttccaa taacccagct tgcgtcctgc 360

acacttgtgg cttccgtgca cacattaaca actcatggtt ctagctccca gtcgccaagc 420

gttgccaagg cgttgagaga tcatctggga agtcttttac ccagaattgc tttgattcag 480

gccagctggt ttttcctgcg gtgattcgga aattcgcgaa ttcctctggt cctcatccag 540

gtgcgcggga agcaggtgcc caggagagag gggataatga agattccatg ctgatgatcc 600

caaagattga acctgcagac caagcgcaaa gtagaaactg aaagtacact gctggcggat 660

cctacggaag ttatggaaaa ggcaaagcgc agagccacgc cgtagtgtgt gccgcccccc 720

ttgggatgga tgaaactgca gtcgcggcgt gggtaagagg aaccagctgc agagatcacc 780

ctgcccaaca cagactcggc aactccgcgg aagaccaggg tcctgggagt gactatgggc 840

ggtgagagct tgctcctgct ccagttgcgg tcatcatgac tacgcccgcc tcccgcagac 900

catgttccat gtttctttta ggtatatctt tggacttcct cccctgatcc ttgttctgtt 960

gccagtagca tcatctgatt gtgatattga aggtaaagat ggcaaacaat atgagagtgt 1020

tctaatggtc agcatcgatc aattattgga cagcatgaaa gaaattggta gcaattgcct 1080

gaataatgaa tttaactttt ttaaaagaca tatctgtgat gctaataagg aaggtatgtt 1140

tttattccgt gctgctcgca agttgaggca atttcttaaa atgaatagca ctggtgattt 1200

tgatctccac ttattaaaag tttcagaagg cacaacaata ctgttgaact gcactggcca 1260

ggttaaagga agaaaaccag ctgccctggg tgaagcccaa ccaacaaaga gtttgtcctc 1320

aggactacag aagcagttca cattttacag atcaaacgga cgacacacac attctttcca 1380

ctgcaaattg tcctttctcc actagaaggt atcagtttct ccaaataaat tgtatcaact 1440

tgagggcaga cacttaatta catcttatta tctcgatccc catcattgca tatccagaaa 1500

gagcacataa agcgtttttc aatgcttatt ttagttgatg gactatttgt ttctttgttt 1560

tgaccaataa gactgaataa agataactga ggggaaaaaa attaacaact aatcaggaaa 1620

taaacttttt tcggatttat gaaataattt gttgacatgc tctacaggag tgaccttaac 1680

atacctaatg gtaactaaaa ctgttctctt taattacaaa attcccagca tctatcctac 1740

tatgatacta tctgaagata ggcaccaata atacaaatgt ttatccaaa 1789

<210> 12
<211> 474
<212> DNA
<213> Homo sapiens

<400> 12
tcctcaggac tacagaagca gttcacattt tacagatcaa acggacgaca cacacattct 60

ttccactgca aattgtcctt tctccactag aaggtatcag tttctccaaa taaattgtat 120

caacttgagg gcagacactt aattacatct tattatctcg atccccatca ttgcatatcc 180

agaaagagca cataaagcgt ttttcaatgc ttattttagt tgatggacta tttgtttctt 240

tgttttgacc aataagactg aataaagata actgagggga aaaaaattaa caactaatca 300

ggaaataaac ttttttcgga tttatgaaat aatttgttga catgctctac aggagtgacc 360

ttaacatacc taatggtaac taaaactgtt ctctttaatt acaaaattcc cagcatctat 420

cctactatga tactatctga agataggcac caataataca aatgtttatc caaa 474

<210> 13
<211> 157
<212> PRT
<213> Homo sapiens

<400> 13

Met Phe His Val Ser Phe Arg Tyr Ile Phe Gly Leu Pro Pro Leu Ile
1 5 10 15

Leu Val Leu Leu Pro Val Ala Ser Ser Asp Cys Asp Ile Glu Gly Lys
20 25 30

Asp Gly Lys Gln Tyr Glu Ser Val Leu Met Val Ser Ile Asp Gln Leu
35 40 45

Leu Asp Ser Met Lys Glu Ile Gly Ser Asn Cys Leu Asn Asn Glu Phe
50 55 60

Asn Phe Phe Lys Arg His Ile Cys Asp Ala Asn Lys Glu Gly Met Phe
65 70 75 80

Leu Phe Arg Ala Ala Arg Lys Leu Arg Gln Phe Leu Lys Met Asn Ser
85 90 95

Thr Gly Asp Phe Asp Leu His Leu Leu Lys Val Ser Glu Gly Thr Thr
100 105 110

Ile Leu Leu Asn Cys Thr Gly Gln Val Lys Gly Arg Lys Pro Ala Ala
115 120 125

Leu Gly Glu Ala Gln Pro Thr Lys Ser Leu Val Glu Leu Ile Ile Pro
130 135 140

Ser Cys Met Pro Pro Leu Leu Ser Ser Thr Ser Asn Ser
145 150 155

<210> 14
<211> 19
<212> PRT
<213> Homo sapiens

<400> 14

Val Glu Leu Ile Ile Pro Ser Cys Met Pro Pro Leu Leu Ser Ser Thr
1 5 10 15

Ser Asn Ser

<210> 15
<211> 1541
<212> DNA
<213> Homo sapiens

<400> 15
aagacgaata gtttgattta ttagccaatt cagataaatg tgcacgtgga agtcatagtt 60

aaatattatc gtcagtttcc acgtcctgcg tttaatttgg ggtttgattt tccaaataca 120

acacttacca gattaggtgg acccacagga ttatttttcc ttgaggtctc acctgagcag 180

gtgcatgtac agcagacgga gcagaaagag actgattaga gaggttggag tggtagaggg 240

cgtgaccctc ttaatcattc ttcacttcct tttttaaaag acgacttggc atcgtccacc 300

acatccgcgg caacgcctcc ttggtgtcgt ccgcttccaa taacccagct tgcgtcctgc 360

acacttgtgg cttccgtgca cacattaaca actcatggtt ctagctccca gtcgccaagc 420

gttgccaagg cgttgagaga tcatctggga agtcttttac ccagaattgc tttgattcag 480

gccagctggt ttttcctgcg gtgattcgga aattcgcgaa ttcctctggt cctcatccag 540

gtgcgcggga agcaggtgcc caggagagag gggataatga agattccatg ctgatgatcc 600

caaagattga acctgcagac caagcgcaaa gtagaaactg aaagtacact gctggcggat 660

cctacggaag ttatggaaaa ggcaaagcgc agagccacgc cgtagtgtgt gccgcccccc 720

ttgggatgga tgaaactgca gtcgcggcgt gggtaagagg aaccagctgc agagatcacc 780

ctgcccaaca cagactcggc aactccgcgg aagaccaggg tcctgggagt gactatgggc 840

ggtgagagct tgctcctgct ccagttgcgg tcatcatgac tacgcccgcc tcccgcagac 900

catgttccat gtttctttta ggtatatctt tggacttcct cccctgatcc ttgttctgtt 960

gccagtagca tcatctgatt gtgatattga aggtaaagat ggcaaacaat atgagagtgt 1020

tctaatggtc agcatcgatc aattattgga cagcatgaaa gaaattggta gcaattgcct 1080

gaataatgaa tttaactttt ttaaaagaca tatctgtgat gctaataagg aaggtatgtt 1140

tttattccgt gctgctcgca agttgaggca atttcttaaa atgaatagca ctggtgattt 1200

tgatctccac ttattaaaag tttcagaagg cacaacaata ctgttgaact gcactggcca 1260

ggttaaagga agaaaaccag ctgccctggg tgaagcccaa ccaacaaaga gtttggtgga 1320

actgatcatt ccttcatgta tgcctccact gctcagctca acaagtaact cttaataacc 1380

taccacctgt tatctctggg agagggacat atgtttgcca atttctatct tcaatgctta 1440

tcacaaattt tcttatattt gaaataatct gattcaaatg agaactttaa cctaaaactt 1500

taattggaaa gacaatctta taaaaatctt ataacatatt c 1541

<210> 16
<211> 225
<212> DNA
<213> Homo sapiens

<400> 16
tggaactgat cattccttca tgtatgcctc cactgctcag ctcaacaagt aactcttaat 60

aacctaccac ctgttatctc tgggagaggg acatatgttt gccaatttct atcttcaatg 120

cttatcacaa attttcttat atttgaaata atctgattca aatgagaact ttaacctaaa 180

actttaattg gaaagacaat cttataaaaa tcttataaca tattc 225

<210> 17
<211> 153
<212> PRT
<213> Homo sapiens

<400> 17

Met Gly Asn Ser Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu
1 5 10 15

Asn Phe Glu Arg Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn Cys Pro
20 25 30

Ala Gly Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser Pro Cys
35 40 45

Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp Ile
50 55 60

Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu Cys Ser Ser
65 70 75 80

Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe His Cys Leu Gly
85 90 95

Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln Gly Gln Glu Leu
100 105 110

Thr Lys Lys Gly Cys Lys Asp Cys Cys Phe Gly Thr Phe Asn Asp Gln
115 120 125

Lys Arg Gly Ile Cys Arg Pro Trp Thr Asn Ile Arg Val Ala Asp Glu
130 135 140

Trp Asn His Asp Ser Gln Glu Lys Tyr
145 150

<210> 18
<211> 15
<212> PRT
<213> Homo sapiens

<400> 18

Ile Arg Val Ala Asp Glu Trp Asn His Asp Ser Gln Glu Lys Tyr
1 5 10 15

<210> 19
<211> 946
<212> DNA
<213> Homo sapiens

<400> 19
gagaccaagg agtggaaagt tctccggcag ccctgagatc tcaagagtga catttgtgag 60

accagctaat ttgattaaaa ttctcttgga atcagctttg ctagtatcat acctgtgcca 120

gatttcatca tgggaaacag ctgttacaac atagtagcca ctctgttgct ggtcctcaac 180

tttgagagga caagatcatt gcaggatcct tgtagtaact gcccagctgg tacattctgt 240

gataataaca ggaatcagat ttgcagtccc tgtcctccaa atagtttctc cagcgcaggt 300

ggacaaagga cctgtgacat atgcaggcag tgtaaaggtg ttttcaggac caggaaggag 360

tgttcctcca ccagcaatgc agagtgtgac tgcactccag ggtttcactg cctgggggca 420

ggatgcagca tgtgtgaaca ggattgtaaa caaggtcaag aactgacaaa aaaaggttgt 480

aaagactgtt gctttgggac atttaacgat cagaaacgtg gcatctgtcg accctggaca 540

aacatcagag tggctgacga atggaatcat gattcacaag aaaagtattg actattttct 600

cggacttagc tgaattctgt ctttggaaag tggctttttt aaaaagctgt tctttggatg 660

gaaagtctgt gcttgtgaat gggacgaagg agagggacgt ggtctgtgga ccatctccag 720

ccgacctctc tccgggagca tcctctgtga ccccgcctgc ccctgcgaga gagccaggac 780

actctccgca gatcatctcc ttctttcttg cgctgacgtc gactgcgttg ctcttcctgc 840

tgttcttcct cacgctccgt ttctctgttg ttaaacgggg cagaaagaaa ctcctgtata 900

tattcaaaca acgtaagatt aacataatca tattacagct ctggca 946

<210> 20
<211> 104
<212> DNA

<213> Homo sapiens

<400> 20
catcagagtg gctgacgaat ggaatcatga ttcacaagaa aagtattgac tattttctcg 60

gacttagctg aattctgtct ttggaaagtg gctttttaa aaag 104

<210> 21
<211> 131
<212> PRT
<213> Homo sapiens

<400> 21

Met Gly Trp Leu Cys Ser Gly Leu Leu Phe Pro Val Ser Cys Leu Val
1 5 10 15

Leu Leu Gln Val Ala Ser Ser Gly Asn Met Lys Val Leu Gln Glu Pro
20 25 30

Thr Cys Val Ser Asp Tyr Met Ser Ile Ser Thr Cys Glu Trp Lys Met
35 40 45

Asn Gly Pro Thr Asn Cys Ser Thr Glu Leu Arg Leu Leu Tyr Gln Leu
50 55 60

Val Phe Leu Leu Ser Glu Ala His Thr Cys Ile Pro Glu Asn Asn Gly
65 70 75 80

Gly Ala Gly Cys Val Cys His Leu Leu Met Asp Asp Val Val Ser Ala
85 90 95

Asp Asn Tyr Thr Leu Asp Leu Trp Ala Gly Gln Gln Leu Leu Trp Lys
100 105 110

Gly Ser Phe Lys Pro Ser Glu His Val Leu Pro Pro Leu Lys Arg Ser
115 120 125

Trp Ser Gln
130

<210> 22
<211> 10
<212> PRT
<213> Homo sapiens

<400> 22

Leu Pro Pro Leu Lys Arg Ser Trp Ser Gln
1 5 10

<210> 23
<211> 4848
<212> DNA
<213> Homo sapiens

<400> 23
tgcagtgccc gacagattgt actagttact gattgaaggg ctgttttact atccaaatgt 60

ggctggagta ggagttgggt aaacatttat tgaagaatgt gcaaccactc tcacttggaa 120

gccgggctgt taggaagggg aggaggattc cagtcgccca gccctccccc accaaacgca 180

actgccccgg cgcaaaagag gccgcggagg ccaggcagga gcaggtcctg gaggcctggt 240

cggcgtgggc gttttattcc gagaccaagg ggatccactg cagagttctc cgctgggcgt 300

gacctcgggc tacggcgtgg gaggaagcgc gcggcaagac acccagcgag gtgctggggt 360

cgcccccagg agaggacggc ggctcggact gtccggcggc ggcggcgggg acagcgacag 420

gggcgcgagg tggccgggac ccgggccggg cgcgccgggc ggggcggcgc atgcaaatct 480

gccgggcgcc ggggcgggga gcaggaagcc ggggcgggct gggtctccgc gcccaggaaa 540

gccccgcgcg gcgcgggcca gggaagggcc acccaggggt cccccacttc ccgcttgggc 600

gcccggacgg cgaatggagc aggggcgcgc agataattaa agatttacac acagctggaa 660

gaaatcatag agaagccggg cgtggtggct catgcctata atcccagcac ttttggaggc 720

tgaggcgggc agatcacttg agatcaggag ttcgagacca gcctggtgcc ttggcatctc 780

ccaatggggt ggctttgctc tgggctcctg ttccctgtga gctgcctggt cctgctgcag 840

gtggcaagct ctgggaacat gaaggtcttg caggagccca cctgcgtctc cgactacatg 900

agcatctcta cttgcgagtg gaagatgaat ggtcccacca attgcagcac cgagctccgc 960

ctgttgtacc agctggtttt tctgctctcc gaagcccaca cgtgtatccc tgagaacaac 1020

ggaggcgcgg ggtgcgtgtg ccacctgctc atggatgacg tggtcagtgc ggataactat 1080

acactggacc tgtgggctgg gcagcagctg ctgtggaagg gctccttcaa gcccagcgag 1140

catgtcctcc caccttttgaa acggagctgg tcgcagtaga ccaccaagcc cccttcagcc 1200

cagctgtttc caccccctgaa cttaagtgcc caggaaggcg tattgagatg aggtgtgctt 1260

gctggaaggc atgcctgctg ctgattgaaa accgaactgg gaacagtcct tccattctgt 1320

gtccactggt cagctgctgc ggctttggat ggtcttgacc gtggaaggct gaccttcttc 1380

tggtacccgg agtccctgca ggaatccccc ttgagcttgc tgggctgtgg tgacaggagt 1440

ttaaaacatg cgttgtattc cagtgatgca tgatatgaca tgcatcacag gaataaaaac 1500

ctgaggtctc atggatatga ttgcttcaaa ggagaccaag ttttaaaaca gatgaatcaa 1560

aataaagaaa aatactcagt aaatcatcat aaagtacaga gatgtggcca aaggtgtgaa 1620

ggatgcagct gtaaaagctg aagtttgagg ccgggtgtgg tggttcatgc ctataatccc 1680

agcactttgg gaggccgagc ccagcggatc accggaggtc aggagttcga gaccagcctg 1740

gacaacatgt gaaacccagg gccccaggaa acctgacagt tcacaccaat gtctccgaca 1800

ctctgctgct gacctggagc aacccgtatc cccctgacaa ttacctgtat aatcatctca 1860

cctatgcagt caacatttgg agtgaaaacg acccggcaga tttcagaatc tataacgtga 1920

cctacctaga accctccctc cgcatcgcag ccagcaccct gaagtctggg atttcctaca 1980

gggcacgggt gagggcctgg gctcagtgct ataacaccac ctggagtgag tggagcccca 2040

gcaccaagtg gcacaactcc tacagggagc ccttcgagca gcacctcctg ctgggcgtca 2100

gcgtttcctg cattgtcatc ctggccgtct gcctgttgtg ctatgtcagc atcaccaaga 2160

ttaagaaaga atggtgggat cagattccca acccagcccg cagccgcctc gtggctataa 2220

taatccagga tgctcagggg tcacagtggg agaagcggtc ccgaggccag gaaccagcca 2280

agtgcccaca ctggaagaat tgtcttacca agctcttgcc ctgttttctg gagcacaaca 2340

tgaaaaggga tgaagatcct cacaaggctg ccaaagagat gcctttccag ggctctggaa 2400

aatcagcatg gtgcccagtg gagatcagca agacagtcct ctggccagag agcatcagcg 2460

tggtgcgatg tgtggagttg tttgaggccc cggtggagtg tgaggaggag gaggaggtag 2520

aggaagaaaa agggagcttc tgtgcatcgc ctgagagcag cagggatgac ttccaggagg 2580

gaagggaggg cattgtggcc cggctaacag agagcctgtt cctggacctg ctcggagagg 2640

agaatggggg cttttgccag caggacatgg gggagtcatg ccttcttcca ccttcgggaa 2700

gtacgagtgc tcacatgccc tgggatgagt tcccaagtgc agggcccaag gaggcacctc 2760

cctggggcaa ggagcagcct ctccacctgg agccaagtcc tcctgccagc ccgacccaga 2820

gtccagacaa cctgacttgc acagagacgc ccctcgtcat cgcaggcaac cctgcttacc 2880

gcagcttcag caactccctg agccagtcac cgtgtcccag agagctgggt ccagacccac 2940

tgctggccag acacctggag gaagtagaac ccgagatgcc ctgtgtcccc cagctctctg 3000

agccaaccac tgtgccccaa cctgagccag aaacctggga gcagatcctc cgccgaaatg 3060

tcctccagca tggggcagct gcagcccccg tctcggcccc caccagtggc tatcaggagt 3120

ttgtacatgc ggtggagcag ggtggcaccc aggccagtgc ggtggtgggc ttgggtcccc 3180

caggagaggc tggttacaag gccttctcaa gcctgcttgc cagcagtgct gtgtccccag 3240

agaaatgtgg gtttggggct agcagtgggg aagaggggta taagcctttc caagacctca 3300

ttcctggctg ccctggggac cctgccccag tccctgtccc cttgttcacc tttggactgg 3360

acagggagcc acctcgcagt ccgcagagct cacatctccc aagcagctcc ccagagcacc 3420

tgggtctgga gccgggggaa aaggtagagg acatgccaaa gcccccactt ccccaggagc 3480

aggccacaga ccccccttgtg gacagcctgg gcagtggcat tgtctactca gcccccttacc 3540

tgccacctgt gcggccacct gaaacagtgt catggccagg aggatggtgg ccagacccct 3600

gtcatggcca gtccttgctg tggctgctgc tgtggagaca ggtcctcgcc ccctacaacc 3660

cccctgaggg ccccagaccc ctctccaggt ggggttccac tggaggccag tctgtgtccg 3720

gcctccctgg caccctcggg catctcagag aagagtaaat cctcatcatc cttccatcct 3780

gcccctggca atgctcagag ctcaagccag acccccaaaa tcgtgaactt tgtctccgtg 3840

ggacccacat acatgagggt ctcttaggtg catgtcctct tgttgctgag tctgcagatg 3900

aggactaggg cttatccatg cctgggaaat gccacctcct ggaaggcagc caggctggca 3960

gatttccaaa agacttgaag aaccatggta tgaaggtgat tggccccact gacgttggcc 4020

taacactggg ctgcagagac tggaccccgc ccagcattgg gctgggctcg ccacatccca 4080

tgagagtaga gggcactggg tcgccgtgcc ccacggcagg cccctgcagg aaaactgagg 4140

cccttgggca cctcgacttg tgaacgagtt gttggctgct ccctccacag cttctgcagc 4200

agactgtccc tgttgtaact gcccaaggca tgttttgccc accagatcat ggcccacatg 4260

gaggcccacc tgcctctgtc tcactgaact agaagccgag cctagaaact aacacagcca 4320

tcaagggaat gacttgggcg gccttgggaa atcgatgaga aattgaactt cagggagggt 4380

ggtcattgcc tagaggtgct cattcattta acagagcttc cttaggttga tgctggaggc 4440

agaatcccgg ctgtcaaggg gtgttcagtt aaggggagca acagaggaca tgaaaaattg 4500

ctgtgactaa agcagggaca atttgctgcc aaacacccat gcccagctgt atggctgggg 4560

gctcctcgta tgcatggaac ccccagaata aatatgctca gccaccctgt gggccgggca 4620

atccagacag caggcataag gcaccagtta ccctgcatgt tggcccagac ctcaggtgct 4680

agggaaggcg ggaaccttgg gttgagtaat gctcgtctgt gtgttttagt ttcatcacct 4740

gttatctgtg tttgctgagg agagtggaac agaaggggtg gagttttgta taaataaagt 4800

ttctttgtct ctttaaaaat tatgtattaa ccaaacatac ctccagac 4848

<210> 24
<211> 605
<212> DNA
<213> Homo sapiens

<400> 24
catgtcctcc cacctttgaa acggagctgg tcgcagtaga ccaccaagcc cccttcagcc 60

cagctgtttc cacccctgaa cttaagtgcc caggaaggcg tattgagatg aggtgtgctt 120

gctggaaggc atgcctgctg ctgattgaaa accgaactgg gaacagtcct tccattctgt 180

gtccactggt cagctgctgc ggctttggat ggtcttgacc gtggaaggct gaccttcttc 240

tggtacccgg agtccctgca ggaatccccc ttgagcttgc tgggctgtgg tgacaggagt 300

ttaaaacatg cgttgtattc cagtgatgca tgatatgaca tgcatcacag gaataaaaac 360

ctgaggtctc atggatatga ttgcttcaaa ggagaccaag ttttaaaaca gatgaatcaa 420

aataaagaaa aatactcagt aaatcatcat aaagtacaga gatgtggcca aaggtgtgaa 480

ggatgcagct gtaaaagctg aagtttgagg ccgggtgtgg tggttcatgc ctataatccc 540

agcactttgg gaggccgagc ccagcggatc accggaggtc aggagttcga gaccagcctg 600

gacaa 605

<210> 25
<211> 229
<212> PRT
<213> Homo sapiens

<400> 25

Met Gly Trp Leu Cys Ser Gly Leu Leu Phe Pro Val Ser Cys Leu Val

```
1               5                   10                  15

Leu Leu Gln Val Ala Ser Ser Gly Asn Met Lys Val Leu Gln Glu Pro
            20                  25                  30

Thr Cys Val Ser Asp Tyr Met Ser Ile Ser Thr Cys Glu Trp Lys Met
        35                  40                  45

Asn Gly Pro Thr Asn Cys Ser Thr Glu Leu Arg Leu Leu Tyr Gln Leu
    50                  55                  60

Val Phe Leu Leu Ser Glu Ala His Thr Cys Ile Pro Glu Asn Asn Gly
65                  70                  75                  80

Gly Ala Gly Cys Val Cys His Leu Leu Met Asp Asp Val Val Ser Ala
                85                  90                  95

Asp Asn Tyr Thr Leu Asp Leu Trp Ala Gly Gln Gln Leu Leu Trp Lys
            100                 105                 110

Gly Ser Phe Lys Pro Ser Glu His Val Lys Pro Arg Ala Pro Gly Asn
        115                 120                 125

Leu Thr Val His Thr Asn Val Ser Asp Thr Leu Leu Leu Thr Trp Ser
    130                 135                 140

Asn Pro Tyr Pro Pro Asp Asn Tyr Leu Tyr Asn His Leu Thr Tyr Ala
145                 150                 155                 160

Val Asn Ile Trp Ser Glu Asn Asp Pro Ala Asp Phe Arg Ile Tyr Asn
                165                 170                 175

Val Thr Tyr Leu Glu Pro Ser Leu Arg Ile Ala Ala Ser Thr Leu Lys
            180                 185                 190

Ser Gly Ile Ser Tyr Arg Ala Arg Val Arg Ala Trp Ala Gln Cys Tyr
        195                 200                 205

Asn Thr Thr Trp Ser Glu Trp Ser Pro Ser Thr Lys Trp His Asn Cys
    210                 215                 220

Glu Tyr Gln Glu Ala
225
```

<210> 26
<211> 6
<212> PRT
<213> Homo sapiens

<400> 26

Cys Glu Tyr Gln Glu Ala

1 5

<210> 27
<211> 1541
<212> DNA
<213> Homo sapiens

<400> 27
tgcagtgccc gacagattgt actagttact gattgaaggg ctgttttact atccaaatgt 60

ggctggagta ggagttgggt aaacatttat tgaagaatgt gcaaccactc tcacttggaa 120

gccgggctgt taggaagggg aggaggattc cagtcgccca gccctccccc accaaacgca 180

actgccccgg cgcaaaagag gccgcggagg ccaggcagga gcaggtcctg gaggcctggt 240

cggcgtgggc gttttattcc gagaccaagg ggatccactg cagagttctc cgctgggcgt 300

gacctcgggc tacggcgtgg gaggaagcgc gcggcaagac acccagcgag gtgctggggt 360

cgcccccagg agaggacggc ggctcggact gtccggcggc ggcggcgggg acagcgacag 420

gggcgcgagg tggccgggac ccgggccggg cgcgccgggc ggggcggcgc atgcaaatct 480

gccgggcgcc ggggcgggga gcaggaagcc ggggcgggct gggtctccgc gcccaggaaa 540

gccccgcgcg gcgcgggcca gggaagggcc acccaggggt cccccacttc ccgcttgggc 600

gcccggacgg cgaatggagc aggggcgcgc agataattaa agatttacac acagctggaa 660

gaaatcatag agaagccggg cgtggtggct catgcctata atcccagcac ttttggaggc 720

tgaggcgggc agatcacttg agatcaggag ttcgagacca gcctggtgcc ttggcatctc 780

ccaatggggt ggctttgctc tgggctcctg ttccctgtga gctgcctggt cctgctgcag 840

gtggcaagct ctgggaacat gaaggtcttg caggagccca cctgcgtctc cgactacatg 900

agcatctcta cttgcgagtg gaagatgaat ggtcccacca attgcagcac cgagctccgc 960

ctgttgtacc agctggtttt tctgctctcc gaagcccaca cgtgtatccc tgagaacaac 1020

ggaggcgcgg ggtgcgtgtg ccacctgctc atggatgacg tggtcagtgc ggataactat 1080

acactggacc tgtgggctgg gcagcagctg ctgtggaagg gctccttcaa gcccagcgag 1140

catgtgaaac ccagggcccc aggaaacctg acagttcaca ccaatgtctc cgacactctg 1200

ctgctgacct ggagcaaccc gtatccccct gacaattacc tgtataatca tctcacctat 1260

gcagtcaaca tttggagtga aaacgacccg gcagatttca gaatctataa cgtgacctac 1320

ctagaaccct ccctccgcat cgcagccagc accctgaagt ctgggatttc ctacagggca 1380

cgggtgaggg cctgggctca gtgctataac accacctgga gtgagtggag ccccagcacc 1440

aagtggcaca actgtgagta tcaagaggcc taagcaatgg taatctccac tctccattct 1500

tcccctgtgg ccagacactt cccctggctg agtctctggg c 1541

<210> 28
<211> 88
<212> DNA
<213> Homo sapiens

<400> 28
gtgagtatca agaggcctaa gcaatggtaa tctccactct ccattcttcc cctgtggcca 60

gacacttccc ctggctgagt ctctgggc 88

<210> 29
<211> 176
<212> PRT
<213> Homo sapiens

<400> 29

Met Gly Arg Gly Leu Leu Arg Gly Leu Trp Pro Leu His Ile Val Leu
1 5 10 15

Trp Thr Arg Ile Ala Ser Thr Ile Pro Pro His Val Gln Lys Ser Val
20 25 30

Asn Asn Asp Met Ile Val Thr Asp Asn Asn Gly Ala Val Lys Phe Pro
35 40 45

Gln Leu Cys Lys Phe Cys Asp Val Arg Phe Ser Thr Cys Asp Asn Gln
50 55 60

Lys Ser Cys Met Ser Asn Cys Ser Ile Thr Ser Ile Cys Glu Lys Pro
65 70 75 80

Gln Glu Val Cys Val Ala Val Trp Arg Lys Asn Asp Glu Asn Ile Thr
85 90 95

Leu Glu Thr Val Cys His Asp Pro Lys Leu Pro Tyr His Asp Phe Ile
100 105 110

Leu Glu Asp Ala Ala Ser Pro Lys Cys Ile Met Lys Glu Lys Lys Lys
115 120 125

Pro Gly Glu Thr Phe Phe Met Cys Ser Cys Ser Ser Asp Glu Cys Asn
130 135 140

Asp Asn Ile Ile Phe Ser Glu Gly Glu Phe Ser Ser Leu Lys Gly Val
145 150 155 160

Gly Pro Glu Ile Cys Ala Asn Phe Leu Tyr Pro Trp Ser Ala Val Ser
165 170 175

<210> 30
<211> 25
<212> PRT
<213> Homo sapiens

<400> 30

Gly Glu Phe Ser Ser Leu Lys Gly Val Gly Pro Glu Ile Cys Ala Asn
1 5 10 15

Phe Leu Tyr Pro Trp Ser Ala Val Ser
20 25

<210> 31
<211> 1850
<212> DNA
<213> Homo sapiens

<400> 31
acctaaagaa aaacatttta caacttgaca gtgtatgcac atacatacat gcatatagac 60

acaactgaag cacaaattta atgaagtaga atttaccgtt actattttat ttgggaaaga 120

aatgtgctcg cgactcaata gattggagta ttcactcctg gatctcaact tgcaatttga 180

aaacgcatct ctaaagcacc taggagcaat ctgaagaaag ctgaggggag gcggcagatg 240

ttctgatcta ctagggaaaa cgtggacgtt ttctgttgtt actttgtgaa ctgtgtgcac 300

ttagtcattc ttgagtaaat acttggagcg aggaactcct gagtggtgtg ggagggcggt 360

gaggggcagc tgaaagtcgg ccaaagctct cggaggggct ggtctaggaa acatgattgg 420

cagctacgag agagctaggg gctggacgtc gaggagaggg agaaggctct cgggcggaga 480

gaggtcctgc ccagctgttg gcgaggagtt tcctgtttcc cccgcagcgc tgagttgaag 540

ttgagtgagt cactcgcgcg cacggagcga cgacaccccc gcgcgtgcac ccgctcggga 600

caggagccgg actcctgtgc agcttccctc ggccgccggg ggcctccccg cgcctcgccg 660

gcctccaggc cccctcctgg ctggcgagcg ggcgccacat ctggcccgca catctgcgct 720

gccggcccgg cgcggggtcc ggagagggcg cggcgcggag gcgcagccag gggtccggga 780

aggcgccgtc cgctgcgctg ggggctcggt ctatgacgag cagcggggtc tgccatgggt 840

cgggggctgc tcaggggcct gtggccgctg cacatcgtcc tgtggacgcg tatcgccagc 900

acgatcccac cgcacgttca gaagtcggtt aataacgaca tgatagtcac tgacaacaac 960

ggtgcagtca agtttccaca actgtgtaaa ttttgtgatg tgagattttc cacctgtgac 1020

aaccagaaat cctgcatgag caactgcagc atcacctcca tctgtgagaa gccacaggaa 1080

gtctgtgtgg ctgtatggag aaagaatgac gagaacataa cactagagac agtttgccat 1140

gaccccaagc tcccctacca tgactttatt ctggaagatg ctgcttctcc aaagtgcatt 1200

atgaaggaaa aaaaaaagcc tggtgagact ttcttcatgt gttcctgtag ctctgatgag 1260

tgcaatgaca acatcatctt ctcagaaggt gagttttctt ctcttaaggg tgtgggacct 1320

gagatctgtg ccaatttttt gtatccttgg tctgcagtgt catagagcac attcctcctg 1380

tggtggattg catacagtgg attaggagct cattcagctg gtggaaagag gggcttgggg 1440

agtagcaggg tttgttctgg ttctcatcaa atatggttga ctggggcaaa cattattatt 1500

tgtctttgac aaatagtttc tttcacctag agcagtgttt ctcaaagtgc ggccccttga 1560

gcagccagca tcagtatcac ctgggaacct gttataaatg cagattctca ggccccacta 1620

aatgagaaac atagagggtg aaccccagct atctgtattt taacaagccc tcccagtaat 1680

tctgtgcagc taaaatttgg taactattgt tctaaagatt tggatggggt tgtttaatct 1740

tggaggagga ctttctttat aactgatgtt gtttcttgta catagtccca ggatttgtct 1800

ttagggtact tgtcatcgat cccatttgag agacactttg caatacagag 1850

<210> 32
<211> 564
<212> DNA
<213> Homo sapiens

<400> 32
aggtgagttt tcttctctta agggtgtggg acctgagatc tgtgccaatt ttttgtatcc 60

ttggtctgca gtgtcataga gcacattcct cctgtggtgg attgcataca gtggattagg 120

agctcattca gctggtggaa agaggggctt ggggagtagc agggtttgtt ctggttctca 180

tcaaatatgg ttgactgggg caaacattat tatttgtctt tgacaaatag tttctttcac 240

ctagagcagt gtttctcaaa gtgcggcccc ttgagcagcc agcatcagta tcacctggga 300

acctgttata aatgcagatt ctcaggcccc actaaatgag aaacatagag ggtgaacccc 360

agctatctgt attttaacaa gccctcccag taattctgtg cagctaaaat ttggtaacta 420

ttgttctaaa gatttggatg gggttgttta atcttggagg aggactttct ttataactga 480

tgttgtttct tgtacatagt cccaggattt gtctttaggg tacttgtcat cgatcccatt 540

tgagagacac tttgcaatac agag 564

<210> 33
<211> 815
<212> PRT
<213> Homo sapiens

<400> 33

Met Ala Phe Pro Pro Arg Arg Arg Leu Arg Leu Gly Pro Arg Gly Leu
1 5 10 15

Pro Leu Leu Leu Ser Gly Leu Leu Leu Pro Leu Cys Arg Ala Phe Asn
20 25 30

Leu Asp Val Asp Ser Pro Ala Glu Tyr Ser Gly Pro Glu Gly Ser Tyr
35 40 45

Phe Gly Phe Ala Val Asp Phe Phe Val Pro Ser Ala Ser Ser Arg Met
50 55 60

Phe Leu Leu Val Gly Ala Pro Lys Ala Asn Thr Thr Gln Pro Gly Ile
65 70 75 80

Val Glu Gly Gly Gln Val Leu Lys Cys Asp Trp Ser Ser Thr Arg Arg
85 90 95

Cys Gln Pro Ile Glu Phe Asp Ala Thr Gly Asn Arg Asp Tyr Ala Lys
100 105 110

Asp Asp Pro Leu Glu Phe Lys Ser His Gln Trp Phe Gly Ala Ser Val
115 120 125

Arg Ser Lys Gln Asp Lys Ile Leu Ala Cys Ala Pro Leu Tyr His Trp
130 135 140

Arg Thr Glu Met Lys Gln Glu Arg Glu Pro Val Gly Thr Cys Phe Leu
145 150 155 160

Gln Asp Gly Thr Lys Thr Val Glu Tyr Ala Pro Cys Arg Ser Gln Asp
165 170 175

Ile Asp Ala Asp Gly Gln Gly Phe Cys Gln Gly Gly Phe Ser Ile Asp
180 185 190

Phe Thr Lys Ala Asp Arg Val Leu Leu Gly Gly Pro Gly Ser Phe Tyr
195 200 205

Trp Gln Gly Gln Leu Ile Ser Asp Gln Val Ala Glu Ile Val Ser Lys
210 215 220

Tyr Asp Pro Asn Val Tyr Ser Ile Lys Tyr Asn Asn Gln Leu Ala Thr
225 230 235 240

Arg Thr Ala Gln Ala Ile Phe Asp Asp Ser Tyr Leu Gly Tyr Ser Val
245 250 255

Ala Val Gly Asp Phe Asn Gly Asp Gly Ile Asp Asp Phe Val Ser Gly
260 265 270

Val Pro Arg Ala Ala Arg Thr Leu Gly Met Val Tyr Ile Tyr Asp Gly
275 280 285

Lys Asn Met Ser Ser Leu Tyr Asn Phe Thr Gly Glu Gln Met Ala Ala
290 295 300

Tyr Phe Gly Phe Ser Val Ala Ala Thr Asp Ile Asn Gly Asp Asp Tyr
305 310 315 320

Ala Asp Val Phe Ile Gly Ala Pro Leu Phe Met Asp Arg Gly Ser Asp
325 330 335

Gly Lys Leu Gln Glu Val Gly Gln Val Ser Val Ser Leu Gln Arg Ala
340 345 350

Ser Gly Asp Phe Gln Thr Thr Lys Leu Asn Gly Phe Glu Val Phe Ala
355 360 365

Arg Phe Gly Ser Ala Ile Ala Pro Leu Gly Asp Leu Asp Gln Asp Gly

370 375 380

Phe Asn Asp Ile Ala Ile Ala Ala Pro Tyr Gly Gly Glu Asp Lys Lys
385 390 395 400

Gly Ile Val Tyr Ile Phe Asn Gly Arg Ser Thr Gly Leu Asn Ala Val
405 410 415

Pro Ser Gln Ile Leu Glu Gly Gln Trp Ala Ala Arg Ser Met Pro Pro
420 425 430

Ser Phe Gly Tyr Ser Met Lys Gly Ala Thr Asp Ile Asp Lys Asn Gly
435 440 445

Tyr Pro Asp Leu Ile Val Gly Ala Phe Gly Val Asp Arg Ala Ile Leu
450 455 460

Tyr Arg Ala Arg Pro Val Ile Thr Val Asn Ala Gly Leu Glu Val Tyr
465 470 475 480

Pro Ser Ile Leu Asn Gln Asp Asn Lys Thr Cys Ser Leu Pro Gly Thr
485 490 495

Ala Leu Lys Val Ser Cys Phe Asn Val Arg Phe Cys Leu Lys Ala Asp
500 505 510

Gly Lys Gly Val Leu Pro Arg Lys Leu Asn Phe Gln Val Glu Leu Leu
515 520 525

Leu Asp Lys Leu Lys Gln Lys Gly Ala Ile Arg Arg Ala Leu Phe Leu
530 535 540

Tyr Ser Arg Ser Pro Ser His Ser Lys Asn Met Thr Ile Ser Arg Gly
545 550 555 560

Gly Leu Met Gln Cys Glu Glu Leu Ile Ala Tyr Leu Arg Asp Glu Ser
565 570 575

Glu Phe Arg Asp Lys Leu Thr Pro Ile Thr Ile Phe Met Glu Tyr Arg
580 585 590

Leu Asp Tyr Arg Thr Ala Ala Asp Thr Thr Gly Leu Gln Pro Ile Leu
595 600 605

Asn Gln Phe Thr Pro Ala Asn Ile Ser Arg Gln Ala His Ile Leu Leu
610 615 620

Asp Cys Gly Glu Asp Asn Val Cys Lys Pro Lys Leu Glu Val Ser Val
625 630 635 640

Asp Ser Asp Gln Lys Lys Ile Tyr Ile Gly Asp Asp Asn Pro Leu Thr
645 650 655

Leu Ile Val Lys Ala Gln Asn Gln Gly Glu Gly Ala Tyr Glu Ala Glu
660 665 670

Leu Ile Val Ser Ile Pro Leu Gln Ala Asp Phe Ile Gly Val Val Arg
675 680 685

Asn Asn Glu Ala Leu Ala Arg Leu Ser Cys Ala Phe Lys Thr Glu Asn
690 695 700

Gln Thr Arg Gln Val Val Cys Asp Leu Gly Asn Pro Met Lys Ala Gly
705 710 715 720

Thr Gln Leu Leu Ala Gly Leu Arg Phe Ser Val His Gln Gln Ser Glu
725 730 735

Met Asp Thr Ser Val Lys Phe Asp Leu Gln Ile Gln Ser Ser Asn Leu
740 745 750

Phe Asp Lys Val Ser Pro Val Val Ser His Lys Val Asp Leu Ala Val
755 760 765

Leu Ala Ala Val Glu Ile Arg Gly Val Ser Ser Pro Asp His Ile Phe
770 775 780

Leu Pro Ile Pro Asn Trp Glu His Lys Glu Asn Pro Glu Thr Glu Glu
785 790 795 800

Asp Val Gly Pro Val Val Gln His Ile Tyr Glu Val Cys Ser Cys
805 810 815

<210> 34
<211> 4
<212> PRT
<213> Homo sapiens

<400> 34

Val Cys Ser Cys
1

<210> 35
<211> 3379
<212> DNA
<213> Homo sapiens

<400> 35
gataaaaagc tttcctcatt tttaaacaac agtcgcacgg aagttcccgg cgggacaagg 60

gaacgtgggt gcccttgcta ctcccgtgga cgcgggtaga ttgggacgct ggaccgtatc 120

tccccgcccc cgcccccacg cctcctcagg tgctcagcct gaggccttcg tccaggagcg 180

ctgccgctga cccaggctca ggagctgggg gcccctgcac agacgcccag gtctcgggac 240

aggcggcgac tgcactcacg gaagtacgct gagctctccc ctgtagaagg gcgcctctcc 300

tcccccactt cctcctccag ctccacagca gcctcccggg ccggctcctc ctccttccag 360

gtctcctccc agtgccgccg cggctctcag gcctgaggtg cggcgctcac cccggcagtc 420

cccagcctca gacgctgcgt ggagcggcgg agccggaggg aagcaaagga ccgtctgcgc 480

tgctgtcccc gccccgcgcg ctctgcgccc ctcgtccctg gcggtcgctc cgaagctcag 540

ccctcttgcc tgccccggag ctgtcccggg ctagccgaga agagagcggc cggcaagttt 600

gggcgcgcgc aggcggcggg ccgcgggcac tgggcgcctc gctggggcgg ggggaggtgg 660

ctaccgctcc cggcttggcg tcccgcgcgc acttcggcga tggcttttcc gccgcggcga 720

cggctgcgcc tcggtccccg cggcctcccg cttcttctct cgggactcct gctacctctg 780

tgccgcgcct tcaacctaga cgtggacagt cctgccgagt actctggccc cgagggaagt 840

tacttcggct tcgccgtgga tttcttcgtg cccagcgcgt cttcccggat gtttcttctc 900

gtgggagctc ccaaagcaaa caccacccag cctgggattg tggaaggagg gcaggtcctc 960

aaatgtgact ggtcttctac ccgccggtgc cagccaattg aatttgatgc aacaggcaat 1020

agagattatg ccaaggatga tccattggaa tttaagtccc atcagtggtt tggagcatct 1080

gtgaggtcga aacaggataa aattttggcc tgtgccccat tgtaccattg gagaactgag 1140

atgaaacagg agcgagagcc tgttggaaca tgctttcttc aagatggaac aaagactgtt 1200

gagtatgctc catgtagatc acaagatatt gatgctgatg gacagggatt ttgtcaagga 1260

ggattcagca ttgattttac taaagctgac agagtacttc ttggtggtcc tggtagcttt 1320

tattggcaag gtcagcttat ttcggatcaa gtggcagaaa tcgtatctaa atacgacccc 1380

aatgtttaca gcatcaagta taataaccaa ttagcaactc ggactgcaca agctattttt 1440

gatgacagct atttgggtta ttctgtggct gtcggagatt tcaatggtga tggcatagat 1500

gactttgttt caggagttcc aagagcagca aggactttgg gaatggttta tatttatgat 1560

gggaagaaca tgtcctcctt atacaatttt actggcgagc aggatggctgc atatttcgga 1620

ttttctgtag ctgccactga cattaatgga gatgattatg cagatgtgtt tattggagca 1680

cctctcttca tggatcgtgg ctctgatggc aaactccaag aggtggggca ggtctcagtg 1740

tctctacaga gagcttcagg agacttccag acgacaaagc tgaatggatt tgaggtcttt 1800

gcacggtttg gcagtgccat agctcctttg ggagatctgg accaggatgg tttcaatgat 1860

attgcaattg ctgctccata tgggggtgaa gataaaaaag gaattgttta tatcttcaat 1920

ggaagatcaa caggcttgaa cgcagtccca tctcaaatcc ttgaagggca gtgggctgct 1980

cgaagcatgc caccaagctt tggctattca atgaaaggag ccacagatat agacaaaaat 2040

ggatatccag acttaattgt aggagctttt ggtgtagatc gagctatctt atacagggcc 2100

agaccagtta tcactgtaaa tgctggtctt gaagtgtacc ctagcatttt aaatcaagac 2160

aataaaacct gctcactgcc tggaacagct ctcaaagttt cctgttttaa tgttaggttc 2220

tgcttaaagg cagatggcaa aggagtactt cccaggaaac ttaatttcca ggtggaactt 2280

cttttggata aactcaagca aaagggagca attcgacgag cactgtttct ctacagcagg 2340

tccccaagtc actccaagaa catgactatt tcaaggggg gactgatgca gtgtgaggaa 2400

ttgatagcgt atctgcggga tgaatctgaa tttagagaca aactcactcc aattactatt 2460

tttatggaat atcggttgga ttatagaaca gctgctgata caacaggctt gcaacccatt 2520

cttaaccagt tcacgcctgc taacattagt cgacaggctc acattctact tgactgtggt 2580

gaagacaatg tctgtaaacc caagctggaa gtttctgtag atagtgatca aaagaagatc 2640

tatattgggg atgacaaccc tctgacattg attgttaagg ctcagaatca aggagaaggt 2700

gcctacgaag ctgagctcat cgtttccatt ccactgcagg ctgatttcat cggggttgtc 2760

cgaaacaatg aagccttagc aagactttcc tgtgcattta agacagaaaa ccaaactcgc 2820

caggtggtat gtgaccttgg aaacccaatg aaggctggaa ctcaactctt agctggtctt 2880

cgtttcagtg tgcaccagca gtcagagatg gatacttctg tgaaatttga cttacaaatc 2940

caaagctcaa atctatttga caaagtaagc ccagttgtat ctcacaaagt tgatcttgct 3000

gttttagctg cagttgagat aagaggagtc tcgagtcctg atcatatctt tcttccgatt 3060

ccaaactggg agcacaagga gaaccctgag actgaagaag atgttgggcc agttgttcag 3120

cacatctatg aggtttgcag ttgttagatt ttactcaaac ctcgtgagca agccaacgaa 3180

gagaggaaca actaagctac tttaaaaaaa aaattctatg taatttttat gtaaactcta 3240

cattggttaa gtatgtgtca gagatttctt tgaatatttt ccctatacat aaattcattt 3300

ttatttgaca aatagacttg tttaaataaa gcagtttata taatttgttg tttaaaataa 3360

attagttcta cttgaataa 3379

<210> 36
<211> 247
<212> DNA
<213> Homo sapiens

<400> 36
gtttgcagtt gttagatttt actcaaacct cgtgagcaag ccaacgaaga gaggaacaac 60

taagctactt taaaaaaaaa attctatgta atttttatgt aaactctaca ttggttaagt 120

atgtgtcaga gatttctttg aatattttcc ctatacataa attcattttt atttgacaaa 180

tagacttgtt taaataaagc agtttatata atttgttgtt taaaataaat tagttctact 240

tgaataa 247

<210> 37
<211> 222
<212> PRT
<213> Homo sapiens

<400> 37

Met Ala Trp Ser Leu Gly Ser Trp Leu Gly Gly Cys Leu Leu Val Ser

1 5 10 15

Ala Leu Gly Met Val Pro Pro Pro Glu Asn Val Arg Met Asn Ser Val
20 25 30

Asn Phe Lys Asn Ile Leu Gln Trp Glu Ser Pro Ala Phe Ala Lys Gly
35 40 45

Asn Leu Thr Phe Thr Ala Gln Tyr Leu Ser Tyr Arg Ile Phe Gln Asp
50 55 60

Lys Cys Met Asn Thr Thr Leu Thr Glu Cys Asp Phe Ser Ser Leu Ser
65 70 75 80

Lys Tyr Gly Asp His Thr Leu Arg Val Arg Ala Glu Phe Ala Asp Glu
85 90 95

His Ser Asp Trp Val Asn Ile Thr Phe Cys Pro Val Asp Asp Thr Ile
100 105 110

Ile Gly Pro Pro Gly Met Gln Val Glu Val Leu Ala Asp Ser Leu His
115 120 125

Met Arg Phe Leu Ala Pro Lys Ile Glu Asn Glu Tyr Glu Thr Trp Thr
130 135 140

Met Lys Asn Val Tyr Asn Ser Trp Thr Tyr Asn Val Gln Tyr Trp Lys
145 150 155 160

Asn Gly Thr Asp Glu Lys Phe Gln Ile Thr Pro Gln Tyr Asp Phe Glu
165 170 175

Val Leu Arg Asn Leu Glu Pro Trp Thr Thr Tyr Cys Val Gln Val Arg
180 185 190

Gly Phe Leu Pro Asp Arg Asn Lys Ala Gly Glu Trp Ser Glu Pro Val
195 200 205

Cys Glu Gln Thr Thr His Asp Val Phe Gly Pro Ser Ser Ser
210 215 220

<210> 38
<211> 7
<212> PRT
<213> Homo sapiens

<400> 38

Val Phe Gly Pro Ser Ser Ser
1 5

<210> 39

<211> 1806
<212> DNA
<213> Homo sapiens

<400> 39
cccgcccatc tccgctggtt cccggaagcc gccgcggaca agctctcccg ggcgcgggcg 60

ggggtcgtgt gcttggagga agccgcggaa cccccagcgt ccgtccatgg cgtggagcct 120

tgggagctgg ctgggtggct gcctgctggt gtcagcattg ggaatggtac cacctcccga 180

aaatgtcaga atgaattctg ttaatttcaa gaacattcta cagtgggagt cacctgcttt 240

tgccaaaggg aacctgactt tcacagctca gtacctaagt tataggatat tccaagataa 300

atgcatgaat actaccttga cggaatgtga tttctcaagt ctttccaagt atggtgacca 360

caccttgaga gtcagggctg aatttgcaga tgagcattca gactgggtaa acatcacctt 420

ctgtcctgtg gatgacacca ttattggacc ccctggaatg caagtagaag tacttgctga 480

ttctttacat atgcgtttct tagcccctaa aattgagaat gaatacgaaa cttggactat 540

gaagaatgtg tataactcat ggacttataa tgtgcaatac tggaaaaacg gtactgatga 600

aaagtttcaa attactcccc agtatgactt tgaggtcctc agaaacctgg agccatggac 660

aacttattgt gttcaagttc gagggtttct tcctgatcgg aacaaagctg gggaatggag 720

tgagcctgtc tgtgagcaaa caacccatga cgtttttggg ccatcctcat cataacacac 780

ttctgttttt ctcctttcca ttgtcggatg agaatgatgt ttttgacaag ctaagtgtca 840

ttgcagaaga ctctgagagc ggcaagcaga atcctggtga cagctgcagc ctcgggaccc 900

cgcctgggca ggggccccaa agctaggctc tgagaaggaa acacactcgg ctgggcacag 960

tgacgtactc catctcacat ctgcctcagt gagggatcag ggcagcaaac aagggccaag 1020

accatctgag ccagccccac atctagaact cccagaccct ggacttagcc accagagagc 1080

tacattttaa aggctgtctt ggcaaaaata ctccatttgg gaactcactg ccttataaag 1140

gctttcatga tgttttcaga agttggccac tgagagtgta attttcagcc ttttatatca 1200

ctaaaataag atcatgtttt aattgtgaga aacagggccg agcacagtgg ctcacgcctg 1260

taataccagc accttagagg tcgaggcagg cggatcactt gaggtcagga gttcaagacc 1320

agcctggcca atatggtgaa acccagtctc tactaaaaat acaaaaatta gctaggcatg 1380

atggcgcatg cctataatcc cagctactcg agtgcctgag gcaggagaat tgcatgaacc 1440

cgggaggagg aggaggaggt tgcagtgagc cgagatagcg gcactgcact ccagcctggg 1500

tgacaaagtg agactccatc tcaaaaaaaa aaaaaaaaaa ttgtgagaaa cagaaatact 1560

taaaatgagg aataagaatg gagatgttac atctggtaga tgtaacattc taccagatta 1620

tggatggact gatctgaaaa tcaacctcaa ctcaagggtg gtcagctcaa tgctacacag 1680

agcacggact tttggattct ttgcagtact ttgaatttat ttttctacct atatatgttt 1740

tatatgctgc tggtgctcca ttaaagtttt actctgtgtt gcactatatg tgttcatgat 1800

aaaaaa 1806

<210> 40
<211> 65
<212> DNA
<213> Homo sapiens

<400> 40
tcagaatctt ttattgtctt ttttaaaaat gtagctagac ataataaaag taattctata 60

ctgta 65

<210> 41
<211> 441
<212> PRT
<213> Homo sapiens

<400> 41

Met Val Val Leu Leu Gly Ala Thr Thr Leu Val Leu Val Ala Val Ala
1 5 10 15

Pro Trp Val Leu Ser Ala Ala Ala Gly Gly Lys Asn Leu Lys Ser Pro
20 25 30

Gln Lys Val Glu Val Asp Ile Ile Asp Asp Asn Phe Ile Leu Arg Trp
35 40 45

Asn Arg Ser Asp Glu Ser Val Gly Asn Val Thr Phe Ser Phe Asp Tyr
50 55 60

Gln Lys Thr Gly Met Asp Asn Trp Ile Lys Leu Ser Gly Cys Gln Asn
65 70 75 80

Ile Thr Ser Thr Lys Cys Asn Phe Ser Ser Leu Lys Leu Asn Val Tyr
85 90 95

Glu Glu Ile Lys Leu Arg Ile Arg Ala Glu Lys Glu Asn Thr Ser Ser
100 105 110

Trp Tyr Glu Val Asp Ser Phe Thr Pro Phe Arg Lys Ala Gln Ile Gly
115 120 125

Pro Pro Glu Val His Leu Glu Ala Glu Asp Lys Ala Ile Val Ile His
130 135 140

Ile Ser Pro Gly Thr Lys Asp Ser Val Met Trp Ala Leu Asp Gly Leu
145 150 155 160

Ser Phe Thr Tyr Ser Leu Val Ile Trp Lys Asn Ser Ser Gly Val Glu
165 170 175

Glu Arg Ile Glu Asn Ile Tyr Ser Arg His Lys Ile Tyr Lys Leu Ser
180 185 190

Pro Glu Thr Thr Tyr Cys Leu Lys Val Lys Ala Ala Leu Leu Thr Ser
195 200 205

Trp Lys Ile Gly Val Tyr Ser Pro Val His Cys Ile Lys Thr Thr Val
210 215 220

Glu Asn Glu Leu Pro Pro Pro Glu Asn Ile Glu Val Ser Val Gln Asn
225 230 235 240

Gln Asn Tyr Val Leu Lys Trp Asp Tyr Thr Tyr Ala Asn Met Thr Phe
245 250 255

Gln Val Gln Trp Leu His Ala Phe Leu Lys Arg Asn Pro Gly Asn His
260 265 270

Leu Tyr Lys Trp Lys Gln Ile Pro Asp Cys Glu Asn Val Lys Thr Thr
275 280 285

Gln Cys Val Phe Pro Gln Asn Val Phe Gln Lys Gly Ile Tyr Leu Leu
290 295 300

Arg Val Gln Ala Ser Asp Gly Asn Asn Thr Ser Phe Trp Ser Glu Glu
305 310 315 320

Ile Lys Phe Asp Thr Glu Ile Gln Ala Phe Leu Leu Pro Pro Val Phe
325 330 335

Asn Ile Arg Ser Leu Ser Asp Ser Phe His Ile Tyr Ile Gly Ala Pro
340 345 350

Lys Gln Ser Gly Asn Thr Pro Val Ile Gln Asp Tyr Pro Leu Ile Tyr
355 360 365

Glu Ile Ile Phe Trp Glu Asn Thr Ser Asn Ala Glu Arg Lys Ile Ile
370 375 380

Glu Lys Lys Thr Asp Val Thr Val Pro Asn Leu Lys Pro Leu Thr Val
385 390 395 400

Tyr Cys Val Lys Ala Arg Ala His Thr Met Asp Glu Lys Leu Asn Lys
405 410 415

Ser Ser Val Phe Ser Asp Ala Val Cys Glu Lys Thr Lys Pro Gly Gln
420 425 430

Asn Leu Leu Leu Ser Phe Leu Lys Met
435 440

<210> 42
<211> 10
<212> PRT

<213> Homo sapiens

<400> 42

Gln Asn Leu Leu Leu Ser Phe Leu Lys Met
1 5 10

<210> 43
<211> 1512
<212> DNA
<213> Homo sapiens

<400> 43
agaagaggcg gcgcgtgcgt agaggggcgg tgagagctaa gaggggcagc gcgtgtgcag 60

aggggcggtg tgacttagga cggggcgatg gcggctgaga ggagctgcgc gtgcgcgaac 120

atgtaactgg tgggatctgc ggcggctccc agatgatggt cgtcctcctg ggcgcgacga 180

ccctagtgct cgtcgccgtg gcgccatggg tgttgtccgc agccgcaggt ggaaaaaatc 240

taaaatctcc tcaaaaagta gaggtcgaca tcatagatga caactttatc ctgaggtgga 300

acaggagcga tgagtctgtc gggaatgtga ctttttcatt cgattatcaa aaaactggga 360

tggataattg gataaaattg tctgggtgtc agaatattac tagtaccaaa tgcaactttt 420

cttcactcaa gctgaatgtt tatgaagaaa ttaaattgcg tataagagca gaaaaagaaa 480

acacttcttc atggtatgag gttgactcat ttacaccatt tcgcaaagct cagattggtc 540

ctccagaagt acatttagaa gctgaagata aggcaatagt gatacacatc tctcctggaa 600

caaaagatag tgttatgtgg gctttggatg gtttaagctt tacatatagc ttagttatct 660

ggaaaaactc ttcaggtgta gaagaaagga ttgaaaatat ttattccaga cataaaattt 720

ataaactctc accagagact acttattgtc taaaagttaa agcagcacta cttacgtcat 780

ggaaaattgg tgtctatagt ccagtacatt gtataaagac cacagttgaa aatgaactac 840

ctccaccaga aaatatagaa gtcagtgtcc aaaatcagaa ctatgttctt aaatgggatt 900

atacatatgc aaacatgacc tttcaagttc agtggctcca cgccttttta aaaaggaatc 960

ctggaaacca tttgtataaa tggaaacaaa tacctgactg tgaaaatgtc aaaactaccc 1020

agtgtgtctt tcctcaaaac gttttccaaa aaggaattta ccttctccgc gtacaagcat 1080

ctgatggaaa taacacatct ttttggtctg aagagataaa gtttgatact gaaatacaag 1140

ctttcctact tcctccagtc tttaacatta gatcccttag tgattcattc catatctata 1200

tcggtgctcc aaaacagtct ggaaacacgc ctgtgatcca ggattatcca ctgatttatg 1260

aaattatttt ttgggaaaac acttcaaatg ctgagagaaa aattatcgag aaaaaaactg 1320

atgttacagt tcctaatttg aaaccactga ctgtatattg tgtgaaagcc agagcacaca 1380

ccatggatga aaagctgaat aaaagcagtg tttttagtga cgctgtatgt gagaaaacaa 1440

aaccaggtca gaatctttta ttgtcttttt taaaaatgta gctagacata ataaaagtaa 1500

ttctatactg ta 1512